



## Centrifugal microfluidic platforms: Advanced unit operations and applications

Journal:	<i>Chemical Society Reviews</i>
Manuscript ID:	CS-REV-11-2014-000371.R2
Article Type:	Review Article
Date Submitted by the Author:	08-May-2015
Complete List of Authors:	<p>Strohmeier, Oliver; Hahn-Schickard, Lab on a Chip            Keller, Mark; Hahn-Schickard, Lab on a Chip; University of Freiburg/IMTEK Inst of Microsystem Tech., Laboratory for MEMS Application            Schwemmer, Frank; University of Freiburg/IMTEK Inst of Microsystem Tech., Laboratory for MEMS Application            Zehnle, Steffen; Hahn-Schickard, Lab on a Chip            Mark, Daniel; University of Freiburg/IMTEK Inst of Microsystem Tech., Laboratory for MEMS Application            von Stetten, Felix; University of Freiburg/IMTEK Inst of Microsystem Tech., Laboratory for MEMS Application            Zengerle, Roland; University of Freiburg/IMTEK Inst of Microsystem Tech., Laboratory for MEMS Application            Paust, Nils; Hahn-Schickard, Lab on a Chip</p>

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1 **Authors:** O. Strohmeier<sup>\*1,2</sup>, M. Keller<sup>\*1,2</sup>, F. Schwemmer<sup>\*2</sup>, S. Zehnle<sup>\*1</sup>,  
2 D. Mark<sup>1,2</sup>, F. von Stetten<sup>1,2</sup>, R. Zengerle<sup>1,2,3</sup>, and N. Paust<sup>1,2,†</sup>

3 **Affiliations:** <sup>1)</sup> Hahn-Schickard,  
4 Georges-Koehler-Allee 103, 79110 Freiburg, Germany  
5 <sup>2)</sup> Laboratory for MEMS Applications, IMTEK - Department of  
6 Microsystems Engineering, University of Freiburg, Georges-Koehler-  
7 Allee 103, 79110 Freiburg  
8 <sup>3)</sup> BIOS Centre for Biological Signalling Studies, University of  
9 Freiburg, Schaenzlestr. 18, 79104 Freiburg  
10 <sup>\*)</sup> Authors contributed equally  
11 <sup>†)</sup> To whom correspondence should be addressed  
12 Nils.Paust@Hahn-Schickard.de (Phone: +49 761 203-73245)

## 13 1 Abstract

14 Centrifugal microfluidics has evolved into a mature technology. Several major diagnostic  
15 companies either have products on the market or are currently evaluating centrifugal  
16 microfluidics for product development. The fields of application are widespread and include  
17 clinical chemistry, immunodiagnosics and protein analysis, cell handling, molecular  
18 diagnostics, as well as food, water, and soil analysis. Nevertheless, new fluidic functions and  
19 applications that expand the possibilities of centrifugal microfluidics are being introduced at a  
20 high pace. In this review, we first present an up-to-date comprehensive overview of  
21 centrifugal microfluidic unit operations. Then, we introduce the term “process chain” to review  
22 how these unit operations can be combined for the automation of laboratory workflows. Such  
23 aggregation of basic functionalities enables efficient fluidic design at a higher level of  
24 integration. Furthermore, we analyze how novel, ground-breaking unit operations may foster  
25 the integration of more complex applications. Among these are the storage of pneumatic  
26 energy to realize complex switching sequences or to pump liquids radially inward, as well as  
27 the complete pre-storage and release of reagents. In this context, centrifugal microfluidics  
28 provides major advantages over other microfluidic actuation principles: The pulse-free inertial  
29 liquid propulsion provided by centrifugal microfluidics allows for closed fluidic systems that  
30 are free of any interfaces to external pumps. Processed volumes are easily scalable from  
31 nanoliters to milliliters. Volume forces can be adjusted by rotation and thus, even for very  
32 small volumes, surface forces may easily be overcome in the centrifugal gravity field which  
33 enables the efficient separation of nanoliter volumes from channels, chambers or sensor  
34 matrixes as well as the removal of any disturbing bubbles.

35 In summary, centrifugal microfluidics takes advantage of a comprehensive set of fluidic unit  
36 operations such as liquid transport, metering, mixing and valving. The available unit

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

37 operations cover the entire range of automated liquid handling requirements and enables  
38 efficient miniaturization, parallelization, and integration of assays.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

## 39 **2 Introduction**

40 Microfluidics enables the miniaturization, integration, and automation of laboratory processes  
41 ranging from basic operations to complex biochemical assays. Obviously, an increase in the  
42 research activities in this field has been accompanied by a much slower conversion of  
43 microfluidic approaches into products. The reasons for this tardy technology transfer have  
44 been extensively discussed in previous studies <sup>1 2</sup>, stating for instance a lack of flexibility of  
45 the microfluidic implementations, which allow for a very limited number of applications for a  
46 single microfluidic device. All of the research, development, and certification expense would  
47 have to be paid off by these very limited number of applications developed for a small market  
48 segment.

49 As one possible solution, microfluidic platform-based approaches have been suggested <sup>3 4</sup>. A  
50 microfluidic platform provides a set of microfluidic unit operations such as liquid transport,  
51 metering, mixing and valving. The unit operations are validated, scalable, and standardized,  
52 and can be combined in an easy and consistent manner. In some cases, it might be possible  
53 that a fixed set of unit operations is implemented within a generic disposable cartridge, in  
54 which different applications can be processed, simply by adjusting chemistry. In general, the  
55 key advantage of using platforms is the possibility to make use of building blocks from  
56 existing solutions to implement new applications with reduced effort and risk, and to address  
57 an increased market, which can be as large as the number of applications implemented  
58 within a platform.

59 The company Cepheid impressively demonstrated platform based automation of biochemical  
60 analysis. An application specific cartridge was introduced, but the cartridge is capable of  
61 performing analysis for many different targets by changing the analysis chemistry. Thus, a  
62 single cartridge covers a large range of products for nucleic acid-based sample-to-answer  
63 testing with high market penetration (e.g., \$411 million annual turnover by Cepheid, 2014) <sup>5</sup>.  
64 Based on one cartridge format, 22 different tests are currently available, covering

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

65 applications in the fields of healthcare-associated infections, critical infectious diseases<sup>6,7</sup>,  
66 sexual health, and oncology. In dependency of the desired throughput, processing devices  
67 for 1, 2, 4, or 16 cartridges in parallel are available <sup>5</sup>. Another success story for in-vitro  
68 diagnostics testing at the point-of-care is the handheld device and the microfluidic cartridges  
69 from Abbott's i-STAT system, for which more than 35 million tests were sold in 2014 <sup>8</sup>.  
70 Cartridges are available for measuring blood chemistries and electrolytes, hematology, blood  
71 gases, coagulation, or cardiac markers <sup>8</sup>. It has been predicted that the market for  
72 microfluidic automation will continue to grow. The market for microfluidic devices for point-of-  
73 care applications alone is expected to grow from US\$200 million today to a US\$800 million  
74 turnover in 2019 <sup>9</sup>. In order to be successful, a microfluidic platform has to fully cover the  
75 functionalities from sample input to data analysis for the desired range of applications.  
76 Several recent publications e.g. by *Mark et al.*, *Sin et al.* or *Madou et al.*, provide criteria to  
77 select an appropriate microfluidic platform <sup>10 11 12</sup>.

78 This review intends to deepen the understanding of platform-based microfluidic automation.  
79 It focuses exclusively on platforms making use of centrifugal microfluidics in order to provide  
80 detailed insight into this obviously emerging technology. When compared to other  
81 microfluidic platforms, centrifugal microfluidics has several strengths: The centrifugal  
82 propulsion mechanism allows for a closed fluidic system, free of any interfaces to external  
83 pumps. The removal of any bubbles that may interfere with the proper performance of an  
84 assay is particularly simple due to the scalable buoyancy in the centrifugal gravity field. In  
85 addition, residual liquids that may be trapped due to surface forces can be removed from  
86 channels, chambers and sensor matrixes, again, simply by adjusting the volume forces by  
87 rotation. The strength of centrifugal microfluidics is reflected by an enormous breadth of  
88 available unit operations and initiated an increase in research activity on the one hand and  
89 an increasing commitment by major diagnostic companies on the other hand. Panasonic,  
90 Roche, Samsung, 3M, and Abaxis already have centrifugal microfluidic-based products on

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

91 the market and a considerable number of additional companies are currently evaluating the  
92 use of centrifugal microfluidics for their applications.

93 The last published comprehensive review on centrifugal microfluidics focused on the history  
94 and individual biomedical applications <sup>13</sup>. Since then, more than 300 papers have been  
95 published on centrifugal microfluidics. An overview of the scientific journal publications and  
96 selected milestones in technology transfer is depicted in **Fig. 1**. Among the scientific  
97 publications, a clear trend toward the full integration of a complex sample-to-answer analysis  
98 can be observed. In addition, ground breaking novel unit operations have been developed  
99 that have the potential of making significant contributions to the field in the near future.  
100 Consequently, our review highlights these recent innovations. Special focus is directed  
101 towards the process of translating the assay step by step into a microfluidic layout,  
102 particularly the method used for combining unit operations to facilitate the miniaturization,  
103 integration, and automation of laboratory processes on centrifugal microfluidic platforms.  
104 Whereas basic fluidic functionalities are called unit operations, for a concatenation of such  
105 basic functionalities representing a laboratory workflow, we introduce the term “process  
106 chain.” In this context, we propose to standardize fluidic unit operations for the  
107 implementation of basic stand-alone functionalities such as metering, valving, and mixing.  
108 For the integration of frequently applied complete laboratory workflows, process chains  
109 should be standardized to allow for their efficient implementation without the need to deal  
110 with the basic functionalities. Examples of process chains are chemical cell lysis, nucleic acid  
111 purification and amplification, blocking to avoid unspecific binding, washing, immunocapture,  
112 etc. The terms used to describe the centrifugal microfluidic platform-based approach are  
113 defined in **Table 1**. Application examples for the hierarchy of a fluidic layout using process  
114 chains are depicted in the respective application chapter. Throughout this review, wherever  
115 suitable, we attempt to explain the implemented centrifugal microfluidic applications using the  
116 categories “process chains” and the underlying “unit operations.”

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

117 This review is structured as follows. First, the physics of centrifugal microfluidics is briefly  
118 outlined, followed by a comprehensive review of the established and recently proposed  
119 centrifugal microfluidic unit operations. Based on the review of microfluidic unit operations,  
120 we reach conclusions about how some of the described developments will foster the  
121 integration of more complex applications. Subsequently, we review centrifugal microfluidic  
122 implementations of nucleic acid-based analysis; immunodiagnostics; clinical chemistry; and  
123 the analysis of food, water, and soil. Specific embodiments of centrifugal microfluidic  
124 systems, e.g., specific platforms using centrifugal microfluidics that are commercially  
125 available or under development are briefly outlined thereafter. Finally, we summarize the  
126 strengths and limitations and identify and discuss future trends.

127

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

128


**Table 1:** Definitions. The terms microfluidic platform, microfluidic chip, processing device, fluidic unit operations, and process chains are used throughout the review and defined accordingly.

Term	Definition
Microfluidic platform	A microfluidic platform provides a set of validated fluidic unit operations, which are designed for easy combination within a standardized fabrication technology <sup>10</sup> . The platform approach enables efficient implementation of various laboratory workflows and/or applications.
Microfluidic chip/microfluidic cartridge	A microfluidic chip, which is often referred to as a microfluidic cartridge, is a substrate that provides structures like chambers, channels, etc. for the hardware implementation of the fluidic unit operations. For most applications, microfluidic chips are disposed of after use to avoid cross contamination and/or save regeneration cost.
Fluidic unit operations	... are basic fluidic functionalities such as the following: <ul style="list-style-type: none"> <li>• liquid inlet/outlet</li> <li>• reagent pre-storage and release</li> <li>• liquid transport</li> <li>• valving and switching</li> <li>• metering and aliquoting</li> <li>• mixing</li> <li>• separation</li> <li>• droplet generation</li> <li>• detection</li> <li>• ....</li> </ul>
Processing device	The processing device (often also called the “instrument”) is a piece of reusable hardware that provides additional means to operate the microfluidic chip. This may comprise the main actuator (e.g., spinning drive) to control the fluids, as well as external means such as temperature control and/or magnetic, electric, optic, pneumatic, or mechanical features, including a means for detection/read-out.
Process chains	... are assemblies of fluidic unit operations and external means that represent laboratory workflows on a higher level of integration. Examples of process chains are ... <ul style="list-style-type: none"> <li>• blood plasma separation</li> <li>• cell lysis</li> <li>• nucleic acid purification</li> <li>• nucleic acid amplification</li> <li>• immunocapture</li> <li>• washing</li> <li>• blocking</li> <li>• ...</li> </ul>

129

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications



**Fig. 1:** Annual number of publications related to centrifugal microfluidics (Source: Thomson Reuters ISI web of science; search term: “centrifug\* AND (microfluid\* OR analyzer\* OR analyser” in the category “topic”; accessed on March 15, 2015) and landmarks in technology transfer. The highlighted landmarks were selected based on their importance for the field starting from the basic idea in 1969 through the era of centrifugal analyzers, the launch of the first diagnostic product in 1995 (Abaxis PiccoloXPress) and companies that generated basic IP in the field (such as Tecan and Gyros), to the market entry of several global players (3M, Roche, Samsung). Further information on the history of centrifugal microfluidics is given in section 5 “Embodiments of centrifugal microfluidic platforms”.

130

131

132

133

134

135

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

## 136 2.1 Physics of centrifugal microfluidics

137 In order to understand the unit operations used in centrifugal microfluidics, we hereby  
 138 introduce the forces that are exploited on this platform, as illustrated in **Fig. 2**. In general, we  
 139 differentiate between intrinsic forces—sub-classified into pseudo-forces and non-pseudo  
 140 forces—that are induced merely by the presence or absence of centrifugation, and extrinsic  
 141 forces resulting from the use of external means.

### 142 2.1.1 Intrinsic forces

143 **Pseudo-forces** are inertial body forces acting on fluids or particles in rotating systems. In  
 144 centrifugal microfluidics, they arise from the centripetal acceleration of the rotor and are  
 145 therefore easily controllable. Pseudo-forces comprise the centrifugal force ( $F_c$ ), Coriolis force  
 146 ( $F_{Co}$ ), and Euler force ( $F_E$ ). The forces exerted on a point-like body (mass  $m$ ) at position  $r$  in a  
 147 system rotating with an angular rotational frequency  $\omega$  are given by **Eq. 1-3**:

$$F_c = -m \omega \times (\omega \times r) \quad (1) \quad F_{Co} = -2 m \omega \times \frac{d}{dt} r \quad (2) \quad F_E = -m \frac{d}{dt} \omega \times r \quad (3)$$

148 For the basic design of fluidic elements, it is convenient to use scalar differential pressures  
 149  $\Delta p$  rather than vectorial forces  $F$ , so that the centrifugal pressure over a liquid column  
 150 (density  $\rho$ ) yields

$$\Delta p_c = \frac{1}{2} \rho \omega^2 (r_2^2 - r_1^2) \quad (4)$$

151 where  $r_1$  is the inner radial point, and  $r_2$  is the outer radial point of the liquid column.

152 Non-pseudo forces are present in rotating systems, as well as in non-rotating systems.  
 153 Hence, they are not limited to centrifugal platforms, but still play a major role in many  
 154 centrifugal unit operations. The most dominant and most exploited non-pseudo forces and  
 155 their corresponding differential pressures are the viscous dissipation ( $\Delta p_v$ ) (**Eq. 5**), pneumatic

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

156 force ( $\Delta p_p$ ) (**Eq. 6**) exerted by a pressurized gas, capillary force ( $\Delta p_{\text{cap}}$ ) (**Eq. 7**), and fluidic  
 157 inertia ( $\Delta p_i$ ) (**Eq. 8**).

$$\Delta p_v = -R_{\text{hyd}} q \quad (5) \quad \Delta p_p = p_0 \left( \frac{V_0}{V} - 1 \right) \quad (6) \quad \Delta p_{\text{cap}} = \sigma \kappa \quad (7) \quad \Delta p_i = -\rho l a \quad (8)$$

158 Here,  $R_{\text{hyd}}$  is the hydraulic resistance, which is proportional to the dynamic viscosity  $\eta$ ;  $q$  is  
 159 the volumetric flow rate;  $p_0$  denotes the ambient pressure;  $V_0$  is the volume of a gas bubble  
 160 at  $p_0$ ; and  $V$  is the gas volume in a compressed (or expanded) state. Furthermore, we define  
 161  $\sigma$  to be the surface tension of a processed liquid, and  $\kappa$  to be the curvature of its meniscus,  
 162 while  $l$  is the length of a fluidic channel filled with the liquid, and  $a$  is the acceleration of the  
 163 liquid.

164 In the case of particle transport in fluids, such as in sedimentation processes, the particles  
 165 are subject to a viscous force: the drag force ( $F_d$ ). It is given by


$$F_d = C_d \frac{\rho_{\text{fluid}}}{2} u^2 A_{\text{particle}} \quad (9)$$

166 where  $\rho_{\text{fluid}}$  and  $u$  are the density and velocity of the fluid relative to a particle, respectively;  
 167  $A_{\text{particle}}$  is the particle's cross sectional area; and  $C_d$  is the drag coefficient. For the laminar  
 168 flow regime (Stoke's drag), the drag coefficient is proportional to the fluid viscosity  $\mu$  and  
 169 inversely proportional to its velocity  $u$  relative to the particle, such that for a spherical particle  
 170 with radius  $r$ , the drag force yields

$$F_s = 6\pi \mu r u \quad (10).$$

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications



**Fig. 2:** Pseudo-forces acting in centrifugal microfluidics. While the centrifugal force always acts radially outward, the Coriolis force acts perpendicular to both  $\omega$  and the fluid velocity, and the Euler force is proportional to the angular acceleration.

172

### 173 2.1.2 Extrinsic forces

174 Extrinsic forces are used whenever centrifugation alone cannot fulfill the tasks to be  
 175 accomplished in a centrifugal microfluidic cartridge. Such forces can be magnetic, electric, or  
 176 pneumatic forces that bring fluids or particles into motion. The intentions of exploiting  
 177 extrinsic forces are manifold and range from the mixing of liquids using magnetic beads or  
 178 pneumatic stirring to the pumping of liquids and magnetophoretic or dielectrophoretic  
 179 separation.

180 Paramagnetic beads are commonly used in suspensions and attracted by external magnets  
 181 on- or off-chip. The magnetic force  $F_{\text{mag}}$  acting on a spherical paramagnetic bead exposed to  
 182 a magnetic flux density  $\mathbf{B}$  is given by

$$F_{\text{mag}} = V_{\text{bead}} \frac{\chi_{\text{bead}}}{\mu_0} (\nabla \mathbf{B}) \mathbf{B} \quad (11)$$

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

183 where  $V_{\text{bead}}$  is the volume of the magnetic bead,  $\chi_{\text{bead}}$  is its magnetic volume susceptibility,  
184 and  $\mu_0$  is the magnetic vacuum permeability. The susceptibility of the surrounding medium is  
185 neglected.

186 Electric forces can be applied in centrifugal systems via electrodes, which are preferably  
187 integrated into the microfluidic cartridge. This ensures the permanent and proximal exposure  
188 of samples to an electric field to perform electrolysis, dielectrophoresis, and other separation  
189 processes. The use of an external pneumatic pressure in centrifugal microfluidics can be  
190 realized in a non-contact fashion such as by directing a pressurized gas jet at certain  
191 openings of a rotating platform. Thus, the impact pressure of the gas is applied to the  
192 microfluidic network <sup>14</sup>.

193

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

## 194 **3 Unit Operations**

195 A microfluidic platform provides a set of validated fluidic unit operations, which are designed  
196 for easy combination within a standardized fabrication technology <sup>10</sup>. Unit operations are  
197 defined as the basic fluidic functionalities of a microfluidic platform. Examples of unit  
198 operations include liquid intake, reagent pre-storage and release, liquid transport, valving  
199 and switching, metering, aliquoting, mixing, and detection. Assemblies of unit operations  
200 enable the efficient implementation of various process chains, which are laboratory  
201 workflows and/or applications on a higher level of integration. Examples of such process  
202 chains include blood plasma separation, cell lysis, nucleic acid purification, nucleic acid  
203 amplification, immunocapture, washing, and blocking. In the following, prominent unit  
204 operations are introduced and discussed in the light of their applications.

### 205 **3.1 Sample and reagent supply**

206 It is inherently necessary to load the sample material and certain reagents for sample  
207 processing and analysis into the centrifugal microfluidic cartridge, either prior to or during  
208 processing. In more advanced applications and commercially available products, reagents  
209 are typically prestored in the cartridge to facilitate handling. Despite their importance, sample  
210 supply and reagent prestorage are seldom considered in academic publications. The  
211 following section will give an overview of the relevant concepts for sample loading and  
212 prestorage and the release of reagents in centrifugal microfluidic cartridges.

#### 213 **3.1.1 Sample supply**

214 In the majority of academic studies and some commercially available products (e.g., Abaxis  
215 Piccolo XPress), centrifugal microfluidic cartridges are loaded with the sample by manually  
216 pipetting them into microfluidic chambers via inlet holes using pipettes <sup>15</sup> or syringes <sup>16</sup>.  
217 Conversely, solutions for automated sample addition have been demonstrated using  
218 pipetting robots <sup>17</sup>. Both approaches to reagent supply, however, require open connections to

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

219 the environment and can only be performed while the cartridge is not rotating. The latter can  
220 be avoided by applying concepts for the non-contact addition of reagents onto rotating  
221 cartridges<sup>18 19 20</sup>.

222 The direct uptake of whole blood via a cartridge-integrated capillary was demonstrated by  
223 *Rombach* et al.<sup>21</sup>. An integrated capillary primes upon contact with a fingerprick blood  
224 sample and fills up with a defined volume. Subsequently, the blood is centrifuged to  
225 downstream processing chambers and directly processed by the cartridge to detect  
226 cholesterol. The uptake of whole blood by capillary forces was also integrated into the Roche  
227 Cobas b 101 system<sup>22</sup>.

### 228 **3.1.2 Integrated reagent prestorage**

229 For the commercialization of centrifugal microfluidics, it is important to facilitate the ease of  
230 use and reduce the hands-on time and cross contamination (e.g., via openings to the  
231 environment). This requires the integration of on-board reagent prestorage, and the  
232 controlled release of liquid reagents or rehydration of dry reagents at a certain assay step<sup>23</sup>.  
233 Furthermore, on-board reagent prestorage eliminates the risk associated with mixing  
234 reagents from different production batches, which facilitates quality control. Prestorage in  
235 general can be subdivided into the prestorage of liquids, dried reagents, and functional  
236 immobilisation of reagents onto surfaces. Whereas the prestorage of dried reagents and  
237 surface functionalizations are rather biochemical challenges and intensively discussed  
238 elsewhere<sup>24,25</sup>, this review focuses on liquid reagent prestorage and their release in  
239 centrifugal microfluidic cartridges. For a deeper insight into reagent prestorage in  
240 microfluidics in general, the interested reader is directed to *Hitzbleck* et al.<sup>23</sup>.

241 The prestorage of liquid reagents allows complete hands-off automation obviating the need  
242 for manual reagent addition during processing. The diverse nature of chemical and  
243 biochemical reagents, including alcohols, solvents, aqueous solutions, e.g., with a high salt  
244 concentration<sup>26</sup> or proteins and enzymes, renders their long-term stable prestorage

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

245 extremely challenging. Alcoholic reagents evaporate easily and therefore need to be  
246 prestored in materials with low vapor transmission rates. Solvents and aqueous solutions  
247 might chemically interact with the surrounding material. Proteins and enzymes can degrade  
248 over time, with a loss in activity or change in concentration in the solution as a result of  
249 adsorption to the cartridge and container material.

250 The concepts for the prestorage of liquid reagents can be roughly divided into two groups: (1)  
251 prestorage in suitable containers that are placed in the cartridge or (2) prestorage directly in  
252 microfluidic chambers on the cartridge. The prestorage of reagents in additional containers  
253 might be a superior way to reduce physical and chemical interactions between the reagent  
254 and the cartridge material (mainly polymers) and is less critical with respect to swelling, water  
255 uptake, and vapor transmission <sup>26</sup>. However, the required technologies for container  
256 fabrication and the mechanisms for releasing the reagents from the containers into the fluidic  
257 networks are more complex. Because of its advantages, commercially available centrifugal  
258 microfluidic systems like the Abaxis Piccolo Xpress <sup>27</sup> or Roche Cobas b 101 <sup>22</sup> use reagent  
259 prestorage in additional containers.

260 The long-term stable prestorage of liquid reagents for DNA extraction has been  
261 demonstrated by *Hoffmann* et al. <sup>26</sup>. Washing- and elution-buffers were encapsulated in glass  
262 ampoules, which were placed in the cartridge. To release the reagents into the microfluidic  
263 structures, the glass ampoules were crushed manually prior to processing. Ethanol and  
264 water have been prestored for time periods of up to 300 days without any noticeable losses.  
265 Glass ampoules have further been used to prestore rehydration buffer for lyophilized  
266 polymerase pellets (**Fig. 3b**) <sup>28</sup>. A prestorage concept with a release mechanism that solely  
267 relies on centrifugal forces was presented by *van Oordt* et al. Liquid reagents were packed in  
268 miniature stick packs, which were fabricated from vapor-tight aluminum composite foil. Liquid  
269 was released via a peelable seal <sup>29</sup> on the outer side of the stick pack by exceeding a defined  
270 centrifugal force (**Fig. 3a**). A 250- $\mu$ L quantity of 10% v/v isopropanol in water did not show

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications


271 any significant evaporation after storage at 70 °C for 21 days, which corresponded to 18  
272 months of storage at room temperature <sup>30</sup>. This concept has later been used by *Czilwik* et al.  
273 for prestorage and on-demand release of a rehydration buffer for PCR reagents <sup>31</sup>. The  
274 reagent release by centrifugation would furthermore enable the handling of highly wetting  
275 reagents, such as alcoholic buffer solutions, which could cause unwanted capillary priming of  
276 the microfluidic channel network if loaded to the disk in absence of centrifugal forces. The  
277 prestorage of highly reactive bromine water in inert Teflon or glass tubes sealed by ferrowax  
278 plugs was demonstrated by *Hwang* et al. The reagent release was controlled by melting the  
279 wax plugs via laser irradiation allowing the bromine to diffuse out while the diffusion was  
280 stopped after resolidification of the wax. This principle allowed the release of reagents in  
281 small increments depending on the progress of the chemical reaction <sup>32</sup>. *Kawai* et al.  
282 presented a rotatable reagent cartridge that was placed in a centrifugal microfluidic disk.  
283 Different reagents for an enzymatic L-lactate assay with volumes between 230 nL and 10 µL  
284 were sequentially released by rotating the container, and thereby connecting the respective  
285 compartment with the microfluidic channel network. The recovery of more than 96% of the  
286 prestored reagents was reported <sup>33</sup>.

287 Liquid reagent prestorage directly within a cyclic olefin polymer (COP) cartridge has been  
288 demonstrated with fluid reservoirs connected to the microfluidic system via optofluidic valves.  
289 Prestorage without noticeable fluid loss was demonstrated for a period of one month <sup>34 35</sup>.  
290 The prestorage of tetramethyl benzidine (TMB), washing buffer, and detection antibody  
291 solution directly in the cartridge was demonstrated by *Kim* et al. The single reservoirs were  
292 connected to the microfluidic network via ferrowax valves that were opened by laser  
293 irradiation <sup>36</sup>. A similar concept was used to connect the prestored liquids to the microfluidic  
294 channel network via wax valves with different melting temperatures, thereby making it  
295 possible to sequentially release liquids into the network by melting the valves using infra-red  
296 heating <sup>37</sup>.


Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

## a) Prestorage in miniature stick packs



## b) Prestorage in glass ampoules



**Fig. 3:** Different concepts for liquid reagent prestorage in containers. (a) Prestorage of liquids in miniature stick packs and release via peelable seal<sup>30, 29</sup>. (Reproduced with permission from The Royal Society of Chemistry) (b) Prestorage of liquid in glass ampoules and release by crushing the ampoules<sup>28</sup>. (Reproduced with permission from The Royal Society of Chemistry)

297

298 Recently, the Labtube was introduced as a new concept for centrifugal microfluidics based  
 299 on stacked microfluidic elements<sup>38</sup>. A centrifugally actuated ballpen mechanism enables the  
 300 simultaneous axial and rotatory movement of the stacked elements “revolvers” relative to  
 301 each other. A first revolver comprises cavities for the storage of reagents with pierceable  
 302 aluminum foil. A second revolver is equipped with lancing structures. The serial release of  
 303 reagents is controlled by the ballpen mechanism, which lances the reagent cavities either in  
 304 parallel or one after the other.

305 The prestorage of dry reagents is mostly conducted by drying reagents to the surface or  
 306 placing dry/lyophilized pellets or functional beads into microfluidic chambers during  
 307 fabrication. Drying of reagents directly onto the cartridge surface has successfully been  
 308 demonstrated for polymerase chain reaction (PCR) primers and probes<sup>39 40 41 42</sup> and  
 309 genomic DNA<sup>43</sup>. In another work, dry enzyme pellets for the detection of nitrite and  
 310 hexavalent chromium were prestored in microfluidic chambers on the cartridge. After a

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

311 storage period of 31 days in a desiccator, the relative standard deviation of the concentration  
312 adjusted absorbance was 7.91%<sup>44</sup>. The prestorage of lyophilized enzymes for DNA  
313 amplification was demonstrated by *Lutz et al.*<sup>28</sup> and *Strohmeier et al.*<sup>45</sup>.

### 314 **3.2 Transport of liquids**

315 A fundamental unit operation in centrifugal microfluidics is the transport of liquids within a  
316 fluidic network of channels and chambers. Typically, centrifugal forces, created by a defined  
317 rotation, have been exploited to transport fluids from a radially inward position (high level of  
318 potential energy) to a radially outward position (low level of potential energy). Because of the  
319 flow directed from the cartridge center radially outward, the number of cascadable unit  
320 operations and process chains is limited by the radius of the cartridge. In many cases, the  
321 available radius may not be large enough for the integration of all the process chains that are  
322 needed for a desired application. As a consequence, alternatives to the use of centrifugal  
323 forces to drive liquid transport in any direction—particularly radially inward—have been  
324 required and have recently been developed to enable the integration of larger and more  
325 complex fluidic networks.

326 A straightforward approach for pumping liquids radially inward was demonstrated by *Kong et*  
327 *al.*, and involved directing an external gas stream through orifices into a rotating microfluidic  
328 cartridge<sup>14</sup>. At closely defined spinning frequencies and gas flow rates, the gas displaces a  
329 liquid within the cartridge radially inward. Similar approaches for displacement pumping have  
330 been presented, employing an additional liquid that is introduced into a microfluidic cartridge.  
331 When the displacer liquid is pumped radially outward, it forces the sample liquid to move to a  
332 position situated closer to the center of rotation<sup>46 47</sup>.

333 Other approaches have exploited on-chip gas generation or expansion to displace and pump  
334 liquids. For this purpose, external heat sources have been used to heat up a gas volume  
335 entrapped in a microfluidic chamber, causing it to expand thermally. Thereby, water was  
336 transferred radially inward at constant spin frequencies between 5 and 20 Hz (**Fig. 4a**)<sup>48</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

337 The same principle was applied in reverse. A decrease in temperature was used for the  
338 thermal contraction of an entrapped gas volume. The resulting underpressure “pulled” the  
339 liquid into a chamber located at a radially inward position <sup>49</sup>. Instead of thermal expansion,  
340 the on-chip electrolysis of water has been used to generate a gas volume that displaces  
341 liquids radially inward (**Fig. 4c**) <sup>50</sup>. All of the methods described so far require additional  
342 external or disk-integrated means for operation (**Table 2**).


343 Recently, centrifugo-dynamic pumping has been presented, which does not require any  
344 external means but relies solely on the dynamics of deceleration from higher to lower spin  
345 frequencies <sup>51</sup>. At high spin frequencies, a sample liquid is directed into a microfluidic dead-  
346 end chamber, where it entraps and compresses an air volume. The access channel to this  
347 dead end chamber branches into a narrow inlet channel, through which the liquid enters a  
348 wider outlet channel. The fast deceleration to a low spin frequency (6 Hz) leads to a fast  
349 expansion of the compressed air volume and, because of the lower flow resistance, most of  
350 the liquid is pumped from the dead-end chamber through the wider outlet channel to a  
351 radially more inward position (**Fig. 4b**).

352 Other methods for temporary liquid displacement to a radially inward position include  
353 capillary priming <sup>52 53</sup>, pneumatic pumping <sup>54</sup>, magneto-pneumatic pumping <sup>55</sup>, and suction-  
354 enhanced siphon priming <sup>56</sup>. These pumping techniques do not transfer liquids permanently  
355 to a position situated radially more inward. Instead, they can be used for enhanced fluid  
356 control. In combination with siphon valves for example, these pumping techniques are used  
357 to prime the siphon for subsequent transfer of liquid to a radially outward position.


Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications


a) Pumping by thermal expansion



b) Pumping by electrolytic gas generation



c) Centrifugo-dynamic inward pumping



**Fig. 4:** Liquid transport on centrifugal microfluidic platforms exploiting (a) gas-overpressure generated by heat<sup>48</sup> (With kind permission from Springer Science and Business Media) and (b) electrolytic gas generation<sup>50</sup> (Reproduced with permission of the Electrochemical Society). In (c), air compression at high centrifugation, followed by air expansion at a low spin frequency is used in combination with different hydraulic resistances of the inlet and outlet channels to pump liquids radially inward<sup>51</sup>. (Reproduced with permission from The Royal Society of Chemistry)

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

**Table 2:** Pumping methods for liquid transfer radially inward.  $p_c$  = centrifugal pressure (Eq. 4);  $p_v$  = pressure loss due to viscous dissipation (Eq. 5) and  $p_{pneu}$  = pneumatic pressure (Eq. 6)

Reference	Actuation principle	External means	Actuation pressures	Pumping rate <sup>1</sup> [ $\mu\text{L/s}$ ]	Pump efficiency <sup>1</sup>
Zehnle S. et al. <sup>51</sup>	Centrifugodynamic	---	$p_c, p_{pneu}, p_v$	18.2	91%
Kong M.C.R. et al. <sup>46</sup>	Displacer liquid	---	$p_c, p_{pneu}$	0.6	60%
Noroozi Z. et al. <sup>50</sup>	Electrolytic gas generation	Electrical connection	$p_c, p_{pneu}$	9.0	100%
Abi-Samra K. et al. <sup>48</sup>	Thermal gas expansion	Radiation source	$p_c, p_{pneu}$	17.6	100%
Kong M.C.R. et al. <sup>14</sup>	Pneumatic (external)	Pressurized gas	$p_c, p_{pneu}$	1.1	100%

<sup>1</sup> Maximum values reported in the cited publication

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

### 360 **3.3 Valving and switching**


361 Valving is regarded as one of the most essential unit operations on the centrifugal  
362 microfluidic platform <sup>37</sup> because it controls the flow of the fluid through the fluidic network.  
363 Typical requirements include rapid liquid passage at a distinctive point in the spatio-temporal  
364 domain, compatibility with a broad range of physicochemical liquid properties, and low dead-  
365 volumes <sup>57</sup>. Valves can be grouped into active and passive valves, the latter referring to an  
366 actuation principle solely controlled by centrifugal forces <sup>57</sup>. Obviously, passive actuation is  
367 advantageous to reduce the need for external means, which add to the complexity of the  
368 entire centrifugal microfluidic system <sup>13</sup>. The initial state of a valve can be normally closed  
369 (NC) or normally open (NO). An overview of the implementations of valves in centrifugal  
370 microfluidics is given in **Table 3**. Embodiments of valves that feature more than one outlet  
371 and allow a liquid flow to be directed to a defined outlet are referred to as “switches”. The  
372 following sections discuss valves and switches, starting with passive ones.

#### 373 **3.3.1 Passive valves**

374 All embodiments of integrated passive valves in centrifugal microfluidics are implemented as  
375 normally closed. The burst or opening of a normally closed passive valve is triggered either  
376 by centrifugal pressure (Eq. 4), capillary forces (Eq. 7), or in rare cases the Rayleigh–Taylor  
377 instability on a liquid/gas interface. To describe valves using a reproducible model, the  
378 centrifugal pressures are recommended for all valves. The often-used rotational frequency is  
379 not sufficient without knowing the radial position, radial length of the liquid column, and  
380 density of the liquid. A graphical depiction of different implementations of passive valves is  
381 given in **Fig. 5**.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications



**Fig. 5:** Passive valves solely actuated by centrifugal forces (Eq. 1): (a) capillary, (b) hydrophobic, (c) burstable seal, (d) centrifugo-pneumatic overpressure, (e) centrifugo-pneumatic under pressure, (f) remotely vented collection chamber (e.g., by wetting a dissolvable film<sup>58</sup>), (g) remotely vented inlet chamber (e.g., by a clepsydra structure<sup>59</sup>), (h) capillary siphon, (i) overflow siphon, and (j) pneumatic siphon valve.

382

383 Early implementations of passive valves used the effect of liquid meniscus pinning at abrupt  
 384 and sharp channel widenings. To pass the valve, the centrifugal pressure (Eq. 4) has to  
 385 exceed the capillary counter pressure (Eq. 7). As the pinning effect of the fluid flow is solely  
 386 based on the capillary counter pressure, these valves are referred to as “capillary valves”  
 387 (**Fig. 5a**). Capillary valves have been demonstrated in complex fluidic networks, e.g., by  
 388 *Duffy et al.*<sup>60</sup> and *Lai et al.*<sup>61</sup>. Later, the flow sequencing of five different liquids using  
 389 capillary valves with different burst pressures (as a result of defined channel cross sections  
 390 at different radial positions) and parallel valving of up to 120 single 40-nL aliquots were  
 391 successfully demonstrated by *Madou et al.*<sup>62</sup> and *Schwemmer et al.*<sup>63</sup>, respectively. Multiple  
 392 studies have investigated the dependency of the burst pressure on the micro-channel  
 393 dimensions, surface tension, and contact angle of the liquid using analytical modeling<sup>64 65 66</sup>  
 394<sup>67</sup>. In that context, deviations in the dimensions and low surface quality have been identified  
 395 as critical parameters for burst pressure prediction and reproducibility<sup>60 64 66</sup>. To circumvent  
 396 stringent manufacturing requirements, the implementation of fused silica capillaries instead

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

397 of monolithically integrated capillary valves was reported <sup>68</sup>. Different burst pressures were  
398 realized by integrating fused silica capillaries with different inner diameters ranging from 12  
399 to 100  $\mu\text{m}$ . The concept of integrated fused silica capillaries was later adopted by *Kong et al.*  
400 <sup>46</sup> and *Kazarine et al.* <sup>69</sup>.

401 Geometric capillary valves become increasingly unstable for wetting liquids when the contact  
402 angles drop below  $45^\circ$  <sup>70</sup>. To increase the reproducibility for liquids with low contact angles,  
403 local hydrophobic surface coatings have been applied. The valving principle is then based on  
404 stopping a liquid flow at the hydrophobic coating, and corresponding valves are referred to as  
405 "hydrophobic valves" (**Fig. 5b**). The flow continues when the centrifugal pressure (Eq. 4)  
406 overcomes the capillary pressure (Eq. 7). The demonstrated surface coatings include mostly  
407 fluorinated polymer solutions, which are applied by spraying <sup>71</sup> or dispensing <sup>72</sup>. An example  
408 of the highly parallel integration of 208 hydrophobic valves was given by *Honda et al.* <sup>73</sup>.  
409 Another approach demonstrated rapid surface modification for hydrophobic valves by means  
410 of a laser printer. Printed toner spots in a microchannel led to an increase in the contact  
411 angles from  $51^\circ$  to  $111^\circ$  (measured for DI-water). Depending on the density of the toner  
412 spots, a broad range of burst pressures, ranging from  $158 \pm 18 \text{ Pa}$  to  $573 \pm 16 \text{ Pa}$ , was  
413 realized <sup>74</sup>.

414 Another approach to circumvent the need for local surface coatings and high-precision  
415 manufacturing, termed "centrifugo-pneumatic valve" (**Fig. 5d**), was demonstrated by *Mark et*  
416 *al.* Here, the liquid flow is stopped by a combination of the capillary counter pressure (Eq. 7)  
417 at the interface of a channel to a dead-end chamber and the pneumatic counter pressure  
418 (Eq. 6) of the compressed air inside the dead-end chamber. Valving is triggered by the  
419 centrifugal pressure (Eq. 4) overcoming the counter pressures. After the breakthrough, the  
420 complete release of the liquid is ensured by the Rayleigh–Taylor instability of the liquid/air  
421 interface. Centrifugo-pneumatic valving makes it possible to handle highly wetting/low  
422 surface tension liquids with reported burst pressures of  $1300 \pm 400 \text{ Pa}$  for ethanol and  $14000$

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

423  $\pm 2800$  Pa for water <sup>75</sup>. The centrifugo-pneumatic valve was later combined by *Gorkin* et al.  
424 with an integrated water-dissolvable membrane. The membrane was applied to close an  
425 outlet of the dead-end chamber, which allowed centrifugo-pneumatic valving. After contact  
426 with the liquid, the membrane dissolved in as little as 10 seconds, which allowed for  
427 downstream fluidic post processing <sup>76</sup>. Subsequently, microfluidic networks have been  
428 presented with multiple integrated dissolvable films to allow the auto-cascading of valving  
429 sequences <sup>77</sup>. An inversion of the centrifugo-pneumatic valve, representing a centrifugo-  
430 pneumatic under pressure valve (**Fig. 5e**), was reported by *Siegrist* et al. The liquid is initially  
431 allocated in an unvented inlet chamber, and a retaining pneumatic under pressure (Eq. 6) in  
432 the enclosed air volume is generated when the liquid is forced radially outward through the  
433 centrifugo-pneumatic under pressure valve during rotation <sup>78</sup>. *Faqhiri* et al. demonstrated that  
434 burst pressures in both centrifugo-pneumatic over- and under pressure valves can be  
435 controlled by blocking air vents with an auxiliary liquid <sup>79</sup>.

436 To handle evaporating reagents, vapor-tight valves are required. *Hoffmann* et al. presented a  
437 valve that applied centrifugal pressure (Eq. 4) for the well-defined delamination of the sealing  
438 foil of a centrifugal microfluidic cartridge, thereby opening up the fluidic pathway. This valve  
439 is called a "burstable seal valve" (**Fig. 5c**). For centrifugal pressures of 2 bar, release times  
440 of 31 s were reported <sup>80</sup>. In another approach, polydimethylsiloxane (PDMS) membranes  
441 were integrated into a microfluidic network to close the fluidic pathway by bonding the PDMS  
442 membrane to the thermoplastic cartridge. With increasing centrifugal pressure (Eq. 4), the  
443 membrane is deflected and opens up the fluidic pathway. Depending on the membrane  
444 thickness and spin speed, various flow rates were achieved <sup>81</sup>.

445 In contrast to passive valves that open with an increase in centrifugal pressure, "capillary  
446 siphon valves" (**Fig. 5h**) require a temporary state of low centrifugal pressure (Eq. 4) to  
447 trigger the burst event <sup>82</sup>. This valving principle is based on the capillary priming of an S-  
448 shaped siphon channel and thus requires advancing contact angles  $<90^\circ$ . The siphon

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

449 channel connects an inlet reservoir and outlet reservoir and has to fulfill the following  
450 requirements: (a) the inlet of the siphon is located radially inward of the outlet and (b) the  
451 crest of the siphon is situated radially inward of the filling level of the inlet reservoir <sup>3</sup>. The  
452 siphon channel is thus primed by capillary forces (Eq. 7) against the direction of the  
453 centrifugal forces at a low spin speed, while at higher spin speeds, the centrifugal forces  
454 dominate and prevent capillary priming <sup>82</sup>. After priming the siphon, the inlet reservoir is  
455 emptied through the outlet at a sufficiently high centrifugal pressure. *Siegrist* et al.  
456 demonstrated flow sequencing based on serial siphon valving, i.e. the concatenation of  
457 multiple capillary siphons with integrated capillary valves. The integrated capillary valves  
458 prevent the premature priming of the capillary siphon and allow for the release of liquid after  
459 a defined number of rotate-and-halt cycles. However, this results in a minor dead-volume of  
460 liquid that does not reach the outlet. In this approach, plasma treatment has been  
461 recommended to render the surface hydrophilic for liquids with contact angles  $>90^\circ$  <sup>83</sup>.  
462 Because many of the materials used for centrifugal microfluidic cartridges exhibit  
463 hydrophobic properties and surface treatment adds to the complexity of cartridge fabrication,  
464 *Godino* et al. demonstrated the integration of paper-based siphons as a low-cost alternative  
465 <sup>84</sup>. Alternatively, siphon valves can be primed by increasing the filling height inside the inlet  
466 chamber above the siphon crest by adding additional liquid. Such valves are referred to as  
467 “overflow siphon valves” (**Fig. 5i**) <sup>6</sup>.

468 To circumvent the demand for hydrophilic coatings, siphon priming by the release of  
469 pneumatic energy (Eq. 6) from an enclosed and compressed air bubble was exploited in the  
470 so-called “pneumatic siphon valve” (**Fig. 5j**) <sup>54</sup>. Later, the cascading of pneumatically  
471 actuated siphons for sequential release was employed <sup>85</sup>. Another approach demonstrated  
472 suction-enhanced siphon priming by creating an under pressure at the siphon outlet through  
473 an auxiliary liquid. However, in this approach, the siphoned reagent inevitably mixes with the  
474 auxiliary liquid <sup>56</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

475 A small group of passive valves does not rely on centrifugal pressure but provides a time-  
476 dependent release of liquids. Recently, *Schwemmer* et al. introduced a microfluidic timer that  
477 could be used to trigger liquid actuation independent from the spinning speed: The timer  
478 employs temporary storage of pneumatic energy (Eq. 6), which is suddenly released after a  
479 pre-defined period of time. The timer is set by overfilling a first pneumatic chamber, which  
480 results in liquid flowing into a secondary pneumatic chamber through a narrow channel at  
481 high rotational frequencies. Upon decrease of centrifugal pressure (Eq. 4), emptying of the  
482 secondary chamber and channel results in a delay before the pneumatic energy is released  
483 <sup>86</sup>. *Kinahan* et al. demonstrated the integration of a paper strip into a centrifugal microfluidic  
484 cartridge. This paper strip is “connected” to multiple integrated dissolvable films that  
485 sequentially open fluidic pathways as soon as the part of the paper strip in contact with the  
486 dissolvable film is wetted <sup>58</sup> (**Fig. 5f**). *Kinahan* et al. also demonstrated event-triggered  
487 valving, where the completed valving of one liquid opens an air vent by dissolving a film to  
488 triggering the valving of a next liquid. By combination of a fluidic network with dissolvable  
489 films 10 sequential valving events at one rotational frequency were demonstrated in a single  
490 cartridge <sup>87</sup>. *Ukita* et al. reported a microfluidic clepsydra structure connected to the venting  
491 of a loading structure for the sequential release of liquids. Over time, the liquid level in the  
492 clepsydra decreases and thereby sequentially opens the venting for the single loading  
493 structures <sup>59</sup> (**Fig. 5g**).

### 494 3.3.2 Active valves

495 Active valves are controlled by external means and therefore require additional interfaces to  
496 the processing device or user. Active valves have the advantage of being either normally  
497 open or normally closed during fluidic processing. In rare cases, the normally open and  
498 closed states are reversible <sup>88</sup>.

499 Optofluidic valves actuated by a solid state laser were reported by *Garcia-Cordero* et al.  
500 Printed toner spots on a polymer separation layer, COP or polyethylene terephthalate (PET)

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

501 film, were used to increase the light absorbance to melt orifices (30–280  $\mu\text{m}$  in diameter) into  
502 the separation layer, thereby opening the fluidic pathway. When using 100 and 300 mW of  
503 laser power, the response time of the valve was reported to be 0.5 seconds. A fluidic network  
504 with 106 laser printed single addressable optofluidic valves has been presented. Contact  
505 between the liquid and valve had to be avoided during melting because the liquid could be  
506 contaminated by combustion products and absorb thermal energy <sup>35</sup>.

507 Instead of melting the cartridge substrate, paraffin wax valves have been integrated into  
508 centrifugal microfluidic cartridges. Stationary infrared sources were used to melt the wax  
509 under rotation, thereby opening the fluidic pathway. The sequential opening of valves has  
510 been demonstrated by using waxes with different melting temperatures. Response times of  
511 25 seconds were reported for the simultaneous actuation of nine valves <sup>37</sup>. Another approach  
512 used handheld heat guns instead of infrared lamps to melt wax valves <sup>89</sup>. However, it has to  
513 be considered that the molten wax and heat input to the cartridge could have a negative  
514 effect on the reagents used <sup>37</sup>. As an improvement to overcome these limitations, *Al-Faqheri*  
515 et al. relocated the wax valves away from the reagents, thereby preventing direct contact.  
516 Instead of opening the fluidic pathway, connections to the air vents were opened or closed by  
517 melting the valves <sup>57</sup> (**Fig. 6b**).

518 Aiming at minimizing the energy input, single addressable, laser-irradiated ferrowax  
519 microvalves (LIFM) were introduced by *Park* et al. <sup>88</sup> and later implemented for different  
520 applications <sup>90</sup>. For efficient heating, iron oxide nanoparticles were mixed into the wax, which  
521 allowed valve actuation via low-power lasers (1.5 W) and a response time of only  
522 0.5 seconds. The laser ensured that only the nanoparticles were heated and not the  
523 surrounding liquids. The LIFM were reported to be leak-free at a centrifugal pressure of up to  
524  $403.0 \pm 7.6$  kPa. Normally closed, normally open, and even reversible valve actuation has  
525 been demonstrated (**Fig. 6a**).

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust


Title: Centrifugal microfluidic platforms: advanced unit operations and applications

526 *Amasia* et al. demonstrated ice valving to avoid evaporation during PCR thermocycling.  
 527 Liquid plugs were frozen in defined channel areas when the disk was at rest using  
 528 thermoelectric modules. The response time for these ice valves was 30 seconds<sup>91</sup>.


529 An alternative to using thermal energy for active valving has been demonstrated by *Swayne*  
 530 et al. A focused air stream opens a fluidic path for the liquid, which had previously been  
 531 blocked by a gel. Postulated advantage of the valve are the small footprint and ease of  
 532 fabrication<sup>92</sup>.

a) Ferrowax valves


**B. NC-LIFM : closed to open state**



**C. NO-LIFM : open to closed state**



b) Vacuum / Compression valve



**Fig. 6:** Prominent concepts for active valving. (a) *Park* et al. demonstrated laser irradiated ferrowax microvalves (LIFM) to open and close the fluidic pathways of normally closed LIFM (NC-LIFM) and normally opened LIFM (NO-LIFM), respectively, activated by a laser diode (LD)<sup>88</sup>. The layout includes assistant valve chambers (AVC) (Reproduced with permission from The Royal Society of Chemistry). (b) *Al-Faqheri* et al. used wax plugs to open connections to the ventilation<sup>57</sup>. (Reproduced under the Creative Commons Attribution License O)

533

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

**Table 3:** Overview of implementations of passive and active valves in centrifugal microfluidics. NC = normally closed; NO = normally open;  $p_c$  = centrifugal pressure (Eq. 4);  $p_{cap}$  = capillary pressure (Eq. 7);  $p_{cap\ hydrophobic}$  = counter pressure of hydrophobic capillary (Eq. 7), and  $p_{pneu}$  = pneumatic counter pressure (Eq. 6).

Reference	External means	Actuation principle	Mode	Vapor-tight
Lai S. et al. <sup>61</sup>	---	$\Delta p_c > \Delta p_{cap}$	NC	-
Duffy D.C. <sup>60</sup>	---	$\Delta p_c > \Delta p_{cap}$	NC	-
Gorkin R. et al. <sup>76</sup>	---	Integrated film dissolves when brought into contact with liquid. Fluidic pathway is opened.	NC	✓
Mark D. et al. <sup>75</sup>	---	$\Delta p_c > \Delta p_{cap} + \Delta p_{pneu}$	NC	-
Andersson P. et al. <sup>71</sup>	---	$\Delta p_c > \Delta p_{cap\ hydrophobic}$	NC	-
Siegrist J. et al. <sup>83</sup>	---	$\Delta p_{cap} > \Delta p_c$	NC	-
Gorkin R. et al. <sup>56</sup>	---	Pressure drop at T-junction caused by auxiliary liquid pulls sample liquid over siphon crest.	NC	-
Hwang H. et al. <sup>81</sup>	---	Integrated membrane valve opens above critical centrifugal pressure. Fluidic pathway is opened.	NC	✓ <sup>(2)</sup>
Gorkin R. et al. <sup>54</sup>	---	$\Delta p_{pneu} > \Delta p_c$	NC	-
LaCroix–Fralish A. et al. <sup>68</sup>	---	$\Delta p_c > \Delta p_{cap}$	NC	-
Hoffmann J. et al. <sup>80</sup>	---	Delamination of weakly bonded interface by exceeding critical centrifugal pressure. Fluidic pathway is opened.	NC	✓
Ukita Y. et al. <sup>59</sup>	---	Time-dependent decrease of fill level opens connection to venting <sup>1)</sup> .	NC	✓ <sup>(2)</sup>
Zhang H. et al. <sup>67</sup>	---	$\Delta p_c > \Delta p_{cap\ hydrophobic}$	NC	-
Kinahan D.J. et al. <sup>58</sup>	---	Integrated film dissolves when brought into contact with liquid on paper strip. Air vent is opened <sup>1)</sup> .	NC	✓
Kinahan D.J. et al. <sup>87</sup>	---	First liquid dissolves a film to trigger valving of the a next liquid	NC	✓ <sup>(2)</sup>
Siegrist J. et al. <sup>78</sup>	---	$\Delta p_c > \Delta p_{pneu}$	NC	-
Abi–Samra K. et al. <sup>37</sup>	Active: Stationary halogen lamp	Integrated wax valves melted by infrared heating. Fluidic pathway is opened.	NC	✓
Park J.M. et al. <sup>88</sup>	Active: Mobile laser diode	Integrated ferrowax valves are melted by laser. Fluidic pathway is opened or closed.	NO/NC/reversible	✓
Amasia M. et al. <sup>91</sup>	Active: Thermo-electric module	Freezing of a liquid plug blocks fluidic pathway.	NO	✓
Garcia–Cordero J.L. et al. <sup>35</sup>	Active: Laser	Laser melts orifices in polymer separation layer. Fluidic pathway is opened.	NC	✓
Al-Faqheri W. et al. <sup>57</sup>	Active: Hot air gun	Integrated wax valves are melted by heat gun. Connection to venting is opened <sup>1)</sup> .	NO/NC	✓

<sup>1)</sup>Valving principle based on reduction of under pressure after defined opening of air vents.

<sup>2)</sup>Vapor-tightness has not been demonstrated, but valve is expected to be vapor-tight.

### 534 3.3.3 Passive flow switches

535 Similar to passive valves, passive switches are solely controlled by centrifugation (centrifugal  
536 pressure (Eq. 4) and the direction of rotation). Early approaches for flow-switching were

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

537 presented by *Brenner* et al. using an inverse Y-channel with one inlet channel and two  
538 outlets. At low spin-frequencies, the liquid from the inlet channel is equally distributed  
539 between the two outlet channels and is only affected by the manufacturing tolerances of the  
540 channels. At increased spin speeds, the liquid is directed toward one of the outlet ports as a  
541 result of the transversal Coriolis force (Eq. 2). Hence, switching the liquids depends on the  
542 direction and speed of the rotation and the corresponding Coriolis force<sup>93</sup>. The functionality  
543 of the Coriolis switch was later investigated extensively by analytical means<sup>94</sup>. *Thuy* et al.  
544 presented a passive flow switch consisting of an inlet channel branching into two outlet  
545 channels, one with a hydrophobic valve that could be controlled by the rotational speed of  
546 the cartridge. At high rotational frequencies, liquid is routed through the channel with the  
547 hydrophobic valve. At low spin speeds, the hydrophobic valve does not break and liquid  
548 overflows into the other channel.<sup>95</sup>

549 Other approaches for passive flow switching have been demonstrated, including that based  
550 on fluidic capacitance by *Kim* et al.<sup>94</sup> and that based on the pneumatic counter pressure (Eq.  
551 6) of an enclosed air volume by *Mark* et al. The latter exploits centrifugal pressures (Eq. 4),  
552 depending on the speed of rotation to direct liquids to either one of the outlets<sup>96</sup>. Later,  
553 *Müller* et al. demonstrated passive unidirectional switching by closing the connection to the  
554 venting with the overflow volume of one of the assay reagents<sup>97</sup>.

### 555 3.3.4 Active flow switches

556 Active flow switches are controlled by other means than centrifugal pressure. However, they  
557 have the obvious disadvantage of requiring external means. *Al-Faqheri* et al. demonstrated  
558 the use of wax plugs to block or unblock connections to the venting hole when heated.  
559 However, the outlet chamber for a liquid is predefined by the microfluidic network because  
560 the liquid is always directed into the vented microfluidic chamber. Heating times of 8 minutes  
561 were reported to open the melt wax plugs<sup>57</sup>. Another active flow switch was demonstrated by  
562 *Thio* et al. By heating up enclosed air volumes with a hot air gun and then cooling them,

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

563 liquids could be pumped and pulled into different microfluidic chambers. Liquid transfer times  
564 of 3.7–8.3 minutes were reported <sup>49</sup>. *Kong* et al. demonstrated active flow switching by  
565 directing a gas stream from outside the disk through one of two orifices into the microfluidic  
566 network. A liquid could thereby be directed to one of two fluidic chambers <sup>98</sup>. Switching based  
567 on the use of heat to melt wax plugs <sup>57</sup> or for thermal air expansion <sup>49</sup> clearly lacks actuation  
568 speed, while gas pressure-based <sup>98</sup> systems require an open hole within the cartridge, which  
569 might be critical in terms of cross contamination.

### 570 **3.4 Metering and aliquoting**


571 Most microfluidically integrated applications require precise input volumes of liquids in order  
572 to obtain quantitatively reproducible results. Consequently, unit operations for the metering of  
573 liquid volumes are widely employed. Splitting an input liquid volume into multiple defined sub-  
574 volumes is referred to as aliquoting, which mostly involves multiple parallel metering steps.  
575 Aliquoting itself was subcategorized by *Mark* et al. into one-stage and two-stage aliquoting  
576 (**Fig. 7b**). The latter refers to a microfluidic aliquoting process in which single aliquots are  
577 transferred into fluidically separated chambers after metering <sup>99</sup>. The embodiments of  
578 centrifugal microfluidic unit operations for metering and aliquoting are listed in **Table 4**. In the  
579 simplest case, a metering structure consists of a connection channel to an inlet, a metering  
580 chamber with a defined volume, and an overflow to a waste chamber for excess volume (**Fig.**  
581 **7a**). The metering can be combined with valves at the radially outer end of the metering  
582 chamber to allow for further fluidic processing. The demonstrated valves include hydrophobic  
583 <sup>71</sup>, capillary siphon <sup>100</sup>, and centrifugo-pneumatic valves <sup>75</sup>. The metering accuracy is mainly  
584 affected by the variation of the cavity size within the fabrication tolerances <sup>99</sup> and the wicking  
585 effects at liquid interfaces due to capillary forces <sup>101</sup>. Capillary forces (Eq. 7) can be  
586 counteracted by centrifugal forces (Eq. 4), which produces a high metering accuracy in  
587 centrifugal microfluidics even at nanoliter volumes.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

588 In single-stage aliquoting, fluid volumes are metered directly into the receiving chamber.  
 589 Thus, the aliquoting process simply involves the transport of the liquid from an inlet into  
 590 multiple receiving chambers, while the excess is gated into an overflow. As mentioned by  
 591 *Mark et al.*, single stage aliquoting bears the problem of cross contamination between  
 592 adjacent aliquots, because they might still be connected by a liquid film <sup>99</sup>. To avoid cross  
 593 contamination, *Sundberg et al.* used a mineral oil to fill the microfluidic channel and separate  
 594 the aliquoted volumes after the aliquoting process <sup>102</sup>.

595 Two-stage aliquoting allows for full fluidic separation between adjacent aliquots, and  
 596 therefore is usually applied when cross contamination is an issue <sup>39</sup>, or when further fluidic  
 597 processing of the individual aliquots is required. Two-stage aliquoting combines the parallel  
 598 metering of one-step aliquoting with normally closed valves at the radial outer side of each  
 599 metering finger. After metering, the single aliquots can pass the valve and be used for further  
 600 fluidic processing <sup>71 32</sup>.



**Fig. 7:** Centrifugal microfluidic unit operations for metering and aliquoting. (a) Basic principle of metering. A liquid fills a metering chamber with a defined volume. The excess is gated into a waste chamber. The metered volume can subsequently be transferred into the microfluidic network via suitable valves. (b) Different aliquoting concepts <sup>99</sup>. (With kind permission from Springer Science and Business Media)

601

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

**Table 4:** Centrifugal microfluidic unit operations for metering and aliquoting.

Reference	Integrated valve type	Aliquoted volume	CV	Number of parallel aliquots
Schembri C. T. et al. <sup>82</sup>	No valve	Not reported	<2%	4 or 21
Sundberg S. O. et al. <sup>102</sup>	No valve	33 nl	16%	1000
Andersson P. et al. <sup>71</sup>	Hydrophobic valve	200 nl	0.75%	112
Andersson P. et al. <sup>71</sup>	Hydrophobic valve	20 nl	1.90%	1
Mark D. et al. <sup>99</sup>	Centrifugo pneumatic valve	6–10 $\mu$ l	2.2%–3.6%	8 or 16
Steigert J. et al. <sup>100</sup>	Capillary siphon	500 nl	<5%	1
Schwemmer F. et al. <sup>63</sup>	Capillary valve	40 nl	1%–5.5%	120
Li G. et al. <sup>103</sup>	Capillary valve	31 nl	2.80%	24
Hwang H. et al. <sup>32</sup>	Ferrowax-based microvalves	100 $\mu$ l	Not reported	5

602

603

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

### 604 3.5 Mixing

605 The purpose of mixing in microfluidics is to reach a sufficiently high distribution and  
606 homogeneity of sample and reagent molecules such that chemical reactions are accelerated.

607 Conventional mixing in macroscopic standard laboratory processes is mostly performed by  
608 stirring, shaking, or vortexing. However, on a centrifugal microfluidic platform, mixing

609 becomes difficult because the cartridge is rigidly attached to a motor shaft, which rotates the  
610 cartridge with a relatively high moment of inertia. The artificial gravity generated by this

611 rotation makes the centrifugal microfluidic platform particularly useful for the separation of  
612 phases with different mass densities, but not for mixing. Moreover, for liquid volumes ranging

613 from several hundred nanoliters to a few milliliters, purely diffusive mixing is rather inefficient  
614 <sup>104 105</sup>. Since mixing is nevertheless crucial for many biochemical assays, several methods

615 have been researched to mix fluids on the centrifugal microfluidic platform.

616 A concept for the batch-wise “shake-mode” mixing of liquids that relied on continuous  
617 changes in the spin speed of the centrifugal microfluidic cartridge was demonstrated by

618 *Grumann* et al. The angular momentum caused by the acceleration or deceleration induced  
619 Euler forces (Eq. 3) and resulted in layer inversion of the liquids in the microfluidic chamber

620 (**Fig. 8a**). As a measure of the mixing quality, the standard deviation of all the recorded pixel  
621 grayscale values of a mixture containing dyed and undyed liquids was determined using

622 image processing. The mixing time was defined as the time required to reach a 1/e decay in  
623 the standard deviation. As a result, the mixing time in the reported embodiment could be

624 reduced from 7 minutes for purely diffusive mixing down to 3 seconds for shake-mode  
625 mixing. It was found that the mixing quality depended on the acceleration and deceleration

626 rates, as well as the azimuthal span of the rotation and radial position of the mixing chamber.

627 Adding magnetic beads and pulling them through the mixing chamber further reduced the  
628 mixing time to 0.5 seconds. A deflection of the magnetic beads was induced by a set of

629 external permanent magnets that attracted the beads radially in- and outward <sup>104</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

630 *Noroozi* et al. presented another mixing concept that employs the interplay of centrifugal and  
631 pneumatic pressures (Eq. 4 and 6) to transport liquids between two chambers (**Fig. 8 c**)<sup>106</sup>.  
632 This mixing-by-reciprocation concept was later used to maximize the incubation and  
633 hybridization efficiency for the centrifugal microfluidic integration of an immunoassay and  
634 showed a reduction in the processing time and reagent consumption by one order of  
635 magnitude<sup>107</sup>. In this approach, mixing occurs due to micro-vortices and Taylor dispersions,  
636 which are both present in each mixing cycle. The use of the pneumatic counter-pressures of  
637 an entrapped air volume enables frequency oscillations at elevated spin speeds, thus making  
638 mixing by reciprocation easily combinable with pneumatic siphon valving.

639 Instead of pneumatic energy storage, *Aeinehvand* et al. recently integrated a latex  
640 membrane in a stack of PMMA layers and pressure sensitive adhesives. At the radial distal  
641 end of the mixing chamber, the latex membrane could freely expand out of the disk plane  
642 through a hole in the solid PMMA, thus forming a micro-balloon. The reciprocating flow of the  
643 reagents to be mixed was induced by oscillations of the spin frequency. At a high spin speed,  
644 the centrifugal pressure drove the reagents into the inflating micro-balloon, thereby stretching  
645 the latex membrane. At rest, the absence of the centrifugal pressure allowed the latex  
646 membrane to return to its initial flat shape. This version of mixing by reciprocation was  
647 proven to be suitable for low operating frequencies in the range of 0-14 Hz and chamber  
648 depths in the range of a few hundred micrometers. For such shallow chambers, mixing by  
649 reciprocating the flow was shown to be a good alternative to shake-mode mixing<sup>108</sup>. This is  
650 because shake-mode mixing requires moderate aspect ratios in the range of one to provide  
651 sufficient advection.

652 Mixing based on Coriolis pseudo-forces (Eq. 2) was demonstrated by *Haeberle* et al. Here,  
653 two liquids were dispensed into two separate microfluidic inlets on the centrifugal microfluidic  
654 cartridge (**Fig. 8b**). These liquids merged within a Y-shaped channel, where they were mixed  
655 due to transversal convection as a result of the Coriolis forces acting perpendicular to the

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

656 flow direction. After mixing, the product was spun from the cartridge into a receiving vessel,  
657 thereby allowing for continuous mixing <sup>109</sup>. Coriolis mixing was later improved by the  
658 multilamination of flows via a split-and-recombine concept <sup>110</sup>. In another work, Coriolis  
659 mixing was used to fold laminar flows and thereby shorten mixing times by two orders of  
660 magnitude <sup>111</sup>. Further investigations on the mixing regimes of two fluids in a T-shaped  
661 microchannel showed Coriolis force-based mixing at intermediate spin speeds <sup>112</sup>. The  
662 channel geometry, speed of rotation, and flow rates were identified as key impact parameters  
663 on the mixing quality. <sup>110 113</sup> Recently, Coriolis mixers have been employed in serpentine  
664 configurations that also use the Dean effect in channel bends to improve the overall mixing  
665 efficiency. <sup>114 115</sup> The independence from changes in the spin speed makes Coriolis mixing  
666 suitable for applications on a wide range of processing devices, e.g., standard laboratory  
667 centrifuges. A challenge for the integration of Coriolis mixing is that the flow rates of the fluids  
668 entering the mixing channels have to be accurately controlled.


669 Other approaches for mixing at a constant spin speed have recently been explored. Burger  
670 et al. used the disruption of continuous liquid flows to generate discrete droplets and create  
671 multiple alternating lamellae with two different liquids. In this way, the interface between the  
672 two liquid phases was significantly increased, and mixing by diffusion was supported. By  
673 generating droplets with of 60-nL volumes, blood plasma and PBS were mixed and divided  
674 into single aliquots. The protein concentrations in all of the aliquots showed good agreement  
675 with the value expected for a perfect mixture <sup>6</sup>.

676 *Liebeskind* et al. used the catalytic decomposition of H<sub>2</sub>O<sub>2</sub> to water and oxygen as an on-  
677 chip gas source to generate gas bubbles for mixing. The generated gas was pumped into a  
678 mixing chamber, where, due to the buoyancy force in the artificial gravitational field, the  
679 bubbles moved through the liquids to be mixed and caused perturbations. The mixer was  
680 used to perform the lysis and binding steps in the extraction of DNA from whole blood <sup>116</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

681 Active mixing employing an external air stream was used by *Kong* et al. to stir liquids within a  
 682 microfluidic chamber. The air stream was directed from outside the disk through an orifice  
 683 into the microfluidic structures, which allowed mixing at constant and low spin frequencies.  
 684 Within 11.2 seconds, a 30-fold increase in mixing quality was reported compared to diffusive  
 685 mixing at a spin frequency of 7.5 Hz <sup>117</sup>.



**Fig. 8:** Different concepts for mixing of liquids employed in centrifugal microfluidics. (a) Shake-mode mixing at alternating spin frequencies <sup>104</sup>. (Reproduced with permission from The Royal Society of Chemistry) (b) Coriolis mixing exploiting Coriolis force induced transversal flow <sup>109</sup>. (Preprinted with permission of John Wiley and Sons) (c) Mixing by reciprocating the flow at alternating spin frequencies <sup>107</sup> (Reprinted with permission from AIP Publishing LLC).

686

### 687 3.6 Separation

688 The separation of different substances from each other is an essential unit operation in many  
 689 (bio-) chemical processes. The target substances can be small molecules such as  
 690 metabolites, macromolecules like nucleic acids and proteins, and larger elements such as

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

691 cells or solid particles that have to be isolated from a surrounding medium. Typically,  
692 differences in the chemical or physical properties of these substances are exploited for the  
693 technical implementation. This review chapter is structured as follows. First, we review  
694 publications on physical separation techniques, including filtering and sedimentation,  
695 followed by a discussion of the implementations of chemical separation within centrifugal  
696 microfluidics.

### 697 **3.6.1 Separation based on differences in physical properties**

698 The majority of physical separation techniques that have been demonstrated on centrifugal  
699 microfluidic platforms are based on filtering and sedimentation. In microfluidic structures,  
700 filtering can be used to remove or concentrate solid particles from a liquid phase based on  
701 the particle size. Pre-filtering can be implemented to avoid clogging microfluidic channels<sup>68</sup>  
702 or to prevent negative interference with the assay if the permeate, the liquid that passes the  
703 filter, is processed in the downstream application. Other implementations employ filtering to  
704 enhance the assay sensitivity by concentrating cells or bacteria in the retentate, the  
705 substances that are retained by the filter. Instead of particle size, sedimentation exploits  
706 density differences between the separated element and the surrounding media. Driven by  
707 centrifugal forces (*Eq. 1*), denser objects sediment radially outwards along the centrifugal  
708 force vector, while the cleared supernatant can be transferred to downstream microfluidics.  
709 Typical applications for sedimentation include the removal of solid particles or blood cells.  
710 These are explained in more detail in the corresponding application section.

711 Filtering by cartridge-integrated geometric restrictions was demonstrated by *Czugala et al.* In  
712 this implementation, the height of a microfluidic channel was decreased step-wise from 1500  
713  $\mu\text{m}$  to 86  $\mu\text{m}$ . Via these restrictions, up to 94% of the particles were filtered from a river-water  
714 sample and used for downstream analysis<sup>118</sup>. Instead of geometric restrictions, filter  
715 membranes have successfully been integrated into centrifugal microfluidic cartridges to  
716 remove bacteria from water samples<sup>20</sup> or particulates from soil<sup>119</sup>. Both publications report

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

717 filtration efficiencies of 100% of the tested particulates. Also based on filter membranes,  
718 selective filtering of circulating tumor cells from a whole blood sample was demonstrated.  
719 Filtration efficiencies were reported to be up to 84 %<sup>7</sup>.

720 Specific filtering by di-electrophoresis exploiting the electrical polarizability of molecules has  
721 been demonstrated by *Martinez-Duarte* and co-workers. Cartridge integrated carbon  
722 electrodes powered via electrical contacts with a slip-ring on the rotor shaft specifically  
723 filtered yeast cells from a mixture of yeast cells and latex particles<sup>120</sup>. *Boettcher* and  
724 colleagues presented the manipulation of particles and cells using a rotating microfluidic di-  
725 electrophoresis chip. Two co-rotating batteries powered the chip, while a co-rotating  
726 generator provided the required alternating currents. Using the described di-electrophoretic  
727 setup, sedimenting cells and particles could be directed to a defined branch of a Y-shaped  
728 channel<sup>121</sup>.

729 *Burger* et al. presented an implementation for capturing beads during sedimentation using  
730 arrays of V-shaped structures. The implementation aimed at a sharp peak in bead-  
731 distribution, i.e., capturing exactly one bead per cup. The size and density of the V-cup  
732 structures, as well as the size of the beads, were identified as important parameters for the  
733 bead distribution and number of empty cups. Up to 99.7% single bead-occupancy per V-cup  
734 was reported with 5% of the cups remaining empty<sup>122</sup>.

735 *Kirby* et al. presented a concept for centrifugo-magnetophoretic particle separation. Magnetic  
736 particles sediment in a stagnant fluid due to centrifugal forces. Permanent-magnets  
737 integrated into the rotating cartridge cause a defined deflection of the magnetic particles  
738 perpendicular to the centrifugal forces while non-magnetic particles sediment in direction of  
739 the centrifugal force. Thereby, particles could be routed to one of three outlets depending on  
740 their size, density, and magnetic properties and on the spin speed<sup>123</sup>. This concept was later  
741 employed by *Glynn* et al. for separating beads with captured CD4+ cells from whole blood.

742 <sup>124</sup>

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

743 A unit operation for the sedimentation of solid particles from turbid samples and the  
744 subsequent transfer of clear supernatant was demonstrated by *LaCroix-Fralish* et al. Fused  
745 silica capillaries (<110  $\mu\text{m}$  in diameter) were used as the connection between two  
746 microfluidic chambers. The liquid above the sedimented fraction of solid particles was  
747 decanted by placing one end of the capillary in the upstream chamber <sup>68</sup>. In another  
748 implementation, saw-toothed obstacles in an inlet chamber were used to hold back  
749 sedimented particles from seawater samples. After sedimentation, a wax valve was opened  
750 to release the clear seawater into an aliquoting structure <sup>32</sup>.

751 Similar concepts have been employed for blood-plasma separation based on the  
752 sedimentation of the denser cellular blood content from the cell-free blood plasma. The  
753 implementations basically differ in the implemented unit operations for plasma transfer after  
754 sedimentation, which included centrifuge-pneumatic gating <sup>125</sup>, centrifuge-pneumatic siphon  
755 valving <sup>126</sup>, capillary siphon valving <sup>100</sup>, decanting <sup>127</sup>, or using an integrated Y-channel that  
756 allowed denser cell content to enter the radially outward branch of the Y-channel, while the  
757 plasma was transferred into the downstream microfluidics via the radial inward channel <sup>128</sup>.  
758 Because blood-plasma separation is a discrete process chain in many laboratory workflows,  
759 it is discussed in detail with respect to the reported performance parameters in section 4.3.1.

### 760 **3.6.2 Separation based on chemical properties**

761 All centrifugal microfluidic implementations of chemical separation are based on the affinity of  
762 a target substance to a suitable mobile or non-mobile support. Mobile or non-mobile supports  
763 have to be brought in contact with the target substance and different assay reagents in a  
764 sequential order. Non-mobile supports have to be embedded into a network of microfluidic  
765 unit operations, valves, and switches, to allow for the sequential transport of the sample and  
766 reagents, while mobile supports can actively be moved to the location of a reagent or  
767 sample. The implementation of mobile or non-mobile supports and fluidic unit operations is  
768 discussed in the respective application chapters because their combination can be regarded

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

769 as a process chain, while we report some commonly exploited affinity mechanisms here. The  
770 underlying principles for the manipulation of mobile supports, which are mostly based on  
771 magnetic interaction, are included in the description in this chapter.

772 A common affinity mechanism for the separation of nucleic acids exploits the binding of DNA  
773 and RNA to silica surfaces under high chaotropic salt conditions <sup>129</sup>. Implementations have  
774 been demonstrated using non-mobile cartridge-integrated silica membranes <sup>26 97</sup>, glass bead  
775 columns <sup>130</sup>, or silica sol-gel <sup>131</sup>. Other separation principles involve the hybridization of  
776 nucleic acids to complementary strands that are immobilized to the cartridge surface <sup>132 133</sup>  
777 <sup>134</sup>. The affinity mechanism exploited for immunoassays and immunoseparation relies on the  
778 binding of antibodies to antigens. Antibodies (and in rare cases antigens) have been  
779 immobilized to a variety of non-mobile solid supports, including trapped antibody-coated  
780 polystyrene beads <sup>73 135</sup>, glass beads <sup>136</sup>, silica beads <sup>137</sup>, PMMA disks <sup>61</sup>, and nitrocellulose  
781 membranes <sup>107</sup>, which are then passed by the sample and other liquid reagents.

782 Demonstrated implementations with mobile support include a simple approach for the  
783 separation of nucleic acids using magnetic silica beads as the mobile support. Depending on  
784 the azimuthal position of the centrifugal microfluidic cartridge with respect to an external  
785 magnet, the beads could be transported through multiple reagent-filled microfluidic chambers  
786 <sup>138</sup>. *Cho* et al. used antibody-coated magnetic beads for pathogen capturing and immuno-  
787 magnetic separation from a whole blood sample. The beads were manipulated by a  
788 cartridge-integrated magnet and an external magnet on a linear gear. Thereby, the mixing of  
789 the beads or temporary immobilization of the beads in a dedicated location could be  
790 achieved while the surrounding media were exchanged <sup>90</sup>. Another approach for  
791 immunomagnetic separation was demonstrated by *Chen* and co-workers, where antibody-  
792 labeled magnetic beads were used to capture target cells. After binding, the beads were  
793 trapped by a co-rotating magnet, while the cell sample was gated into a waste reservoir <sup>139</sup>.  
794 *Glynn* et al. and *Kirby* et al. demonstrated centrifugo-magnetophoretic separation to separate

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

795 magnetic from non-magnetic particles or cells. In this approach, co-rotating disk-integrated  
796 magnets were used to deflect sedimenting magnetic particles with attached target cells to  
797 designated reservoirs <sup>123 124</sup>.

798 *Schaff* and *Sommer* demonstrated the sedimentation of beads through a density media for  
799 an immunoassay. Antibody-labeled beads were used to capture antigen and detection  
800 antibodies from a sample layered on top of a density medium. After capture, the beads were  
801 separated from the sample by sedimentation through the density medium <sup>89</sup>.

### 802 **3.7 Droplet handling**

803 While droplet-based microfluidics is a very active field in pressure-driven microfluidics, so far  
804 little work on droplet handling has been performed in centrifugal microfluidics. The reported  
805 unit operations are limited to the generation of droplets <sup>140</sup> or bubbles <sup>141</sup>. In these  
806 publications, both the droplets and bubbles were generated in oil.

807 With respect to applications, droplet generation in centrifugal microfluidics has been  
808 employed to create particles. Chitosan/alginate droplets <sup>142 143</sup> were generated at a nozzle in  
809 air and dispensed into a cross-linking solution. Upon contact with the hardening solution, the  
810 droplets became solid, forming microparticles. The reported advantages compared to other  
811 microfluidic bead generation methods are low dead volumes, uniform droplets due to the  
812 pulse free propulsion, and possible parallelization by a straightforward and even distribution  
813 of hydrostatic pressure on an array of nozzles. In particular, the dispensing method using an  
814 air gap, which prevents contact between the nozzle and hardening solution and thus  
815 circumvents nozzle clogging, is reported to be a unique feature.

816 Dispensing through an air gap was later applied to form 3D multi-compartmental particles  
817 using a multi-barreled capillary as a nozzle <sup>144</sup>. Up to six-compartment body compositions  
818 with custom designed geometries were reported in this work. These were produced on a  
819 tabletop centrifuge equipped with a swinging bucket rotor.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

820

821 Within centrifugal microfluidics, besides particle generation, we see the potential for the  
822 automation of highly parallel applications such as emulsion-based nucleic acid amplification  
823 as sample preparation for sequencing or digital amplification, or the implementation of digital  
824 immunoassays. The advantages include artificial gravity-based pulse-free propulsion, and  
825 thus the ability to form well-defined highly parallel micro-droplets with minimal dead volume.  
826 For example, centrifugal step emulsification can be employed for absolute quantification of  
827 nucleic acids by digital droplet RPA<sup>145</sup>. Furthermore, the integration of droplet-based  
828 operations, together with complex sample preparation such as nucleic acid purification, may  
829 enable sample-to-answer implementations of digital assays.

830

831

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

## 832 **3.8 Detection**

833 Although not a classical fluidic functionality, we consider detection to be a unit operation  
834 because it represents a basic building block for the assessment or quantification of the result  
835 of an assay. With respect to fluidics, detection usually requires maintaining the analyzed  
836 volume at a certain position or defined flow rate. The more relevant aspect of detection,  
837 however, is the general principle with which the quantification is assessed. Therefore, we  
838 categorize the unit operations used for detection into optical, electrochemical, and other  
839 detection principles.

### 840 **3.8.1 Optical detection**

841 Optical detection is very common in centrifugal microfluidics for several reasons. i) Costly  
842 optical detectors are usually integrated into the processing devices, which makes it possible  
843 to keep the disposable cartridges cheap. ii) A multitude of azimuthal locations on a spinning  
844 disk can be analyzed sequentially by rotation, which only requires a single detector. iii) The  
845 spinning rotors are capable of precisely positioning readout cavities relative to the detector  
846 position, which enables the alignment of the optical system at no additional cost. The optical  
847 detection section is structured as follows. First, we review systems that allow for the visual  
848 detection of the assay result, followed by methods for absorbance- and fluorescence-based  
849 detection. A final section is dedicated to publications that use commercially available CD or  
850 DVD drive pick-up heads for detection.

851 *Kim et al.* presented a centrifugal microfluidic cartridge with an integrated lateral flow strip.  
852 Gold nanoparticle-stained antibodies were bound to a DNA amplification product and created  
853 a visible line on the lateral flow strip <sup>146</sup>. Another molecular biological application exploited a  
854 color change from purple to blue during isothermal DNA amplification <sup>147</sup>. *Riegger et al.*  
855 presented a system for the visual detection of hematocrit. A disk-imprinted scale next to a  
856 dead-end channel allowed for the visual read-out of hematocrit after centrifugation by

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

857 identifying the location of the interface between the sedimented red blood cells and the  
858 plasma.<sup>148</sup>

859 *Grumann* et al. employed the total internal reflection for absorbance measurements. A light  
860 beam directed onto the disk plane was deflected by a cartridge-integrated V-groove and  
861 gated through a microfluidic chamber in the azimuthal direction. A second V-groove deflected  
862 the light beam out of the disk plane to the detector. Thereby, the path length for the  
863 absorption measurement (and thus the sensitivity) was increased from 1 mm to 10 mm  
864 compared to direct light incidence (**Fig. 9a**).<sup>149</sup> *Czugala* et al. used a paired emitter detector  
865 diode (PEDD) device for absorption detection. In the PEDD setup, two light emitting diodes  
866 were used. One diode served as the light source and was placed above the cartridge, while  
867 the second diode, operated in the reverse bias mode, served as the light detector for the  
868 transmitted light. An improved sensitivity and signal-to-noise ratio along with a low cost, small  
869 size, and low power consumption, were reported as the major advantages of the PEDD  
870 setup compared with the standard setup using an LED and a photodiode (**Fig. 9b**)<sup>118</sup>.

871 *LaCroix-Fralish* et al. presented the spectrophotometric detection of a bioassay using a  
872 halogen light source, which emitted light in the ultraviolet and visible regime, and a Czerny–  
873 Turner type spectrometer with a photodiode array for the detection of the transmitted light.  
874 For the detection, the disk had to be removed from the spinning device and mounted in the  
875 path of the spectrometer<sup>44</sup>.

876 Detection via fluorescence measurement is frequently conducted for nucleic acid analysis  
877 and in some cases also for immunoassays, and typically provides a more sensitive and  
878 specific detection<sup>150</sup> compared to other optical detection methods. *Focke* et al. presented a  
879 microfluidic cartridge with a line-up of reaction cavities close to the rim of the cartridge.  
880 Fluorescence signals from these reaction cavities were detected using a commercially  
881 available PCR thermocycler by exploiting the inbuilt fluorescence detection unit, i.e., an LED  
882 excitation source and a photo-multiplier for detection<sup>40</sup>. The same concept was later adapted

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

883 for other applications<sup>39 41 43 28</sup>. *Nwankire* et al. presented a microfluidic cartridge with an  
884 integrated supercritical angle fluorescence chip that allowed the selective measurement of  
885 fluorescent signals generated in close proximity to the surface. The optical setup was  
886 completed by a laser for fluorescence excitation and a photomultiplier for detection<sup>150</sup>.  
887 Various papers have reported the implementation of CCD cameras, especially for spatially  
888 resolved optical information. *Riegger* et al. demonstrated a detection concept for multiplexing  
889 via color-coding composed of an LED for excitation and a CCD camera for detection. In a  
890 first step, the camera acquired the spectral information of a layer of quantum dot beads for  
891 decoding the various bead types used and subsequently detected the fluorescence signals  
892 on the bead surfaces to quantify the bead-specific analyte reactions. The fluorescence on the  
893 bead surfaces was associated with the assay result, while the color of the beads  
894 corresponded to the assay target<sup>151</sup>. *Ukita* et al. presented a stroboscopic fluorescence  
895 microscope for observation of fluorescent objects such as 6  $\mu\text{m}$  particles on a spinning disk  
896 at a rotational frequency of up to 3.000 rpm<sup>152</sup>. The detection of multiple ions using a  
897 cartridge-integrated optode array was demonstrated by *Watts* et al. The detection principle  
898 was based on a change in the fluorescence signal due to the exchange of cations from the  
899 sample with the hydrogen in the optode membrane<sup>153</sup>.

900 *Otsuka* and colleagues developed a cartridge-integrated surface plasmon resonance sensor  
901 for the detection of protein adsorption to a gold surface. The adsorption of proteins  
902 influenced the resonance frequency of the surface plasmons, which resulted in a shift in the  
903 light intensity distribution with respect to the wavelength. The light intensity was measured  
904 using a CCD camera<sup>154</sup>.


905 Recently, multiple papers have been published on the use of standard optical CD and DVD  
906 pick-up heads for detection. One of the driving forces for their implementation is the cost  
907 benefit<sup>155 156</sup> because they are already produced in large numbers for consumer electronics.  
908 *Li* and coworkers demonstrated the read-out of different binding assays using an unmodified

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust


Title: Centrifugal microfluidic platforms: advanced unit operations and applications

909 CD read-out system by exploiting the error-signals in the detection because  
 910 biomolecule/nanoparticle conjugates, bound to the surface of a CD, block the laser beam.  
 911 The detected error-signal corresponded to a physical location or spot on the disk <sup>157</sup>. A  
 912 similar principle for the detection of immobilized immunoreaction products based on the error  
 913 distribution as a function of the “playtime” was presented by *Moraís* et al. using a standard  
 914 DVD drive. In the same work, another detection concept was introduced, where signal  
 915 changes from the DVD drive-integrated detection photodiode were acquired, as the reflection  
 916 of the laser beam was attenuated when striking the immunoreaction product <sup>155</sup>. *Lange* et al.  
 917 used a modified CD pick-up head for the detection of silver grains on the CD surface, which  
 918 were catalyzed by surface immobilized, gold-labeled antibodies. The silver grains caused a  
 919 change in reflectivity <sup>158</sup>. A DVD pickup head for the detection of binding events was  
 920 employed by *Bosco* et al. Binding biomolecules to gold-coated cantilevers caused a  
 921 deflection, a change in the resonant frequency and optical roughness, which was detected by  
 922 the DVD laser <sup>159</sup>.

a) Beam guidance via total internal reflection on chip-integrated V-grooves



b) Paired emitter detector diode setup for absorption detection in transmission



**Fig. 9:** Different setups for optical detection. (a) Enhancement of sensitivity by on-chip beam guidance using chip-integrated V-grooves. <sup>149</sup> (With kind permission from Springer Science and Business Media) (b) Paired emitter detector diode (PEDD) setup as sensitive and cheap alternative to common LED–photodiode setups for absorption measurement in transmission <sup>118</sup>. (Reproduced with permission from The Royal Society of Chemistry)

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

### 923 **3.8.2 Electrochemical detection**

924 Multiple electrochemical, instead of optical, detection approaches have been demonstrated  
925 on centrifugal microfluidic platforms<sup>160 36 161</sup>. All these approaches used an integrated three-  
926 electrode setup, comprising a working electrode, reference electrode, and counter electrode,  
927 and were exploited for the chrono-amperometric quantification of liquid flow rates and  
928 visualization of flow patterns like droplet formation<sup>160</sup> or for measuring the concentration of a  
929 protein biomarker<sup>36</sup>. The latter application reported a 17-fold increase in sensitivity for the  
930 electrochemical measurement compared to the conventional optical read-out. Both  
931 approaches used a slip ring around the axis to provide an electrical contact to the cartridge  
932 under rotation. Another implementation of a three-electrode setup, combined with an enzyme  
933 layer on the working electrode, was used to measure concentrations of hydrogen peroxide,  
934 that was generated by the enzymatic reaction of the working electrode with a set of metabolic  
935 parameters<sup>161</sup>.

### 936 **3.8.3 Others detection principles**

937 Surface acoustic wave (SAW)-based sensing was demonstrated by *W. Lee* and colleagues.  
938 Gold-stained antibodies, adsorbing to the surface of the SAW chip, produced a mass-  
939 dependent phase shift with respect to the cartridge-integrated reference SAW sensor. The  
940 SAW concept was demonstrated for the determination of certain biomarker concentrations  
941<sup>162</sup>.

942 *Steinert* et al. promoted a system for protein structure analysis using X-ray crystallography as  
943 the detection principle. In this approach, X-rays from a beamline were transmitted to a  
944 cartridge-integrated crystallization chamber and produced characteristic diffraction patterns  
945<sup>163</sup>. Schwemmer and colleagues later proposed a platform for the small-angle X-ray (SAXS)  
946 scattering-based analysis of protein structures based on the scattering of X-rays transmitted  
947 to reaction chambers on a centrifugal microfluidic cartridge<sup>63</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

### 948 **3.9 Conclusion of unit operations and introduction of process**

#### 949 **chains**

950 Traditionally, centrifugal microfluidics has mainly used the interplay of centrifugal forces and  
951 capillary forces to control the liquid flow <sup>66 64 82</sup>. Both forces are present on centrifugal  
952 microfluidic platforms, because centrifugation is inherently available in rotating systems and  
953 capillary forces become dominant as dimensions shrink. Yet, the increasing demand on  
954 centrifugal microfluidic cartridges, namely for the integration of complex assays and high  
955 reliability/robustness, has led to an expansion of the means that are used to realize specific  
956 unit operations.

957 One of these means is on-chip air compression or expansion by the processing liquid, which  
958 enables new principles for valving and pumping <sup>99 76 54 51</sup>. Similar to centrifugation, this  
959 method is also intrinsically available, but compared to capillary action, it is less dependent on  
960 the surface tension and wetting properties, as well as the fabrication tolerances. Moreover,  
961 the pneumatic forces are usually orders of magnitude higher than the capillary forces,  
962 making pneumatic action particularly robust.

963 Another trend is the use of external radiation sources to selectively heat up areas of the  
964 cartridge or to perform optical measurements <sup>48 37</sup>. The simple implementation of radiation  
965 sources and detectors into processing devices, as well as their non-contact characteristic  
966 and applicability in numerous unit operations, make them exceedingly promising.  
967 Furthermore, such unit operations are widely independent of the liquid properties. These  
968 advantages also apply to external magnets, which are mostly used in combination with  
969 magnetic beads <sup>164 138</sup>. Another advantage of external active means is the extension of the  
970 degrees of freedom in cartridge operation, which allows some unit operations to become  
971 independent of the rotational speed.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

972 The portfolio of unit operations that has been discussed in this review article so far includes  
973 sample and reagent supply, liquid transport, valving and switching, metering and aliquoting,  
974 mixing, separation, droplet generation, and detection. Combining these fluidic unit operations  
975 makes it possible to implement tasks with higher complexity such as blood plasma  
976 separation, cell lysis, nucleic acid purification, and nucleic acid amplification. Here, we  
977 introduce the term “process chain” in order to refer to these tasks with higher complexity.  
978 “Process chains” can usually be implemented by combining “unit operations,” and they are  
979 very useful to describe assay implementations on a higher hierarchical level. Complex  
980 applications such as genotyping assays in molecular diagnostics can be implemented to a  
981 great extent in a straightforward manner by simply concatenating several of the above-  
982 mentioned “process chains” such as “cell lysis,” “nucleic acid purification,” and “nucleic acid  
983 amplification.” Developers may re-use validated “process chains” from other assay  
984 implementations within the same microfluidic platform without the need to know the  
985 underlying fluidic unit operations in great detail, which reduces the costs and risks of  
986 implementing new assays. In that context, applying “process chains” in an assay  
987 implementation is very similar to applying “modules” and/or “subroutines” in programming.  
988 Introducing process chains is advantageous for all kinds of microfluidic platforms.

989 In the following sections, the most relevant applications and underlying process chains that  
990 have been published so far are presented and discussed.

991

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

## 992 **4 Applications**

993 The review of the applications in centrifugal microfluidics starts with a discussion of nucleic  
994 acid-based analysis, which can be subdivided into sample preparation, amplification and  
995 detection, and the implementation of sample-to-answer nucleic acid-based analysis. Here,  
996 the term process chain is used to categorize how the lysis of cells, purification of nucleic  
997 acids, and subsequent amplification and detection are implemented in centrifugal  
998 microfluidics. Subsequently, immunoassay-based analysis is reviewed by separately  
999 discussing the largest group of enzyme-linked immuno-sorbent assays (ELISA) and other  
1000 implementations of immunoassays. Thereby, the implementations of process chains for  
1001 blocking, immunocapture, and washing are discussed. A review of clinical chemistry  
1002 applications follows, including a discussion of the implemented process chains for blood  
1003 plasma separation as an example. Then, we discuss centrifugal microfluidic cell handling; the  
1004 analysis of food, water, and soil; and the analysis of protein structures and functions. Finally,  
1005 applications are reviewed that do not fit into the above-listed categories such as the  
1006 generation of photonic crystals.

### 1007 **4.1 Nucleic acid analysis**

1008 Bench top nucleic acid analysis is applied to a wide range of applications where information  
1009 on the DNA or RNA level is required. Because of the multiplicity of processing steps within  
1010 standard laboratory workflows, significant efforts have been put into automation by  
1011 microfluidic integration, aiming at reducing the laboratory time as well as reagent and  
1012 equipment costs <sup>165</sup>. The automation and integration of all the required steps on one  
1013 cartridge, which can potentially be processed in a portable processing device, will facilitate  
1014 complex nucleic acid testing at the point of care because minimal resources and no special  
1015 laboratory training will be required to perform the test.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1016 The standard laboratory workflow for a nucleic acid analysis can be roughly divided into two  
1017 parts <sup>166</sup>. (1) The first part is sample preparation with the aim to make nucleic acids  
1018 accessible. Process chains include the lysis of eukaryotic or bacterial cells and nucleic acid  
1019 purification or concentration for subsequent analysis. (2) The second part involves the post  
1020 processing of nucleic acids with process chains such as nucleic acid amplification, e.g.,  
1021 mostly PCR and unit operations for the detection of the amplification result.

#### 1022 **4.1.1 Sample preparation for nucleic acid analysis**

1023 The diversity of sample materials (including blood, saliva, urine, sputum, and culture media)  
1024 and the respective preparation protocols for the extraction of high quality and inhibitory free  
1025 DNA and RNA renders sample preparation labor intensive and complex. Thus, it can be  
1026 regarded as the major bottleneck toward fully integrated microfluidic sample-to-answer  
1027 solutions <sup>90</sup>. In this section, studies that used integrated lysis are first reviewed, followed by  
1028 systems with integrated purification and then those with completely integrated extraction. The  
1029 reviewed systems are listed in **Table 5**.

1030 A process chain for mechanical lysis on a centrifugal microfluidic PDMS cartridge was first  
1031 integrated by *Kim* et al. using the collision and friction of glass beads in a rimming flow. The  
1032 rimming flow in a co-axially arranged microfluidic chamber was a result of alternating  
1033 rotation, which depended on the bead density, solid volume fraction, acceleration rate, and  
1034 angular velocity <sup>167</sup>. Another centrifugal microfluidic cartridge for mechanical lysis was  
1035 presented by the same group. Lysis was supported by the collision of glass beads, agitated  
1036 by an oscillating magnetic disk in a radially arranged microfluidic chamber. The cell debris  
1037 was centrifuged radially outward, while the supernatant was transferred to a collection port  
1038 via a capillary siphon. To induce the oscillation of the ferromagnetic disk, integrated  
1039 permanent magnets were rotated above the non-rotating microfluidic cartridge on a second  
1040 spin stand, which consequently required the manual transfer of the cartridge between the  
1041 different processing devices <sup>168</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1042 An improved version of the aforementioned work was presented by *Siegrist* et al., in which  
1043 the ferromagnetic disk in the microfluidic lysis chamber was actuated by the defined rotation  
1044 of the centrifugal microfluidic polycarbonate cartridge over a set of external stationary  
1045 magnets. In this approach, four lysis chambers were arranged isoradially, making it possible  
1046 to process up to four samples in parallel. Centrifugo-pneumatic under-pressure valves were  
1047 used to prevent sample flow into the clarification chamber during lysis. After centrifugation,  
1048 the clear supernatant was transferred to a collection port via a capillary siphon. For the  
1049 subsequent PCR analysis, heat inactivation of the inhibitors in the sample was required <sup>78</sup>.

1050 For nucleic acid purification from lysed whole blood via a bind-wash-elute protocol, the so-  
1051 called "Boom chemistry" <sup>129</sup>, a centrifugal microfluidic cyclic olefin copolymer cartridge with  
1052 on-board liquid reagent prestorage was presented by *Hoffmann* et al. (**Fig. 10a**). As the solid  
1053 phase for DNA purification, silica membranes from commercially available QIAGEN spin  
1054 columns were integrated into the cartridge. During processing, the pre-lysed sample and  
1055 binding buffer mixture first passed through the silica membranes to capture the DNA. This  
1056 was followed by a washing buffer. Finally, an elution buffer was supplied to elute the purified  
1057 DNA from the membrane. An integrated Coriolis switch <sup>169 93</sup> was used to separate the waste  
1058 (lysed sample and washing buffers) and elution buffer containing the purified DNA <sup>26</sup>. A  
1059 similar system was presented by *Müller* et al., which was designed to be operated in a  
1060 standard laboratory centrifuge <sup>97</sup>. In this work, the Coriolis switch was replaced by a switch  
1061 for unidirectional rotation because the centrifuge only supports one direction of rotation.  
1062 Neither approach integrated lysis of the blood.

1063 A microscope slide-shaped microchip for RNA purification from low volumes (5  $\mu$ L) of virus  
1064 lysates via a bind-wash-elute chemistry was reported by *Park* et al. A sol-gel matrix in a  
1065 microfluidically patterned PDMS layer was used as a solid phase for the separation of RNA  
1066 from the lysate (**Fig. 10b**). A lysed sample premixed with ethanol for binding, washing buffer,  
1067 and elution buffer were added to microfluidic reservoirs prior to rotation and sequentially

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1068 released using the differences in the flow resistances of the connecting channels <sup>131</sup>. In a  
1069 later work, the sol-gel solid phase was replaced by a column of tetraethoxy orthosilicate  
1070 (TEOS)-activated glass beads contained in a zig-zag-shaped microfluidic channel. Here,  
1071 capillary valves between the washing buffer reservoirs and the zig-zag channel and a  
1072 capillary siphon between the elution buffer reservoir and the zig-zag channel were exploited  
1073 for the sequential release of the reagents to the glass bead bed <sup>130</sup>. In both approaches, lysis  
1074 of the virus samples was conducted off chip. Although all the reagents could be added to the  
1075 chips at the beginning, the waste (washing buffer and lysate) had to be removed manually  
1076 from the capture chamber during processing.

1077 The purification of DNA from lysate samples with silica-coated magnetic beads was  
1078 demonstrated using integrated-gas-phase transition magnetophoresis (GTM) on a  
1079 microthermoformed foil cartridge. Bead transport was a result of the defined positioning of  
1080 the foil cartridge in relation to an external stationary permanent magnet and did not require  
1081 any human interaction. Initially, beads bound the DNA from the lysate in a first chamber.  
1082 After binding, the beads were automatically transported through an air-gap into a second  
1083 chamber containing washing buffer and finally into a third chamber with elution buffer <sup>138</sup>. The  
1084 modular concatenation of multiple chambers with different volumes was then applied for  
1085 bead-based DNA extraction from whole blood, including lysis <sup>170</sup>. In a later work, this process  
1086 chain for nucleic acid extraction was extensively characterized for extractions from  
1087 logarithmic dilutions of various target pathogens and sample matrices including Gram-  
1088 positive *Bacillus subtilis*, Gram-negative *Escherichia coli*, *Rift Valley fever* RNA viruses from  
1089 blood plasma and human genomic DNA from whole blood <sup>171</sup>.

1090 Recently, the LabTube was introduced as a versatile centrifugal microfluidic platform for  
1091 bind-wash-elute-based DNA extraction from blood and other samples <sup>38</sup>. Microfluidic and  
1092 micromechanical elements are integrated in a centrifuge tube with the outer dimensions of a  
1093 50-mL centrifuge tube, as depicted in **Fig. 10c**. An integrated centrifugally actuated ball-pen

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1094 mechanism enables reagent release and liquid routing. Unit operations for mixing and  
1095 separation-based extraction are also integrated. Using LabTube, extractions of genomic DNA  
1096 from whole blood were demonstrated with yields and purities equal to manual reference runs.  
1097 Sample addition, the transfer of LabTube into the centrifuge, and the withdrawal of a  
1098 standard reaction tube containing the eluate remained as the only manual steps.

1099 A highly comprehensive approach for pathogen specific DNA extraction on a centrifugal  
1100 microfluidic polycarbonate cartridge was presented by *Cho et al.*<sup>90</sup>. In this work, target  
1101 pathogens were separated from a sample by immunomagnetic separation using antibody-  
1102 coated magnetic beads subsequent to disk-integrated blood plasma separation. Pathogens  
1103 were thermally lysed by heating the beads with a laser. Multiple integrated ferrowax  
1104 microvalves (LIFM) could be opened or closed by laser irradiation, thereby defining the fluidic  
1105 routing.


Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications


## a) DNA purification via integrated silica membrane



## b) RNA purification using sol-gel as solid phase



## c) DNA extraction via silica membrane on the LabTube



**Fig. 10:** Centrifugal microfluidic process chains for nucleic acid purification and extraction. (a) DNA purification from lysed whole blood via integrated silica matrix “d” with onboard liquid reagent prestorage “a.” An integrated Coriolis switch “e” is used to direct purified DNA and waste to different microfluidic chambers “f” and “g”<sup>26</sup>, (Reproduced with permission from The Royal Society of Chemistry) (b) RNA purification from virus lysates via sol-gel matrix<sup>131</sup> (Reproduced with permission from The Royal Society of Chemistry), and (c) DNA extraction in LabTube via integrated silica matrix<sup>38</sup>. (Reproduced with permission from The Royal Society of Chemistry)

1106

1107

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

**Table 5:** Comparison of centrifugal microfluidic process chains for lysis and DNA or RNA purification or extraction with respect to performance parameters and processing time.

Reference	Lysis	Purif.	Lysis/purification method	Sample matrix and volume	Target	Performance parameters	Time	Notes
Kim J. et al. <sup>167</sup>	✓		ML: beads in rimming flow	Culture media	CHO-K1 Cells, <i>E. coli</i> and <i>S. cerevisiae</i>	Lysis efficiency 65% vs. conventional lysis protocol	5–7 min	No connection to downstream fluidics demonstrated
Kido H. et al. <sup>168</sup>	✓		ML: magnetically assisted bead beating	70 µL: (1) LB culture media (2) YPD culture media	(1) <i>E. coli</i> and (2) <i>S. cerevisiae</i>	Released DNA from (1) ≤40 µg/mL; (2) ≤60 µg/mL	30–480 s	Two processing stages required
Siegrist J. et al. <sup>78</sup>	✓		ML: magnetically assisted bead beating	4 × 90–95 µL or 1 × 360–380 µL; (1) DI water; (2) Clinical nasopharyngeal aspirate (NPA)	(1) <i>B. subtilis</i> spores (2) Human metapneumo-, entero- or adeno-virus	(1) Equivalent lysis vs. reference; (2) Correct identification of all viruses	<6 min	Lysis of spores demonstrated
Hoffmann J. et al. <sup>26</sup>		✓	SPE; silica matrix integrated into cartridge	32 µL lysed whole blood	Human DNA	≤77% vs. off-chip reference	not stated	Liquid reagent prestorage in glass ampoules
Müller M. et al. <sup>97</sup>		✓	SPE; silica matrix integrated into cartridge	32 µL lysed blood	Human DNA	53 ± 8% vs. reference	66 min	Commercially available reagents prestored
Park B. H. et al. <sup>131</sup>		✓	SPE; silica sol-gel integrated into cartridge	Virus lysate (5 µL)	RNA from Influenza H1N1 virus	RNA capture yield 80%	5 min	Small reagent volumes
Jung J. H. et al. <sup>130</sup>		✓	SPE; integrated glass bead column	3.5 µL RNA sample (0.5 µL virus lysate, 1.25 µL EtOH, 1.75 µL 6M Gu-HCl)	RNA from Influenza H3N2 virus	RNA capture yield ~81%	440 s	Lysis process not included. Elution with RT-PCR cocktail demonstrated
Strohmeier O. et al. <sup>138</sup>		✓	SPE; magnetic silica beads	LB media (50 µL)	DNA from lysed <i>Listeria innocua</i> and Lambda phage	Up to 68% ± 24% for <i>L. innocua</i> and 43% ± 10% for lambda phage vs. manual reference	12.5 min	Novel handling concept for magnetic beads
Wadle S. et al. <sup>170</sup>	✓	✓	SPE; magnetic silica beads	200 µL whole blood	Human DNA	Extracted DNA: 4.6 ± 0.7 ng/µL (disk) vs. 4.1 ± 0.4 ng/µL (reference)	not stated	Commercially available extraction reagents
Strohmeier O. et al. <sup>171</sup>	✓	✓	SPE; magnetic silica beads	200 µL: culture media, blood plasma, whole blood	Human DNA, DNA from <i>B. subtilis</i> and <i>E. coli</i> and RNA from <i>Rift Valley fever virus</i>	Up to 98.5 % for <i>B. subtilis</i> , 102.1 % for <i>E. coli</i> and 34.2 % for <i>Rift Valley fever</i>	~ 30 min	Measurement of PCR inhibitors included. Commercially available reagents
Cho Y. K. et al. <sup>90</sup>	✓	✓	IMS with beads; TL by laser-induced heating	100 µL whole blood	<i>E. coli</i> and <i>Hepatitis B virus</i> (HBV)	Comparable to bench top extractions	12 min	Blood plasma separation included
Kloke A. et al. <sup>38</sup>	✓	✓	SPE; silica matrix integrated into cartridge	200 µL whole blood	Human DNA	Equal to manual reference	50 min	Operated on standard laboratory centrifuge

ML: Mechanical lysis; TL: Thermal lysis; SPE: Solid phase extraction; IMS: Immunomagnetic separation

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1108

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

#### 1109 **4.1.2 Nucleic acid amplification and detection**

1110 The most common method for nucleic acid analysis is amplification and subsequent  
1111 detection. Amplification can be divided into the standard method, the polymerase chain-  
1112 reaction (PCR) that requires different temperatures, typically between 55°C and 95°C, and  
1113 isothermal methods (such as loop mediated isothermal amplification (LAMP), recombinase  
1114 polymerase amplification (RPA), rolling circle amplification (RCA), and helicase dependent  
1115 amplification (had)). Monitoring the PCR in real-time allows for the highly sensitive  
1116 quantification of DNA down to the single molecule level. Isothermal methods are significantly  
1117 faster and achieve a similar sensitivity, but often have deficiencies in their quantification  
1118 capability.

1119 Detection can be achieved using fluorescently labeled probes, by intercalating fluorescent  
1120 dyes, after PCR, e.g., by the detection of the PCR product via gel- or capillary  
1121 electrophoresis, or by hybridization to immobilized DNA capture probes (DNA microarrays).  
1122 Although the application of centrifugal microfluidics for automating process chains like  
1123 nucleic acid amplification has advantages (i.e., a reduced risk of cross contamination  
1124 because of the closed systems, homogeneous temperature distribution, and recondensation  
1125 of vapor), the interfaces required for thermocycling and optical readout remain technically  
1126 challenging. In this context, the review of the amplification and detection methods is  
1127 structured as follows. First, centrifugal microfluidic systems that only integrate the  
1128 amplification process chain are reviewed. Then, systems with additionally integrated unit  
1129 operations for detection are reviewed. These systems are compared by the degree of  
1130 multiplexing (i.e., the ability to simultaneously detect different target nucleic acids),  
1131 sensitivity, and time to result (**Table 6**). At the end of the section, we review centrifugal  
1132 microfluidic systems that were exploited for processing microarrays.

1133 A centrifugal microfluidic cartridge for PCR-based amplification has been presented where  
1134 contact heating and cooling using three thermoelectric modules was employed for

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1135 thermocycling (1 module) and in parallel for freezing sub-volumes of the PCR buffer in the  
1136 channel network (2 modules) to *ice valves*. These ice valves were integrated to block the  
1137 connection channel between the PCR chamber and venting hole and thus prevent cross  
1138 contamination through the vent because stationary thermocycling was conducted, without  
1139 rotating the disk <sup>91</sup>. *Jung* et al. developed a PDMS/glass cartridge for the reverse  
1140 transcriptase PCR detection of viral RNA. The microfluidic cartridge was serially rotated over  
1141 three temperature blocks at different temperatures for denaturation, annealing, and extension  
1142 <sup>172</sup>. In both approaches, the detection of the generated PCR product had to be conducted off-  
1143 disk using gel electrophoresis <sup>91</sup> or microcapillary electrophoresis <sup>172</sup>.

1144 Further applications have been demonstrated using centrifugal forces to force a bacterial  
1145 sample through 24 zig-zag shaped channels integrated into a centrifugal microfluidic PDMS  
1146 cartridge. Single bacterial cells from the sample were distributed into multiple 1.5-nL  
1147 microchambers connected to each zig-zag channel. For the thermal lysis of the cells and  
1148 PCR-based amplification, the cartridge was placed on a custom-made thermocycling system  
1149 for contact heating. After PCR, the fluorescence intensity was measured by placing the  
1150 cartridge into an image analyzer <sup>173</sup>.


1151 Digital PCR on centrifugal microfluidic cartridges was presented by *Sundberg* et al. By  
1152 spinning the disk, a PCR mixture that included plasmid DNA was forced through a spiral  
1153 channel and aliquoted into one thousand 33-nL amplification wells (**Fig. 12**). Afterward, the  
1154 PCR mixture aliquots in the wells were separated by forcing mineral oil through the spiral  
1155 channel. An air-mediated temperature setting for thermocycling allowed PCR cycle times of  
1156 33 seconds <sup>102</sup>. The proposed digital PCR platform has been commercialized and distributed  
1157 by Espira Inc. <sup>174</sup>.

1158 Centrifugal microfluidic cartridges have been exploited for the real-time PCR-based  
1159 genotyping of methicillin-resistant *Staphylococcus aureus* (MRSA) <sup>40</sup>. Cartridges were  
1160 fabricated from thin polymer foils using microthermoforming <sup>175</sup> to allow fast, air-mediated,

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1161 heat transfer (**Fig. 12**). An integrated unit operation for two-step aliquoting made it possible  
 1162 to divide and fluidically separate an initial volume of PCR mastermix into eight aliquots of 10  
 1163  $\mu\text{L}$  each. The aliquots were then transferred into a separate amplification chamber harboring  
 1164 a set of dryly prestored primers and probes. Thereby, “geometric” multiplexing was achieved.  
 1165 Up to four separate DNA samples could be analyzed per cartridge <sup>40</sup>. To increase the  
 1166 sensitivity, an advanced version of the aforementioned cartridge was presented by the same  
 1167 group, which included pre-amplification prior to aliquoting and a downstream nested PCR. A  
 1168 translation of the integrated functionality into a schematic description highlighting the  
 1169 implemented process chains and unit operations is depicted in **Fig. 11**. As an advantage, the  
 1170 integration of the pre- and main amplification into the same cartridge circumvented the risk of  
 1171 cross contamination by sample handling after pre-amplification <sup>39</sup>.



**Fig. 11:** Schematic interpretation of integrated functionality of Focke et al. <sup>39</sup>. Dashed boxes represent process chains, and solid boxes depict unit operations and the demonstrated implementation (Sup.: Sample or reagent Supply; Val.: Valving; Mix: Mixing; Aliq.: Aliquoting; Det.: Detection). Circles illustrate application specific laboratory functionalities that are controlled by external means.

1172

1173

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications


1174 A similar cartridge has been used for isothermal real-time amplification by recombinase  
1175 polymerase amplification (RPA). In this work, a lyophilized polymerase pellet and liquid  
1176 rehydration buffer were prestored on the cartridge. Thus, only a template DNA addition was  
1177 required. The rehydration of the lyophilized polymerase pellet was achieved by integrated  
1178 shake mode mixing before the RPA mastermix was transferred into an aliquoting structure  
1179 via a capillary siphon valve. Up to six samples could be analyzed per cartridge <sup>28</sup>. For  
1180 multiplex point mutation detection, an allele-specific PCR has been integrated into centrifugal  
1181 microfluidic foil disk-segments to allow the independent processing of up to four samples per  
1182 run. The automation comprises the aliquoting of a PCR mastermix into multiple fluidically  
1183 separated amplification chambers with dryly prestored primers and probes, followed by an  
1184 allele-specific PCR <sup>41</sup>. In another approach, *Strohmeier* et al. presented a cartridge for the  
1185 detection of six common food borne pathogens. This cartridge included amplification  
1186 chambers for integrated positive and negative controls and demonstrated the capability for  
1187 quantitative real-time PCR by the parallel amplification of integrated DNA standards <sup>43</sup>. As an  
1188 advantage, all the cartridges and disk segments could be processed in a modified,  
1189 commercially available centrifugal real-time PCR thermocycler for fluidic processing,  
1190 amplification, and fluorescence detection, and did not require additional equipment. Recently,  
1191 *Czilwik* et al. presented a passive microfluidic vapor diffusion barrier to reduce pressure  
1192 increase during thermocycling. The application of this unit operation was demonstrated for  
1193 PCR amplification and subsequent transport of the amplification product for further  
1194 analysis<sup>176</sup>.

1195 Recently, Focus Diagnostics and 3M introduced the Integrated Cyclor, a real time PCR  
1196 cycler, to the market. Up to 96 pre-extracted nucleic acid samples can be pipetted to a  
1197 universal single-use disk. Each of the 96 radially inward inlet wells is directly connected to  
1198 one of 96 amplification wells located at the outer rim of the cartridge. Contact heating is  
1199 employed for thermocycling. Up to four fluorescence channels are available in the instrument  
1200 for real-time detection. In 2012, Focus Diagnostics' Flu Test for use in combination with the

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1201 3M integrated cyclers was approved by the FDA <sup>177</sup>. A list of the relevant patents for the  
 1202 disposable disk and device can be found on the website <sup>178</sup>.



**Fig. 12:** Centrifugal microfluidic cartridges for nucleic acid amplification: (a) cartridge for digital PCR using unit operation for one-step aliquoting to 1000 1-nL amplification wells <sup>102</sup> (Reprinted with permission from the American Chemical Society) and (b) cartridge for pre amplification and subsequent multiplex real-time PCR-based main amplification, including integrated two-stage aliquoting into fourteen 10- $\mu$ L amplification wells. <sup>39</sup> (Reproduced with permission from The Royal Society of Chemistry)

1203

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

**Table 6:** Comparison of centrifugal microfluidic cartridges for nucleic acid amplification and detection.

Reference	Amplification	Target	Degree of geometric multiplexing	Sensitivity	Time (Cycles)	Detection Technology	Heating Technology
Focke M. et al. <sup>40</sup>	PCR	Resistance genes in <i>S. aureus</i>	7 + 1 internal control	<10 DNA copies per well <sup>1</sup>	110 min (50 cycles)	FAM-labeled hydrolysis probes; real-time fluorescence detection	Air mediated in commercially available PCR thermocycler
Lutz S. et al. <sup>28</sup>	RPA	<i>mecA</i> gene in <i>S. aureus</i>	Monoplex	<10 DNA copies per well <sup>1</sup>	<15 min	real-time fluorescence detection	Air mediated in commercially available PCR thermocycler
Focke M. et al. <sup>39</sup>	Multiplex-preamplification, nested PCR	Resistance genes in <i>S. aureus</i>	Up to 4	down to 7 copies per sample	17 min (10 cycles) pre-amp, 52 min (50 cycles) main amplification <sup>1)</sup>	FAM-labeled hydrolysis probes; real time fluorescence detection	Air mediated in commercially available PCR thermocycler
Strohmeier O. et al. <sup>41</sup>	Allel specific PCR	<i>KRAS</i> point mutations on tumor cell DNA	8	Not stated	Not stated	FAM-labeled hydrolysis probes; real-time fluorescence detection	Air mediated in commercially available PCR thermocycler
Strohmeier O. et al. <sup>43</sup>	PCR	DNA from 6 different food borne pathogens	6	0.1 pg DNA per well for <i>Salmonella</i> and <i>Listeria</i>	~2 h (50 cycles)	FAM-labeled hydrolysis probes; real-time fluorescence detection	Air mediated in commercially available PCR thermocycler
Sundberg S. O. et al. <sup>102</sup>	Digital PCR	300 base pair plasmid DNA	Monoplex	Amplification in 58 out of 1000 wells (DNA concentr.: $6 \times 10^0$ copies $\mu\text{L}^{-1}$ )	~25 min (45 cycles); additional 25 min for loading, fluorescent imaging and image analysis	Intercalating dye; "accumulated" real-time fluorescence detection of hundreds of wells for melting curve analysis; post PCR image acquisition with CCD camera for digital well analysis	Air mediated
Furutani S. et al. <sup>173</sup>	PCR	<i>invA</i> gene in <i>Salmonella enterica</i>	Monoplex	PCR on isolated single cells	95°C/2 min for thermal lysis; Denat. 95°C/5 s, Anneal. 55°C/10 s; Elongate 72°C/10 s optimum 40 cycles	FAM-labeled hydrolysis probes; post-PCR fluorescence detection	Contact
Amasia M. et al. <sup>91</sup>	PCR	<i>Bacillus anthracis</i> ; <i>Bacillus cereus</i>	Monoplex	Not stated	53 min (35 cycles)	Off-chip (analysis of PCR products by gel electrophoresis)	Contact; with thermoelectric modules
Jung J. H et al. <sup>172</sup>	RT-PCR	Influenza A subtypes: H3N2, H5N1, and H1N1	Monoplex and duplex	~2 RNA copies (demonstrated for H3N2)	25.5 min	Off-chip (microcapillary electrophoresis)	Contact; serially on thermal blocks

PCR: polymerase chain reaction; RT-PCR: reverse transcriptase polymerase chain reaction; RPA: recombinase polymerase amplification; *S. aureus*: *Staphylococcus aureus*

1) Time for heating and cooling not included

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1204 In addition to the integration of process chains like those for nucleic acid amplification and  
1205 detection, in the past, multiple centrifugal microfluidic cartridges have been presented for  
1206 automating microarray processing.

1207 *Peng* et al. presented a glass disk that was first attached to a PDMS disk with 96 radial  
1208 channels. Using centrifugal forces, DNA probes were then pumped through the channels for  
1209 “printing” radially DNA probe lines on the glass disk. The first PDMS disk was then peeled off  
1210 and replaced by a second PDMS disk with 96 spiral channels that orthogonally intersected  
1211 the 96 probe lines. Finally, DNA samples were forced through the spiral channels and  
1212 hybridized to the probe lines. Successful hybridization was detected using a fluorescence  
1213 scanner <sup>132</sup>. This centrifugal microfluidic cartridge for DNA hybridization with slightly  
1214 increased channel dimensions was later used by the same group for the detection of PCR  
1215 products from the fungal pathogens *Botrytis cinerea* and *Didymella bryoniae*. The presented  
1216 system was capable of detecting 3-ng PCR products after hybridization for 2 h at 45°C <sup>179</sup>. By  
1217 improving the flow control and channel design and adding an additional fluorescent dye, the  
1218 detection of less than 0.2 ng of PCR products derived from three different fungal pathogens  
1219 (*Didymella bryoniae*, *Botrytis cinerea*, and *Botrytis squamosa*) within 3 min at 23°C <sup>180</sup> was  
1220 presented.

1221 *Peytavi* et al. developed a slide-shaped PDMS chip with integrated microfluidic channels for  
1222 the discrimination of the single nucleotide polymorphisms of four clinically relevant  
1223 *Staphylococcus* species. The serial release of samples (PCR products with incorporated Cy-  
1224 labeled dUTPs), washing buffer, and rinsing buffer into the array chamber was controlled by  
1225 the spin speed and integrated capillary valves. Afterward, the slide was dried during rotation  
1226 at a high spin speed. For readout, the glass slide was transferred into an array scanner. A  
1227 10-fold increase in the hybridization signal was reported for the microfluidic flow-through  
1228 approach compared to passive systems that solely rely on the diffusion of an analyte to the  
1229 capture probe <sup>134</sup>. A similar microfluidic chip was later used for the hybridization of 25-mer

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1230 DNA samples. Enzyme-labeled fluorescence technology was used to generate the signal for  
1231 detection. A threefold increase in fluorescence intensity compared to passive assays was  
1232 reported for similar hybridization times<sup>133</sup>.

### 1233 **4.1.3 Sample-to-answer nucleic acid analysis**

1234 The term “sample-to-answer analysis” of nucleic acids refers to an integrated analytical  
1235 solution that comprises all the necessary process chains for sample preparation and  
1236 subsequent detection. Because of the complexity of microfluidic integration and connecting  
1237 the interfaces to external means (thermocycling, modules for optical detection, etc.), sample-  
1238 to-answer analysis remains very challenging. Although all the required process chains have  
1239 been separately demonstrated on centrifugal microfluidics, to the best of our knowledge, no  
1240 completely integrated and automated system with sample-to-answer capability for nucleic  
1241 acid analysis has so far been reported in a peer-reviewed journal. However, several  
1242 conference proceedings are available and included in the review. Although they showed no  
1243 full sample-to-answer capability, we included systems that have integrated combinations of  
1244 process chains for both sample preparation and post processing in this chapter.

1245 *Hoehl* et al. presented a LabTube<sup>38</sup> with an integrated process chain for solid-phase-based  
1246 DNA purification from lysates of a verotoxin produced by *Escherichia coli* spiked in water,  
1247 milk, and apple juice samples, combined with the subsequent isothermal LAMP amplification.  
1248 In this work, a battery-driven heating system was integrated for the direct amplification in the  
1249 tube. The positive LAMP amplification resulted in a visible color change for the LAMP  
1250 reaction. A reduction in the manual labor time from 45 to 1 minute was reported, requiring  
1251 only a single pipetting step to load the LabTube with the pre-lysed bacterial sample<sup>181</sup>.

1252 *Kim* et al. presented a centrifugal microfluidic cartridge for the detection of *Salmonella* from  
1253 PBS and milk samples that included process chains for laser-induced thermal lysis<sup>90</sup> and  
1254 isothermal amplification via RPA. For sequential fluid control, several ferrowax valves<sup>90</sup> were  
1255 integrated. Read-out of the result was possible via visual detection on an integrated lateral

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1256 flow strip. Detection limits of  $10 \text{ cfu mL}^{-1}$  and  $10^2 \text{ cfu mL}^{-1}$  were reported for the PBS and milk  
1257 samples, respectively, with a time to result of 30 minutes. Not included in the microfluidically  
1258 automated process was the process chain for immunomagnetic sample enrichment from the  
1259 1-mL milk and PBS samples. After capturing the pathogens, the capture beads were  
1260 magnetically collected, washed twice, and resuspended in  $5 \mu\text{L}$  of distilled water, which was  
1261 then loaded onto the cartridge <sup>146</sup>.

1262 *Strohmeier* et al. presented a centrifugal microfluidic polymer foil cartridge for the sample-to-  
1263 answer analysis of bacterial targets from a blood plasma sample. The following process  
1264 chains were combined on the cartridge in sequential order: chemical lysis, magnetic bead-  
1265 based DNA purification, and isothermal amplification via RPA with real-time fluorescence  
1266 detection relying on unit operations such as capillary siphons, gas-phase transition  
1267 magnetophoresis for DNA separation <sup>138</sup>, and aliquoting <sup>99</sup>. The disk could be processed in a  
1268 portable device, and successful sample-to-answer detection was demonstrated for  $6 \times 10^4$   
1269 genome equivalents of *Bacillus anthracis* and  $6 \times 10^6$  genome equivalents of *Francisella*  
1270 *tularensis* spiked into blood plasma samples. A total processing time of 45 minutes was  
1271 reported <sup>45</sup>. An updated version of the aforementioned work demonstrated real-time PCR-  
1272 based detection of *Staphylococcus warneri*, *Streptococcus agalactiae*, *Escherichia coli* and  
1273 *Haemophilus influenzae* from a  $200 \mu\text{L}$  serum sample. Limits of detection were reported to  
1274 be 3, 150, 5 and 18 colony forming units, respectively. In addition to the above-mentioned  
1275 process chains, a stickpack for prestorage and on-demand release of rehydration buffer and  
1276 a process chain for pre-amplification prior to target specific PCR was integrated to increase  
1277 the sensitivity <sup>182 31</sup>. Pre-amplification required further unit operations for metering the eluate  
1278 and pumping <sup>51</sup> the pre-amplified solution toward the center of the cartridge. Processing was  
1279 conducted in a portable PCR device <sup>182</sup>.

1280 *Jung* et al. presented a centrifugal microfluidic cartridge for the purification of viral RNA from  
1281 H3N2 influenza combined with the subsequent amplification and detection. No process chain

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1282 for sample lysis was included. RNA separation from the lysate and purification were  
1283 conducted using a microglass bead solid phase, while an RT-PCR cocktail was used to elute  
1284 the purified RNA from the bead bed. The sample, washing buffers, and RT-PCR mix were  
1285 sequentially released from their inlet chambers by differences in the flow resistance values of  
1286 the respective channels or by capillary siphons <sup>183</sup>.

1287 3M recently commercialized the “direct amplification disc” <sup>184</sup> for the sample-to-answer  
1288 analysis of influenza virus A/B and respiratory syncytial virus (RSV). The “direct amplification  
1289 disc” can be operated in the 3M integrated cycler. The disk allows the real-time amplification  
1290 of up to eight unprocessed clinical samples by making use of direct amplification chemistries  
1291 <sup>185</sup> that can perform nucleic acid extraction and amplification in one protocol. For processing,  
1292 a 50- $\mu$ L patient sample and 50- $\mu$ L reaction mix have to be pipetted to the direct amplification  
1293 disc prior to processing. The microfluidic layout has not been published, although several  
1294 patents might disclose the functionalities of single unit operations such as metering <sup>186</sup> and  
1295 valving <sup>187</sup>. Up to four fluorescence channels are available for detection.

1296 The Canadian company GenePOC Inc. is approaching the market with a centrifugal  
1297 microfluidic disk segment with sample-to-answer capability, which includes process chains  
1298 for mechanical lysis and subsequent amplification and detection. Up to eight disk segments  
1299 can be processed in parallel, allowing the independent analyses of up to eight samples with  
1300 volumes of 100–200  $\mu$ L in parallel. According to the corresponding patent application <sup>188</sup>, the  
1301 system features mechanical lysis using glass beads that are actuated by an additional  
1302 magnetizable element in the microfluidic chamber similar to the system presented by *Kido et*  
1303 *al.* <sup>168</sup>. Afterwards, a portion of the lysate is diluted with a dilution buffer, heated up, and  
1304 aliquoted into three separate amplification chambers that contain specific PCR reagents. By  
1305 using four different dyes, up to 12 targets should be detectable from one sample in less than  
1306 1 hour with less than 3 minutes of hands-on time <sup>189</sup>. A possible system description is given  
1307 in the corresponding international patent application <sup>188</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1308 Although showing full sample-to-answer capability, neither commercial system has an  
1309 integrated process chain for nucleic acid purification after lysis. On the one hand, this makes  
1310 microfluidic integration easy because of the reduced complexity. On the other hand, the  
1311 approach might only be suitable for certain sample materials with low amounts of inhibitors  
1312 and sufficient pathogen-loads because no DNA/RNA concentration step is included.

#### 1313 **4.1.4 Trends and perspectives in nucleic acid analysis**

1314 Platforms based on centrifugal microfluidics have proven to be suitable for the automation of  
1315 nucleic acid analysis. Because no connection to external pressure sources is required, the  
1316 risk of cross contamination is reduced, which might be of particular relevance if bio-  
1317 hazardous material is processed or the release of post-amplification products has to be  
1318 avoided. All the relevant process chains, including lysis, purification, and amplification, have  
1319 successfully been demonstrated on centrifugal microfluidic platforms. However, the  
1320 combination of all these process chains for integrated sample-to-answer analysis has not yet  
1321 been presented in a peer-reviewed journal publication. A possible reason might be the  
1322 limited available space in the radial direction, which would require the implementation of unit  
1323 operations for pumping liquid back toward the center of a disk. Still, many systems require  
1324 manual interaction during processing<sup>131 130 173 132</sup>; lack suitable prestorage concepts,  
1325 particularly for liquid reagents<sup>130 131 45 170 182</sup>; or use fabrication technologies that are not  
1326 compatible with mass production<sup>131 134 132</sup>. In the future, isothermal amplification techniques  
1327<sup>190</sup> such as HDA, LAMP, and RPA might boost the development of fully integrated sample-to-  
1328 answer solutions because no complicated thermocycling is required, while the  
1329 implementation of recently presented unit operations for liquid transport by pneumatic  
1330 pumping and reagent prestorage might be suitable to solve the remaining system integration  
1331 challenges.

1332 To circumvent the need for additional equipment, the processing of centrifugal microfluidic  
1333 cartridges for sample preparation<sup>38</sup> or amplification and detection<sup>40 39 28 41 43 181</sup> in

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1334 commercially available equipment has been demonstrated. These microfluidic chips, which  
1335 extend the functionality of an existing processing device, have been called “microfluidic apps”  
1336 <sup>191</sup>. Other cartridges could be processed in small and portable devices, making them suitable  
1337 for single sample testing and application at the point-of-care <sup>45 170 182</sup>. In addition to single  
1338 sample and point-of-care testing, first applications have been demonstrated for highly parallel  
1339 applications such as digital PCR <sup>102</sup>.

1340 The application of centrifugal microfluidics for automation of nucleic acid analysis provides  
1341 unique advantages for assay automation as multiple standard laboratory process chains  
1342 already exploit centrifugal forces when conducted manually. The advantages include the  
1343 possibility to perform density based separations during sample preparation such as the  
1344 separation of blood plasma from whole blood or the concentration of bacterial pathogens by  
1345 sedimentation. Furthermore, nucleic acid extraction on the bench commonly uses so called  
1346 “*spin columns*” where the sample and liquid reagents are serially forced through solid phase  
1347 membranes by centrifugation. With respect to PCR based nucleic acid amplification,  
1348 centrifugal microfluidic cartridges may benefit from the straight forward approach to remove  
1349 bubbles (due to buoyancy in the centrifugal gravity field) at elevated temperatures.

1350

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

## 1351 4.2 Immunoassays

1352 Immunoassays (IA) are widely established in (bio-) medical diagnostics, biological and  
1353 biochemical studies, drug development, environmental analyses, and food safety <sup>192 156 61</sup>.

1354 Immunoassays are based on the highly specific affinity of antibodies (Ab) to antigens (Ag),  
1355 allowing for the detection of bioanalytes that provide appropriate binding sites (epitopes).

1356 Either the antigen or antibody can be the target bioanalyte. In heterogeneous  
1357 immunoassays, the capture antibody is immobilized either on macroscopic solid supports or  
1358 on microscopic beads suspended in the solution. The analyte is present in the liquid phase.

1359 After a certain incubation period, the bound analyte is measured directly on the surface using  
1360 a suitable transducer or biosensor system, or using a secondary antibody in solution

1361 conjugated with a suitable tracer. In the latter case, an active bound/free separation step,  
1362 e.g., by washing, is required. Alternatively, homogeneous immunoassays do not require a

1363 bound/free separation step. In this case, a signal is generated by the binding of the  
1364 appropriate tracer or tracer combination to the analyte.

1365 A wide variety of immunoassay formats are in place, and two main categories can be  
1366 considered. An immunometric assay employs an antibody labeled with a tracer, which is

1367 advantageous if the target analyte exposes multiple binding sites or epitopes. In this case, for  
1368 example, the primary or capture antibody binds the analyte to the solid phase, and the

1369 secondary labeled antibody builds up a sandwich-type structure with the analyte. After the  
1370 bound/free separation, the tracer bound via the sandwich to the solid phase can be

1371 quantified. Competitive assay formats are often used for small analytes, which expose only  
1372 one binding site or epitope. In this case, an analyte analogon conjugated with a tracer

1373 competes with the analyte in the sample. The analyte analogon is applied in a defined,  
1374 limited concentration to enable balanced competition with the analyte for the binding

1375 antibody.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1376 The integration and automation of immunoassays on centrifugal microfluidic platforms are  
1377 especially regarded as attractive because conventional assay protocols are labor intensive  
1378 and consist of a large number of manual processing steps<sup>61</sup>. As most of the steps are similar  
1379 for a broad variety of assays, platform-based automation offers unique advantages to reduce  
1380 costs and ensure consistent results<sup>193 62 135</sup>. Yet, the most commonly employed platform for  
1381 immunoassays are microtiter plates having, for example, 96 wells in a well-defined pitch<sup>194</sup>,  
1382 where liquid handling can be automated by pipetting robots. In contrast, the microfluidic  
1383 automation of immunoassays offers some unique advantages such as reduced reaction  
1384 times due to reduced diffusion distances, as well as reductions in the reagent and sample  
1385 volumes<sup>156 61</sup>.

1386 As the accuracy of diagnostic findings can be enhanced by simultaneous analyses of  
1387 multiple biomarkers, the degree of multiplexing of one sample within an IA automation is an  
1388 additional important characteristic<sup>194</sup>. Similar to nucleic acid analysis, multiplexing is typically  
1389 achieved by differentiation in the spatiotemporal or spectroscopic domain<sup>194</sup>. In this context,  
1390 we propose an evaluation of centrifugal microfluidic cartridges for immunoassays based on  
1391 the following criteria: the analytical sensitivity (limit of detection, LOD) and  
1392 reproducibility/precision (coefficient of variation, CV) achieved for the specific analysis.  
1393 Further, if the performance criteria for a specific analyte can be met, the time to result and  
1394 degree of automation, integration, parallelization, and multiplexing should be evaluated.  
1395 **Table 7** summarizes important key characteristics of the reviewed systems. The review  
1396 section is split into two subchapters, centrifugal microfluidic systems for ELISA followed by a  
1397 section on other immunoassay formats.

#### 1398 **4.2.1 Centrifugal microfluidic systems for ELISA**

1399 A very prominent format for immunoassays is the enzyme-linked immunosorbent assay  
1400 "ELISA," where an enzyme is used as a tracer in an immunometric assay, and the signal

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1401 generation is a result of a substrate reaction. Different ELISA formats can be realized, such  
1402 as the sandwich and competitive formats mentioned above.

1403 The majority of the steps in the laboratory workflow for a typical heterogeneous sandwich  
1404 ELISA can be automated by utilizing the immunocapture process chain: (1) the  
1405 immobilization of the primary/capture Ab or Ag on a solid phase, (2) binding of the target Ag  
1406 or Ab in the sample to the primary Ab or Ag on the solid phase, and (3) binding of the  
1407 enzyme-labeled secondary/detection Ab to the target Ag or Ab. The blocking process chain  
1408 is thereby applied between the first and second steps to prevent unspecific binding, whereas  
1409 all the steps are separated by multiple washing process chains to rinse away the unbound  
1410 material. The remaining steps for signal generation and detection involve unit operations for  
1411 (4) supplying the substrate solution for the enzymatic reaction, (5) the eventual termination of  
1412 the enzymatic reaction by supplying a stopping solution, and (6) the quantification of the  
1413 enzymatic reaction product. An early centrifugal microfluidic cartridge for ELISA-based  
1414 immunoassays was reported by *Lai* et al. Integrated capillary valves allow for the sequential  
1415 release of pre-loaded reagents into a microchannel with immobilized primary antibodies.  
1416 Each liquid solution displaces the aforementioned into a waste chamber. A singleplex  
1417 analysis of rat IgG from a hybridoma culture proved advantageous with respect to reagent  
1418 consumption and assay time<sup>61</sup>. Later, a similar system was used for the detection of cytokine  
1419 interferon-gamma<sup>192</sup>.

1420 A later approach for direct ELISA was presented by *Riegger* et al. Up to eight separate  
1421 immunoassays could be processed per cartridge in parallel for the detection of the relevant  
1422 biomarkers for acute myocardial infarction. High-speed chemiluminescence detection with a  
1423 photo-multiplier was performed under rotation in less than 1 second<sup>195</sup>.

1424 An increase in parallelization to 18 immunoassays per cartridge was presented by *Nagai* et  
1425 al. A single bead served as the solid phase for the competitive, indirect ELISA targeting a  
1426 mental stress biomarker. Prior to the on-cartridge automation, time-consuming off-chip steps

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1427 had to be performed <sup>136</sup>. An injection-molded cartridge featuring 24 parallel immunoassays  
1428 was reported by *Welte* et al. A multiplicity of unit operations, including capillary siphon and  
1429 hydrophobic valves were integrated to route the reagents. All the reagents had to be loaded  
1430 step-by-step during the protocol <sup>196</sup>.


1431 A totally integrated ELISA for detecting the antigens and antibodies of the hepatitis B virus  
1432 was presented by B. S. *Lee* et al. An integrated process chain for blood-plasma separation  
1433 allowed the use of a whole-blood sample. The routing of the sample and reagents was  
1434 controlled by integrated active laser irradiated ferrowax microvalves. Shake-mode mixing  
1435 was implemented to mix beads (solid phase) with the plasma, detection probe, washing  
1436 buffers, or tetramethyl benzidine (TMB) solution. The parallelization of three separate  
1437 immunoassays allowed tests to be performed for the antigen and antibody of the hepatitis B  
1438 virus, HBsAg and Anti-HBs, and a control, in parallel on a single cartridge. The assay time  
1439 increased by 2/3 compared to processing a single IA. All the required assay components  
1440 were pre-loaded onto the disk <sup>135</sup>. Later, an advanced version of the aforementioned  
1441 injection-molded cartridge, combining the demonstrated IA principle and a biochemical  
1442 analysis applying a lipid test panel (see chapter 4.3) was presented. These tests were  
1443 performed simultaneously from one whole-blood sample, aiming at the detection of CK-MB  
1444 (muscle and brain fraction of creatine kinase) as a biomarker for recent heart attacks <sup>137</sup>.

1445 The combination of a high degree of integration with multiplexing ability was reported by *Park*  
1446 et al. The cartridge featured two ELISAs in parallel (**Fig. 14a**), each capable of testing a  
1447 sample for three targets or controls, respectively. Reagents were pre-loaded onto the  
1448 cartridge prior to the test. An analysis of cardiovascular disease biomarkers in whole saliva  
1449 or blood was performed. The reaction chambers were first flushed with common liquids  
1450 simultaneously. Later, the fluidic pathways were isolated from each other by active laser-  
1451 actuated microvalves for individual substrate and stop solution supply, as well as for

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1452 detection<sup>194</sup>. A schematic representation of the integrated application highlighting the  
 1453 implemented process chains and unit operations is depicted in **Fig. 13**.



**Fig. 13:** Schematic representation of integrated process chains (dashed boxes: blood-plasma separation, immunocapture, and washing) and corresponding sequence of unit operations (solid boxes: Sup.: supply of reagents or sample; Sep.: separation; Val.: valving; Det.: detection)<sup>194</sup>.

1454

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1455 Recently, new readout concepts were the subject of intensified research. A cartridge  
1456 featuring flow-enhanced electrochemical detection under rotation was shown by *Kim* et al.  
1457 This measuring method featured an adjustable sensitivity (LOD values of 21.3, 4.9, and  
1458 84.5 pg/mL for stagnant, flow, and reference, respectively) due to its demonstrated  
1459 dependency on the flow rate. Flow control was realized by integrated active ferrowax  
1460 microvalves. The target biomarkers for cardiovascular disease (CVD) were indirectly  
1461 detected by measuring an electroactive substrate catalyzed by an enzyme conjugated with  
1462 the detection Ab. Liquid reagents were pre-stored on the cartridge prior to sealing <sup>36</sup>.

#### 1463 **4.2.2 Centrifugal microfluidic systems for other immunoassay formats**

1464 The Gyrolab Bioaffy™ cartridge reported the massive parallel integration of fluorescence-  
1465 based immunoassays (FIA). Up to 104 immunoassays can be run in parallel on one  
1466 cartridge. The principle was presented by *Honda* et al. <sup>73</sup> and commercialized by Gyros AB  
1467 <sup>197</sup>. The parallelization degree was realized by omitting the integration of reagent reservoirs  
1468 on the cartridge, while non-contact reagent addition was realized by utilizing the Gyrolab  
1469 Workstation™. Pre-packed bead-microcolumns acting as a solid phase are microfluidically  
1470 connected to individual and mutual inlets, the latter serving eight FIA structures with common  
1471 fluids to reduce processing time. Coating-enhanced capillary filling and hydrophobic valves  
1472 allow for sample volumes down to 200 nL. The injection-molded cartridge was further  
1473 characterized with respect to the recovery, precision, and integration of blood plasma  
1474 separation. The detection of recombinant human interleukin-1 $\beta$  (hIL-1 $\beta$ ), hIL-2, and  
1475 myoglobin for the purpose of determining the performance characteristics was presented by  
1476 *Inganaes* et al. <sup>17</sup>. Up to five cartridges can be processed on the Gyrolab Workstation™ in  
1477 parallel.

1478 Multiplexed FIA for centrifugal microfluidics applying colored beads as the solid phase was  
1479 shown earlier by *Riegger* et al. Here, the beads were color-encoded with dyes or quantum  
1480 dots with theoretical degrees of multiplexing of fifteen and five, respectively. Prior to

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1481 fluorescence readout of the detection Ab, dye and quantum dot beads were identified with  
1482 >90% and >80% reliabilities, respectively. The detection was realized within 15 seconds  
1483 using a color CCD-camera and software algorithm <sup>151</sup>. *Noroozi* et al. demonstrated a  
1484 cartridge with decreased assay time due to enhanced Ag-Ab interaction employing micro-  
1485 mixing by flow reciprocation. Multiplexing was achieved by spotting an array of antigens on  
1486 the surface of the detection chamber <sup>107</sup>. In both setups, reagents had to be loaded step-by-  
1487 step onto the cartridge. Later, the combination of color-coded multiplexing with beads,  
1488 captured in V-shaped cups, was presented by *Burger* et al., where reagents had to be  
1489 introduced to the cartridge step-by-step. <sup>122</sup>

1490 A cartridge replacing the conventional washing steps by the centrifugation of beads through  
1491 a density medium was presented by *Schaff* and *Sommer*. Sedimentation allowed the  
1492 multiplexing of two inflammation biomarkers (interleukin 6 (IL-6)/C-reactive protein (CRP))  
1493 inside a single channel by separating beads of different sizes and densities. A theoretical  
1494 multiplexing degree of >15 was reported. A whole-blood sample (IL-6) could be processed  
1495 without the need of plasma separation. Wax valves employing phase change paraffin were  
1496 integrated into the cartridge for fluidic routing <sup>89</sup>. The presented work was extended by *Koh* et  
1497 al., who showed the detection of three high priority potential bioterrorism agents (**Fig. 14b**)  
1498 <sup>198</sup>.


1499 An early demonstration of label-free IA on a centrifugal cartridge was presented by *Cho* et al.  
1500 <sup>199</sup>. Resonant frequency changes in electromechanical cantilever sensors were used for the  
1501 IA readout. The cantilever required drying *via* centrifugation prior to readout. Reagents were  
1502 pre-loaded prior to testing. Later, a cartridge applying a surface plasmon resonance (SPR)  
1503 sensor for label-free detection was reported by *Otsuka* et al. The SPR allowed for the real-  
1504 time measurement of biomolecular interactions <sup>154</sup>. In this work, the serial fluid transport of all  
1505 the required reagents was realized, similar to *Lai* et al. <sup>61</sup>, by the integration of cascades of  
1506 capillary valves.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1507 A cartridge applying an injection-molded COC surface-confined supercritical angle  
 1508 fluorescence (SAF)-chip in a hybrid assembly for readout was demonstrated by *Nwankire et*  
 1509 *al.* The readout concept allowed simple and cost-efficient hardware components. Hybrid  
 1510 assembly via the stacking of different layers enabled “3D fluidic flow.” Serial capillary siphon  
 1511 valving allowed the sequential release of pre-loaded reagents. All the reagents had to be  
 1512 adjusted for siphon-priming using Tween® 20 <sup>150</sup>.

1513 A rectangular injection-molded cartridge, which could be inserted into a centrifugal  
 1514 processing device, was demonstrated by *W. Lee et al.* The cartridge incorporated a dual-type  
 1515 architecture with two surface acoustic wave (SAW) immunosensors for readout. The liquid  
 1516 flow was controlled by active laser-irradiated ferrowax microvalves, allowing for the  
 1517 preloading of reagents and their release on demand. The sensitivity of the sensor was  
 1518 increased by mass enhancement using gold staining with gold nanoparticle conjugates,  
 1519 along with the detection of Ab targeting biomarkers for acute myocardial infarction. A  
 1520 comparison with a standard laboratory instrument was conducted with 44 patient samples,  
 1521 yielding a correlation coefficient of 0.998 <sup>162</sup>.



**Fig. 14:** Various implementations of immunoassays on the centrifugal microfluidic platform. (a) Bead-based multiplex sandwich ELISA <sup>194</sup>. Depicted are three reaction cavities with differently labeled solid phases and individual substrate solutions (green, red, blue). Shadows were caused by the image acquisition. (Reprinted with permission from the American Chemical Society) (b) Immunoassay based on the sedimentation of antibody-labeled beads through a density medium according to <sup>198</sup>: (1) sample with analyte and (2) detector suspension with beads and labeled antibodies are mixed, forming a layer on (3) a density medium for incubation. Upon rotation, (4) a pellet is formed in the density medium with (5) the sample with unbound label remaining above. (Reprinted with permission from The Chemical and Biological Microsystems Society)

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1522

### 1523 **4.2.3 Trends and perspectives for immunoassay integration**

1524 Besides nucleic acid analyses, immunoassays seem to be the most attractive application for  
1525 automation on centrifugal microfluidic platforms. Centrifugal microfluidics thereby bring the  
1526 unique advantages of reduced assay time and costs, and increased sensitivity to  
1527 immunoassays, by minimizing the diffusion lengths and reagent consumption, and optimizing  
1528 the read-out concepts. Generally, the automation of an immunoassay on a centrifugal  
1529 microfluidic platform proves beneficial for two major operation sites. Either development is  
1530 focused on the maximization of the degree of parallelization<sup>136 196 73</sup> or on the level of  
1531 integration<sup>135 137</sup>, with the ability of point-of-care testing (POCT). Recently, the latter has  
1532 evolved to mature cartridges comprising the pre-storage of all the required reagents and their  
1533 processing in sophisticated devices<sup>137 162</sup>. As parallelization decreases with the increase in  
1534 integration due to the space-consumption of reagent reservoirs and valving concepts, the  
1535 corresponding systems aim at small- to medium-throughput laboratories, doctors' offices,  
1536 patient self-testing sites, or remote areas<sup>135 89</sup>.

1537 Conversely, the required handling steps for cartridges featuring a high degree of  
1538 parallelization may be conventionally automated off-chip by robotic dispensing, as  
1539 demonstrated in the Gyrolab Workstation™<sup>197</sup>. The corresponding systems must thus be  
1540 operated at (already automated) laboratories, with the benefit of bringing the aforementioned  
1541 improvements in centrifugal microfluidics to them.

1542 Independent of the operational site, centrifugal microfluidic systems feature mature process  
1543 chains for the automation of immunoassays. Unique unit operations that are available solely  
1544 on centrifugal microfluidic platforms, are the density difference based separation of plasma  
1545 from blood cells as sample preparation and the excellent performance of bound-free  
1546 separation by scalable volume forces. The latter enabled the miniaturization of

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1547 immunoassays to the nanoliter volume while maintaining sufficient sensitivity and specificity,  
1548 as demonstrated by the Gyrolab Bioaffy LabCD series <sup>200</sup>.

1549 Future research is expected to further improve automation of immunoassays with respect to  
1550 point of care applications. An emphasis could lie on read-out concepts to increase the  
1551 parallelization, sensitivity, and multiplexing, or to improve specificity of label-free detection.

1552 Another emphasis could lie on the reduction of turnaround times.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

**Table 7:** Centrifugal microfluidic systems for immunoassay automation compared by demonstrated degree of multiplexing (defined as number of tested analytes per sample), parallelization (defined as number of tested samples per run), and limit of detection (LOD).

Reference	Assay format/Solid phase/Detection	Sample matrix	Multiplexing	Parallelization	Reagent pre-loading/storage	Total time [min]	Target analyte/LOD
Lai et al. 61	ELISA/channel/florescence	Cell culture	1	up to 24	Yes	> 60	rat IgG/31 nM
Honda et al. 73	FIA/beads/florescence	PBS with BSA	1	104	Yes <sup>1</sup>	50	$\alpha$ -fetoprotein/0.15; interleukin 6/1.25; carcinoembryonic Ag /1.31 pmol L <sup>-1</sup>
Inganaes et al. 17	FIA/beads/florescence	Whole blood	1	104	Yes <sup>1</sup>	50	human interleukin 2; human interleukin 1 $\beta$ ; myoglobin/all subpicomolar
Cho et al. 199	If IA/cantilever/resonance frequency	Buffer solution	1	5	Yes	N/A	Prostate specific Ag/picomolar
Riegger et al. 151	FIA/beads/florescence	Serum	15	4	No	N/A	Tetanus Ab/158; hepatitis A Ab/215 mIU mL <sup>-1</sup>
Riegger et al. 195	ELISA/beads/chemiluminescence	Plasma	1	8	No	N/A	Myoglobin/12.2 ng mL <sup>-1</sup>
Nagai et al. 136	ELISA/beads/fluorescence	Mixture of secretory IgA and HRP-labeled anti-IgA antibodies	1	18	Yes <sup>3</sup>	30 <sup>2</sup>	secretory IgA/6.4 nM
B. S. Lee et al. 135	ELISA/beads/absorbance	Whole blood	1	3	Yes	30 - 50	Hepatitis B Ag/0.51 ng mL <sup>-1</sup> ; anti-hepatitis B Ab/8.6 mIU mL <sup>-1</sup>
Koh et al. 198	FIA/beads/florescence	Serum	N/A	N/A	Yes <sup>3</sup>	< 20	Shiga-like toxin 1/0.8; Ricin/1; Anthrax/1.9 pM
B. S. Lee et al. 137	ELISA/beads/absorbance	Whole blood	1	1	Yes	22	creatine-kinase MB/0.92 ng mL <sup>-1</sup>
Noroozi et al. 107	ELISPOT/membrane/colorimetric	Serum	25	8	No	N/A	Burkholderia Ag/N/A
Schaff and Sommer 89	FIA/beads/florescence	Plasma/whole blood	>15	20	Yes	15	Interleukin 6/63; C-reactive protein/92 pmol L <sup>-1</sup>
Park et al. 194	ELISA/beads/absorbance	Whole blood*/saliva**	3	2	Yes	20	high sens. C-reactive protein/0.27*, 0.30**; cardiac troponin I/0.27*, 0.51**; N-terminal pro-B type natriuretic peptide/0.32*, 0.24** ng mL <sup>-1</sup>
Burger et al. 122	FIA/beads/florescence	PBS with BSA	3	4	No	N/A	mouse anti-ER $\alpha$ IgG; human IgG; rabbit anti-fd bacteriophage IgG/N/A
W. Lee et al.	AuNP IA/SAW sensor/mass	Plasma/whole	1	N/A	Yes	20	cardiac troponin I/6.7 pg mL <sup>-1</sup>

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

<sup>162</sup> Kim et al. <sup>36</sup>	enhancement ELISA/beads/electrochemical	blood PBS	1	3	Yes	< 20	C-reactive protein/4.9 pg mL <sup>-1</sup>
Nwankire et al. <sup>150</sup>	FIA/SAF chip/fluorescence	Bioprocess sample	1	N/A	No	< 30	human IgG/N/A
Welte et al. <sup>196</sup>	CLIA/chamber/chemiluminescence	Standard solution	1	24	No	45	Estradiol/60 pg mL <sup>-1</sup>
Otsuka et al. <sup>154</sup>	If IA/SPR sensor/	Buffer solution	1	8	Yes	N/A	human IgA/N/A

LOD = limit of detection, ELISA = enzyme-linked immunosorbent assay, IgG = immunoglobulin G, FIA = fluorescence based immunoassays, CLIA = chemiluminescent IA, Ag = antigen, PBS = phosphate buffered saline, BSA = bovine serum albumin, If = label-free, Ab = antibody, IgA = immunoglobulin A, HRP = horseradish peroxidase, MB = muscle-brain type, ELISPOT = enzyme-linked ImmunoSpot assay, AuNP = gold nanoparticle, SAW = surface acoustic wave, SPR = surface plasmon resonance, SAF = supercritical angle fluorescence, <sup>1</sup>reagents are automatically dispensed by a robotic loading system, <sup>2</sup>off-chip sample and detection Ab incubation requires 90 min, <sup>3</sup>essential assay steps take place off-chip.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

### 1553 **4.3 Clinical chemistry**

1554 If clinical chemistry parameters can be measured at the point-of-care, patients can be  
1555 diagnosed faster, and treatment can start immediately. A reduced turnaround time for  
1556 laboratory tests offers the opportunity to better monitor a patient's health, reduce  
1557 unnecessary treatments, and reduce hospital costs <sup>201</sup>. Examples of parameters that  
1558 especially benefit from short turnaround times are glucose and electrolytes (e.g., sodium or  
1559 potassium) <sup>201</sup>. Centrifugal microfluidics makes it possible to analyze such parameters in a  
1560 portable device directly from whole blood, by combining centrifuge-based plasma separation  
1561 with subsequent automated assays <sup>82</sup>.

1562 This has made blood-based clinical chemistry analyzers the most commercially successful  
1563 field of centrifugal microfluidics. Among the centrifugal microfluidic systems available are the  
1564 Piccolo xpress (Abaxis), and the Cobas b 101 (Roche). With a total of 1.5 million cartridges  
1565 sold in 2011, the Abaxis piccolo xpress is currently the most-used system <sup>9</sup>.

1566 By nature, most commercial systems do not reveal the detailed fluidics. Nonetheless, to  
1567 discuss blood separation methods as a preparation step for clinical chemistry, this section  
1568 starts with a review of the blood separation techniques presented in scientific journals.  
1569 Subsequently, we highlight the major advances in both commercially available and scientific  
1570 applications of clinical chemistry on centrifugal microfluidic platforms.

#### 1571 **4.3.1 Blood separation techniques**

1572 Blood is one of the biological samples with the most information about a patient's health  
1573 condition. For this reason, it is commonly used in diagnostics. The analysis of blood samples  
1574 requires either whole blood, purified plasma, white blood cells, or rare cells. One of the most  
1575 prominent and best-researched process chains in blood analysis on centrifugal platforms is  
1576 the separation of plasma from whole blood (**Table 8**). It includes two steps, namely the  
1577 sedimentation of blood cells by centrifugation and the decantation of the purified plasma.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1578 These steps can be performed continuously or batchwise. Blood plasma is required for  
1579 determining the concentrations of glucose, lipids, electrolytes, proteins, and other substances  
1580 such as alcohol in human blood. Assays based on colorimetric detection require high-purity  
1581 plasma, i.e., a low concentration of red blood cells. The purity is commonly defined as  $1 -$   
1582  $HCT$ , where  $HCT$  is the hematocrit and denotes the volume fraction of red blood cells in a  
1583 whole blood sample. Other relevant characteristics for blood plasma separation are the  
1584 process duration, maximum hematocrit for operation, and plasma yield, which is defined as  
1585 the fraction of extracted plasma in reference to the total plasma volume.

1586 Continuous plasma separation has been demonstrated employing a quasi-isoradial channel,  
1587 in which the blood cells sediment at the outer perimeter and eventually slide into a waste  
1588 chamber<sup>127</sup>. During this process, the blood plasma also flows into the waste chamber, but  
1589 remains at a radially inner position due to its lower density. As the waste chamber becomes  
1590 full, the purified plasma decants into a collection chamber and is available for further  
1591 downstream processing. The process of cell sedimentation can be amplified by the Coriolis  
1592 force and the inertial force that pushes the cells toward the outer rims of bent channels<sup>202 128</sup>.

1593 In batch plasma separation, for the decantation of supernatant plasma after cell  
1594 sedimentation, a siphon is used in combination with a sedimentation chamber, where the  
1595 cells are concentrated by centrifugation. Dynamics of cell sedimentation are described by the  
1596 equilibrium of centrifugal force and drag force (Eq. 1 vs. Eq. 10). The inlet position of the  
1597 siphon is chosen such that it is located radially inward of the shock interface, i.e., the  
1598 interface between the concentrated cells and purified plasma. Subsequent siphon priming  
1599 can be accomplished either by capillary action at a greatly reduced spin speed<sup>203</sup> or by  
1600 pneumatic action<sup>85 126</sup>. The latter does not require any surface treatment because the  
1601 pneumatic action is independent of the surface properties. In addition, it enables plasma  
1602 extraction at a relatively high spin speed, which allows the cell resuspension by Euler forces  
1603 to be suppressed. Apart from resuspension, the diffusion of cells back into the purified

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1604 plasma should also be minimized, which can be achieved by creating a small interface  
1605 between the two chamber compartments for cells and purified plasma <sup>204</sup>.

1606 An alternative method for batchwise plasma separation without siphon valving has been  
1607 presented for bead-based immunoassay <sup>135</sup> and ELISA <sup>194</sup>. After loading the blood sample  
1608 into the microfluidic disk and the sedimentation of cells by centrifugation, valving of the  
1609 supernatant plasma was performed by opening a ferro-wax valve. The normally closed valve  
1610 opened upon laser irradiation with response times of less than 1 s when the disk was at rest.

**Table 8:** List of methods for blood plasma separation on centrifugal microfluidic cartridge.

Reference	Separation principle	Sample Volume [ $\mu\text{L}$ ]	Duration [s]	Yield* [%]	Purity	Maximum hematocrit (HCT) [%]
Burger R. et al. <sup>125</sup>	Centrifugo-pneumatic gating	5	120	80	20 cells $\mu\text{L}^{-1}$	N/A
Zehnle S. et al. <sup>126</sup>	Centrifugo-pneumatic valving	40	43	88	99.8%	60
Amasia M. et al. <sup>203</sup>	Capillary siphon	2000	320	77	>99.99%	49
Zhang et al. <sup>202</sup>	Multi-force separation	0.5	1-2	22	99%	6
Haerberle S. et al. <sup>127</sup>	Separation by decanting	5	20	N/A	>99.89%	N/A

\*Yield is defined as the portion of plasma volume extracted from the total plasma volume.

### 1611 4.3.2 Centrifugal microfluidic systems for clinical chemistry

1612 One of the roots of centrifugal microfluidics is the centrifugal analyzer. This system was used  
1613 with numerous rotors and applications for several clinical chemistry assays, e.g., ions and  
1614 glucose <sup>205</sup>. The rotor was filled with liquid dispensers. The samples and reagents were  
1615 mixed in end cavities by the centrifugation of the rotor. Read-out was performed via a  
1616 spectrophotometer.

1617 *Nwankire* et al. presented a system for point-of-care liver function screening. The analyzer  
1618 consisted of a small portable disk player and centrifugal microfluidic cartridge. The cartridge  
1619 included automated blood plasma separation from finger-prick samples. After separation, the  
1620 purified blood plasma was aliquoted into five reaction chambers via centrifugo-pneumatic

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust


Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1621 aliquoting based on dissolvable films. The reactions were quantified via colorimetric  
1622 measurements. A translation of the integrated functionality into a schematic description  
1623 highlighting the combination of process chains and unit operations is depicted in **Fig. 15**. The  
1624 authors successfully tested the system in a centralized lab in Nigeria, with a time to result for  
1625 the complete assay panel of 20 min <sup>206</sup>.

1626 *Lin et al.* demonstrated a centrifugal disk for blood coagulation. The disk detects both, partial  
1627 thromboplastin time and activated partial thromboplastin time. After aliquoting of blood, the  
1628 blood plasma is separated <sup>207</sup>. The separated plasma aliquots are then combined with either  
1629 a first reagent for quantification of partial thromboplastin time or with a first and second  
1630 reagent for quantification of the activated partial thromboplastin time <sup>208</sup>. Both parameters  
1631 were quantified via colorimetric measurements in a microfluidic disk analyser <sup>209</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications



**Fig. 15:** Schematic representation of microfluidic process, including implemented process chains (dashed boxes; TBIL: total bilirubin; (a) albumin; (b)  $\gamma$ -glutamyltransferase; ALP: alkaline phosphatase; DBIL: direct bilirubin) and unit operations (solid boxes; Sup.: supply of reagents or sample; Aliq.: aliquoting; Val.: valve; Det.: detection; Mix.: mixing)<sup>206</sup>.

1632

1633

1634

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1635 Typically, clinical chemistry testing involves absorbance-based measurements such as those  
1636 applied to determine the concentrations of glucose<sup>149</sup> and alcohol<sup>101 203</sup> in whole blood.

1637 Recently, an electrochemical lab-on-a-CD system for whole blood analysis was introduced  
1638<sup>161</sup>. This system incorporates nanoporous electrodes coated with an enzyme layer that  
1639 triggers the production of H<sub>2</sub>O<sub>2</sub> in the presence of a specific analyte. By applying a potential,  
1640 the concentration of H<sub>2</sub>O<sub>2</sub> can then be detected electrochemically. The system performance  
1641 was comparable to colorimetric methods for the tested analytes (glucose, lactate, and uric  
1642 acid) and could easily be extended to other enzymatic reactions producing H<sub>2</sub>O<sub>2</sub>.

1643 Most of the centrifugal microfluidics systems for clinical chemistry reported so far have  
1644 focused on blood samples. However, a notable exception is a recently presented cartridge  
1645 featuring an assay for the determination of N-Acetyl- $\beta$ -D-glucosaminidase activity from urine  
1646<sup>210</sup>. From 15  $\mu$ L of artificial urine, 330 nL was metered using two-stage metering with capillary  
1647 valves and mixed with 5  $\mu$ L of a substrate solution. After 20 min of enzyme reaction, the  
1648 incubated mixture was transferred via a second capillary valve to the read-out cavity, where it  
1649 was mixed with a stop solution, and readout was performed using fluorescence detection.

1650 The Abaxis Piccolo Xpress offers a range of cartridges with different lyophilized reagents for  
1651 a wide variety of whole-blood and blood-plasma tests, including a lipid panel and an  
1652 electrolyte panel for veterinary and medical diagnostics. All the cartridges are based on the  
1653 same microfluidic operations, making it a perfect example of a platform-based approach<sup>10</sup>.  
1654 Blood plasma is separated from 100  $\mu$ L of the patient's blood. At the same time, a pre-stored  
1655 diluent is released from a central container. A defined volume of diluent and blood plasma  
1656 are then combined via capillary siphons and mixed using shake-mode mixing. The mixture is  
1657 subsequently aliquoted into 21 test cavities via one-stage aliquoting. Up to 12 test reactions  
1658 can be monitored on one cartridge using nine different wavelengths. For online quality  
1659 control, multiple cuvettes are used to ensure that the sample is introduced and the diluent is  
1660 released properly<sup>211 82</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1661 The Samsung LABGEO A20A system is based on a previously reported combined  
1662 immunoassay (see chapter 4.2) and biochemical analysis of whole blood <sup>137 212</sup>. The system  
1663 reported by *B. S. Lee et al.* uses up to 350  $\mu\text{L}$  of a patient's blood for both the immunoassay  
1664 and biochemical analysis. Plasma separation, valving, incubation, washing, mixing, and  
1665 aliquoting are controlled on the disk using ferrowax valves. In contrast to earlier published  
1666 methods, the system generates two different dilutions of blood plasma. According to the  
1667 authors, this allows for the integration of a wider range of assays. Read-out is done by the  
1668 absorbance at 10 different wavelengths <sup>137</sup>. The total reported analysis time for all the liquid  
1669 operations was 22 min.

1670 The Roche Cobas b 101 currently offers disks for HbA1c and a complete lipid profile. The  
1671 required blood volumes are 2  $\mu\text{L}$  for the HbA1c test and 19  $\mu\text{L}$  for the lipid profile. The  
1672 analysis time for each disk is about 6 minutes. A unique feature of the disks is a sideways lid  
1673 within the disk plane. This lid covers the inlet, which can be used to aspirate a patient's blood  
1674 directly from a finger stick onto the disk, thereby eliminating the need for pipettes or  
1675 capillaries.

### 1676 **4.3.3 Trends and perspectives in clinical chemistry**

1677 With multiple commercial systems already on the market, centrifugal microfluidics for clinical  
1678 chemistry analysis is a comparatively mature technology. A major advantage of centrifugal  
1679 microfluidics for clinical chemistry is the straight forward automation of blood plasma  
1680 separations. To date, plasma separation from whole blood is a well-studied process chain  
1681 and is ready to be integrated in fluidic networks with higher complexity. The recent  
1682 developments confirm the trends observed in the development of unit operations, namely the  
1683 obviation of surface pre-treatment. The functional extension of plasma separation to the  
1684 separation of white blood cells (WBCs) and circulating tumor cells (CTCs) has already been  
1685 realized, and might be of increasing importance in the future. Regarding other applications in  
1686 clinical chemistry, recent trends show potential for future developments in alternate sample

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1687 materials (urine <sup>210</sup>, stool) and in the integration of novel read-out methods like

1688 electrochemical read-out <sup>161</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

#### 1689 **4.4 Cell handling, separation, and analysis**

1690 In the last few years, a growing interest in cell handling on centrifugal microfluidic platforms  
1691 could be observed <sup>213</sup>. Starting from cell suspensions with concentrations generally in the  
1692 range of 10–10<sup>3</sup> cells per microliter, researchers have developed methods to isolate, count,  
1693 and separate different cell types. To date, these methods can be categorized into three  
1694 different types: geometric, magnetophoretic, and dielectrophoretic approaches.

1695 Geometric cell isolation employs centrifugation to pump a suspension of cells along micro-  
1696 cavities in a centrifugal disk. These cavities are arranged to capture and trap mammalian  
1697 cells or bacteria, where they can be used to perform an assay <sup>214 215 173</sup>. Cell isolation  
1698 enables studies and analyses of single cells in a defined environment. As an example, the  
1699 cytotoxicity of paraformaldehyde has been tested using isolated HEK293 cells, and apoptosis  
1700 tests have successfully been performed with isolated Jurkat cells after UV exposure <sup>214</sup>. In  
1701 order to test the applicability of such isolation methods, cell isolation has been combined with  
1702 cell viability tests based on cell staining and fluorescence microscopy. In this way, the  
1703 isolation performance can also be determined by testing the cell occupancy of the cavities  
1704 on-disk. After cell isolation, single cell PCR makes it possible to determine the cell type, as  
1705 demonstrated with *Salmonella enterica*. The bacteria were lysed thermally within the disk,  
1706 and a specific *Salmonella* gene was amplified. In this work, the disk consisted of a micro-  
1707 structured silicon wafer bonded to glass <sup>173</sup>. *Burger et al.* extended their V-cup array for  
1708 geometrical cell capture under stopped flow (cf. section 3.6.1) by an optical setup comprising  
1709 optical tweezers and a fluorescence microscope. In that, cells from different cell lines could  
1710 be discriminated by fluorescence imaging. As a preparative step for single cell assaying, a  
1711 single target cell of the HL-60 line could be selected and moved to a defined location within  
1712 the PDMS disk using the optical tweezers <sup>216</sup>.

1713 While geometrical cell isolation aims at all cell types within a certain size range,  
1714 magnetophoresis can be employed to extract specific cells that are tagged to magnetic

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1715 beads. In this process chain, magnets are used on-disk or off-disk to attract magnetically  
1716 labeled target cells (positive selection) or non-target cells (negative selection). The  
1717 magnetically labeled cells can be either deflected or immobilized using the interplay of  
1718 centrifugal and magnetic forces, and can thus be separated from the non-labeled cells. In  
1719 positive selection approaches, rare MCF-7 cancer cells have been separated from  
1720 background Jurkat cells <sup>217</sup> or whole blood <sup>218</sup> using on-disk magnets. In a negative selection  
1721 approach, non-target cells labeled with magnetic beads were separated from target MCF-7  
1722 cells with rarities down to  $10^{-6}$ . While the labeled non-target cells were kept at a radially inner  
1723 position, the target cells were centrifuged and concentrated radially outward <sup>164</sup>.

1724 A further cell-handling possibility was shown using electrically contacting centrifugal  
1725 microfluidic cartridges <sup>120 219</sup>. These made it possible to combine centrifugation with  
1726 dielectrophoresis. In a hybrid setup, platinum coated glass slides that formed a microfluidic  
1727 channel were mounted onto a centrifugal disk, together with two 9-V batteries for the power  
1728 supply and a signal generator. At a spin frequency of 25 Hz, U-937 lymphocytes were  
1729 separated from erythrocytes in diluted human whole blood <sup>219</sup>.

1730 Apart from the isolation and purification of cells, the cell count is a central parameter to  
1731 obtain quantitative diagnostic results. In particular, the hematocrit is a significant indicator for  
1732 the physiological condition of a patient. With the use of a single dead-end channel in a  
1733 microfluidic disk, cell sedimentation has been demonstrated in a standard CD drive. After  
1734 processing, the hematocrit was determined visually from a scale bar on the disk <sup>148</sup>.

1735 A similar method has been employed to assess the count of bovine somatic cells in milk, as  
1736 well as the fat content of milk <sup>220</sup>. For a case where discrimination between different cell  
1737 types is not required, a standard CD drive was used to run a modified data CD that  
1738 incorporated a microfluidic PDMS layer. Once a cell suspension was injected into the  
1739 microfluidic layer, the CD was run to check the data error rate arising from defects (or

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1740 biological cells) on the CD. It was shown that the error rate was proportional to the  
1741 concentration of cells <sup>221</sup>.

1742 The increasing demand for mobile diagnostic platforms also includes the ability to isolate,  
1743 count, and discriminate between different white blood cells (WBCs). The first publications in  
1744 this field had the goal of centrifugation using gradient density media. Such methods take  
1745 advantage of the fact that different cells have different mass densities. Blood constituents are  
1746 concentrated by centrifuging the blood, together with one or more gradient density media  
1747 (DGM) with densities ranging between those of the blood constituents. In this way,  
1748 concentrated layers of the desired species can be formed, made visible, and quantified by  
1749 specific fluorescent labeling, and even isolated by siphon valving the different layers <sup>222 223</sup>.

1750 *Park et al.* presented a way to use anti-EpCAM to selectively bind rare circulating tumor cells  
1751 (CTCs) to magnetic beads which were centrifuged and collected separately from a 5-mL  
1752 blood sample. The high density of the magnetic beads made it possible to centrifuge the  
1753 bead-bound CTCs through a density gradient medium (DGM) that had a lower density than  
1754 the beads, but a higher density than the blood sample. In this process chain, the fluidic  
1755 routing was realized using laser-triggered ferro-wax valves. The procedure included an  
1756 incubation time of 1 hour to bind the CTCs (100 HCC827 lung cancer cells per 5 mL) to the  
1757 beads, while a recovery rate of over 95%, cell viability of around 90%, and purity of  
1758 approximately 12 remaining leukocytes per milliliter could be achieved <sup>224</sup>. The implemented  
1759 sequence of process chains and unit operations for this work is depicted in **Fig. 16**. Recently,  
1760 *Lee et. al* isolated CTCs from whole blood samples circumventing the need for functionalized  
1761 beads. Instead, a thin membrane with a pore size of 8  $\mu\text{m}$  was implemented in a leak-proof  
1762 fashion in the centrifugal disk. In this way, more than 50 % of MCF-7 cells could be captured  
1763 from whole blood samples with different concentrations of spiked MCF-7 cells. While red  
1764 blood cells could be discarded completely, the number of captured white blood cells could be  
1765 reduced by a factor of 20, compared to the ScreenCell system that was used for reference <sup>7</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications


#### 1766 **4.4.1 Trends and perspectives in cell handling**

1767 The process chains for cell handling and analysis are rather new in the field of centrifugal  
1768 microfluidics, with specific unit operations consisting of geometric, density, or affinity-based  
1769 separation. However, based on the knowledge that has been accumulated in this field, the  
1770 processing of cell suspensions could become more comprehensive. Such processing could  
1771 include cell differentiation between white blood cells, epithelial cells, and rare cells, as well as  
1772 cell counting and multidimensional cell processing. Due to the generation of artificial gravity,  
1773 centrifugal platforms offer unique possibilities for cell collection, similar to blood plasma  
1774 separation techniques. The use of density gradient medium enables the concentration of  
1775 target cells inbetween fluid layers of specific density. On-chip magnetophoresis might be one  
1776 promising approach for multidimensional cell separation, while dielectrophoresis could be  
1777 employed for cell sorting. Together with appropriate analysis techniques, integrated in  
1778 processing devices, cell-based sample-to-answer systems could potentially be realized.

1779

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications



**Fig. 16:** Schematic representation of implemented sequence of process chains (dashed boxes) and unit operations for separation of CTC by immunocapture (solid boxes; Sup.: supply of reagents or samples; Sep.: separation; Val.: valving; Col.: collection of product)<sup>224</sup>.

1780

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

## 1781 **4.5 Water, food, and soil analyses**

1782 Currently, complex environmental and food quality analyses mostly depend on manual  
1783 sample collection and analyses with standard laboratory procedures such as autosamplers  
1784 <sup>225</sup>. However, in many cases, these methods are too labor- and cost-intensive for continuous  
1785 sampling at point-of-care. A possible solution would be a portable bio-sensor, capable of  
1786 sampling environmental or food samples directly on-site with minimal sample preparation.  
1787 For this purpose, centrifugal microfluidics is a promising approach. In the following, we  
1788 describe the available centrifugal microfluidic cartridges for water, food, and soil analyses.

### 1789 **4.5.1 Water analysis**

1790 In water analysis, the most common parameters of interest are ions, pH, turbidity, organic  
1791 contaminants, and waterborne pathogens.

1792 Spa and pool water is one of the largest markets for on-site water analysis <sup>226</sup>. One  
1793 commercially available system is the LaMotte Water Spin for pH and ion sensing. Water is  
1794 inserted into the cartridge via a syringe and split into 10 receiving cavities, containing pre-  
1795 stored reagents, using one-stage aliquoting. Two different test panels with up to ten different  
1796 parameters are available for the system: a chlorine disk and biguanide disk <sup>227</sup>. These disks  
1797 are processed, and reactions are read out on a portable instrument using spectrophotometry.  
1798 According to LaMotte, the system achieves “[...] *greater precision than current water labs*  
1799 *without time consuming procedures or sacrificing accuracy by using test strip scanners*” <sup>16</sup>.

1800 Other fields for water analysis are waste, river, lake, and sea water. *Czugala* et al. introduced  
1801 a cartridge used for turbidity measurement and colorimetric pH analysis. The turbidity is  
1802 measured from particles at a filter structure integrated directly after the sample inlet. Different  
1803 pH levels can be measured via the absorbance of prestored ion-gels. Up to seven samples  
1804 can be processed on one disk (**Fig. 18a**). The capability of the system was first  
1805 demonstrated using water samples from the Tolka River (Dublin, Ireland) <sup>118</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1806 *Hwang* et al. showed a disk for the colorimetric detection of nutrients in water. The disk was  
1807 loaded with up to four samples (**Fig. 18b**). After the on-disk filtration of particulates, each  
1808 sample was aliquoted, and the concentrations of five different targets, ammonium, nitrite,  
1809 nitrate, silicate, and orthophosphate, could be measured in parallel. The integration of the  
1810 high number of independent tests per sample was made possible via the use of ferrowax-  
1811 based microvalves for both liquid routing and reagent pre-storage. The first demonstrations  
1812 of the cartridge were performed using seawater from Chunsu Bay, Korea <sup>32</sup>. The integrated  
1813 process, highlighting the implemented process chains and unit operations, is shown in a  
1814 schematic representation in **Fig. 17**.



Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1821 agreement with those of standard laboratory methods, but did not yet reach the same  
1822 sensitivity <sup>153</sup>.


1823 *LaCroix–Fralish* et al. presented a minimalistic single-step centrifugal microfluidic disk for the  
1824 determination of nitrite and hexavalent chromium in natural water and wastewater. The disk  
1825 consisted of 24 chambers loaded with dry reagents. In each cavity, an individual sample  
1826 could be loaded, mixed, and measured using spectrophotometric detection <sup>44</sup>. The platform  
1827 was later extended to two-step reactions using a single capillary valve between two  
1828 chambers. This cartridge was then used for simultaneous nitrate and nitrite analyses of up to  
1829 twelve samples each <sup>228</sup>. To further extend the dynamic range of the system, *Kong* et al.  
1830 included a serial dilution step in the cartridge. After the first measurement in the first cavity,  
1831 the sample is pumped inward using an external pneumatic source. Part of the sample is  
1832 metered and mixed with a diluent in a second measurement cavity. The system can be used  
1833 for the simultaneous determination of aqueous sulfide in up to three samples. The included  
1834 three-fold dilution allowed for an increase in the dynamic range from 0.4–2.0 mg/L to 0.4–6.0  
1835 mg/L <sup>229</sup>.

1836 To detect trace metals and organic contaminants in drinking water, the pre-concentration of  
1837 the contaminants is often required <sup>230</sup>. *Lafleur* et al. proposed a cartridge for on-site pre-  
1838 concentration using solid-phase extraction. This cartridge consisted of an inlet, a silica gel  
1839 column, and an overflow reservoir. The capability of the cartridge was demonstrated for the  
1840 quantification of trace metals via inductively coupled plasma mass spectrometry <sup>231</sup> and for  
1841 organic contaminations via fluorescent excitation using an external LED <sup>232</sup>. The system  
1842 could be used for the easy handling of sample material at the point of interest and the later  
1843 analysis of the cartridge in a laboratory environment <sup>232</sup>.


Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

a) Cartridge for pH and turbidity measurement of river water



b) Cartridge for determination of nutrients in water



**Fig. 18:** Embodiments of centrifugal microfluidic cartridges for water analysis. (a) Cartridge for turbidity and pH measurement reported to Czugala et al. This cartridge includes a filter region for the removal of solid contaminants larger than  $86\ \mu\text{m}$  (1), along with a sensing area (2) and sedimentation region for solid contaminants smaller than  $86\ \mu\text{m}$ <sup>118</sup>. (Reproduced with permission from The Royal Society of Chemistry) (b) Cartridge for measurement of nutrients in water<sup>32</sup>. Five different reactions can be performed in parallel using a single sample. (Reproduced with permission of the American Chemical Society)

#### 1844 4.5.2 Soil & food analyses

1845 One of the strengths of the platforms based on centrifugal microfluidics is their ability to  
 1846 process comparatively complex sample materials. Examples of such applications are food  
 1847 quality analysis and the analysis of soil for contaminants.

1848 A cartridge for the liquid–solid extraction of pyrene, an organic pollutant from soil was  
 1849 presented by *Duford* et al.<sup>233</sup>. In this cartridge, three cavities are radially connected via  
 1850 capillary valves. In the first cavity, soil samples are mixed by an inserted magnet and  
 1851 external magnetic fields. The extraction is then transferred to the second chamber, where  
 1852 solid particulates are filtered out via sedimentation. Subsequently, the liquid is transferred to  
 1853 the third chamber, where the target analyte can be quantified via UV-absorbance. The same  
 1854 cartridge concept was later used for the inhibition-based determination of pesticide residues  
 1855 of carbofuran in both soil and vegetable samples<sup>232</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1856 A major risk to the integrity of foodstuff and the food supply chain are bio-terroristic attacks.  
1857 One potential candidate for such attacks is botulinum neurotoxin. A large number of  
1858 individuals could be affected if this neurotoxin was used to contaminate the environment or  
1859 food chain. Currently, botulinum neurotoxin is mainly tested in mouse models, which takes  
1860 several days. Alternative in-vitro tests such as ELISA are not sensitive to a wide range of  
1861 toxin forms and types. Thus, *Van Oordt* et al. developed a centrifugal microfluidic cartridge  
1862 for the bioluminescence-based detection of botulinum neurotoxin in water, milk, and other  
1863 food samples. First, the cartridge is filled with a sample and luciferase-coated bead mixture.  
1864 The luciferase is linked to the beads via a peptide linker, which is cleaved specifically by  
1865 enzymatic active botulinum toxin. After the incubation of the beads in the sample, the sample  
1866 is separated by a siphon structure and combined with a luciferin substrate. The concentration  
1867 of active botulinum toxin is determined by the intensity of the bioluminescence signal as a  
1868 result of the luciferase reporter assay<sup>234</sup>.

1869 *Garcia-Cordero* et al. developed a centrifugal microfluidic cytometer for milk quality analysis.  
1870 A milk sample (150  $\mu$ L) is pipetted into the cartridge. Under artificial gravity during  
1871 centrifugation, denser cells are pelleted in a dead-end funnel structure. The less-dense fat  
1872 rises to the top, forming a cream band. By reading out the cell pellets via a microscope, the  
1873 system can determine cell numbers between 50,000 to 3,000,000 to diagnose bovine  
1874 mastitis. The fat content of the milk is measured from the cream band in order to additionally  
1875 estimate the health and nutritional status of the cow<sup>220</sup>.

#### 1876 **4.5.3 Trends and perspectives in water, food, and soil analyses**

1877 In future work, we expect smaller-footprint devices that can be operated on-site, like the one  
1878 presented by *Czugala* et al. and *LaMotte*<sup>227</sup>. In order to get closer to the throughput of the  
1879 currently used autosamplers, more samples might be integrated per disk<sup>32</sup>, or automatic disk  
1880 changers could be integrated into the disk processing devices. The first systems toward the  
1881 nucleic acid-based detection of pathogenic microorganisms in water and food are already in

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1882 the research phase<sup>20</sup> and might enter the industrial validation and product development  
1883 stage in the future<sup>9</sup>. A specific advantage of centrifugal microfluidics in the field of water,  
1884 food and soil analysis is the ability to integrate density driven separations of emulsions and  
1885 suspensions.

#### 1886 **4.6 Analysis of protein structure and function**

1887 Proteins are one of the essential building blocks of life. Consequently, an analysis of the  
1888 structure and function of protein is important for a variety of applications, from basic research  
1889 to pharmaceutical studies. In the following, we present a selection of the contributions to  
1890 protein structure analysis using a centrifugal microfluidic platform.

1891 Protein structures analyzed by X-ray crystallography still constitute the majority of proteins in  
1892 the Protein Data Bank. Protein crystallography could benefit significantly from the reduced  
1893 volumes and increased parallelization offered by microfluidics, because of the large number  
1894 of different screening conditions needed for generating high-quality protein crystals and the  
1895 limited amount of purified protein solutions available<sup>235 103</sup>.

1896 A centrifugal microfluidic cartridge for protein crystallization was presented by *Li* et al. It  
1897 automated the metering of 24 different precipitants and the two-stage aliquoting of the  
1898 protein solution into the respective mixing wells. All the aliquoting and metering was  
1899 controlled via the capillary filling of inverted V-shaped structures, with the valving controlled  
1900 by capillary valves. The cartridge was used to demonstrate the on-disk crystallization and  
1901 analysis of cyan fluorescent protein and lysozyme<sup>103</sup>.

1902 *Steinert* et al. presented a cartridge for the protein crystallization screening of up to 100  
1903 different precipitants on one disk via free interface diffusion. The disks could be filled with  
1904 protein volumes down to 1 nL using PipeJet dispensers<sup>163</sup>. Protein crystals of lysozyme,  
1905 proteinase K, insulin, and catalase were successfully grown and could be measured on-chip  
1906 at a synchrotron beamline<sup>163</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

#### 1907 **4.7 Other applications of centrifugal microfluidics**

1908 Apart from the studies covered in the previous chapters, there are numerous creative  
1909 solutions that do not fit into the previously discussed categories, but deserve to be covered in  
1910 this review.

1911 *Gubala* et al. introduced a simple cartridge to study biomolecule adsorption in microfluidic  
1912 channels. A 40- $\mu$ L sample was introduced on one side of the chip. It was then transported  
1913 through a microfluidic channel by spinning on a standard spin coater. Part of the volume was  
1914 extracted, and the concentration of the Cy5 tagged biomolecules was quantified via a  
1915 fluorescence measurement. The amount of molecules adsorbed could be calculated from the  
1916 difference in the concentrations before and after processing<sup>236</sup>.

1917 *Burchet* et al. investigated the use of a centrifugal microfluidic platform for the analysis of  
1918 nuclear spent fuels. In a typical setting, nuclear spent fuels are dissolved in nitric acid and  
1919 analyzed in a specially shielded hot cell. The authors showed a 1000-fold reduction in the  
1920 required volume using centrifugal microfluidics, which allowed the analysis to be performed  
1921 in a glove box. In a first proof of concept, *Burchet* et al. showed that a centrifugal microfluidic  
1922 cartridge with an integrated monolithic anion exchange stationary phase was capable of  
1923 extracting europium at a yield of ~97%<sup>237</sup>.

1924 *S.-K. Lee* et al. presented a cartridge for the generation of photonic crystals. The cartridge  
1925 was used to centrifuge suspensions of monodisperse silica or polystyrene latex spheres into  
1926 dead-end channels, where the nanoparticles formed closely packed columns with predefined  
1927 shapes. By subsequently spinning different bead solutions, the authors were able to fabricate  
1928 hybrid colloidal crystals<sup>238</sup>.

1929 *Glass* et al. reported on a miniaturized centrifugal microfluidic cartridge for potential use in  
1930 handheld devices (miniLOAD). The 10-mm disk could be rotated by acoustic actuation,

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1931 eliminating the need for moving parts. The authors presented valving and mixing as the first

1932 simple unit operations on this platform <sup>239</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

## 1933 5 Embodiments of centrifugal microfluidic platforms

**Table 9:** Embodiments of centrifugal microfluidic platforms that are either currently commercially available, in precommercial phase announcing release date in near future, or show promising developments.

Reference	Provider (Developer)	Identifier Cartridge/ Name of System	Applications	Commercialization status
<sup>15</sup>	Abaxis	Piccolo Xpress	Blood parameter analysis	Commercially available
<sup>240</sup>	Samsung	LABGEO IB10	Immunoassays	Commercially available
<sup>241</sup>	Focus Diagnostics (3M)	Universal Disc & Direct Amplification Disk/ Integrated Cyclor	Nucleic acid analysis	Commercially available
<sup>242</sup>	Roche (Panasonic)	Cobas 101b	Blood parameter analysis (HbA1c and lipid panel)	Commercially available
<sup>243</sup>	Capital Bio	RTisochip	Nucleic acid analysis (respiratory tract infections)	Commercially available
<sup>197</sup>	Gyros AB	Gyrolab Bioaffy CD	Immunoassays	Commercially available
<sup>16</sup>	LaMotte	Water Link Spin Lab	Water analysis	Commercially available
<sup>244</sup>	Skyla	VB 1 Veterinary Clinical Chemistry Analyzer	Blood chemistry testing for veterinary applications	Commercially available
<sup>245</sup>	Biosurfit	Spinit	Immunoassays/blood parameter analysis	Commercially available
<sup>246</sup>	Radisens Diagnostics	Unknown	Immunoassay, clinical chemistry, and hematology assays	Precom (planned 2015)
<sup>247</sup>	GenePOC-Diagnostics	Unknown	Nucleic acid	Precom (planned 2016)
<sup>248</sup>	Spin Chip Diagnostics	Unknown	Blood analysis	Development
<sup>174</sup>	Espira Inc.	Unknown	Nucleic acid analysis	Development
<sup>38</sup>	HSG-IMIT	LabTube	Various applications	Development
<sup>249</sup>	Sandia National Labs	Spin DX	Various applications	Development

1934

1935 Many different embodiments (platforms) employing centrifugal microfluidics for a wide range  
 1936 of applications have been demonstrated in the quite short history of the field. **Table 9** lists the  
 1937 systems that are either currently commercially available or are in a pre-commercial state.  
 1938 Additionally, we also want to give a brief overview of the history and mention companies that  
 1939 discontinued their developments, but still might be considered, e.g., for patent search.

1940 The history of centrifugal microfluidics dates back to the 1960s, to Oak Ridge National  
 1941 Laboratories' (ORNL) *centrifugal analyzer* for clinical chemistry<sup>13</sup>. At that time, the possibility

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1942 of increasing the throughput for enzymatic assays compared to conventional flow-through  
1943 systems led to the first commercialized centrifugal analyzer systems only a few years after  
1944 the presentation of the original idea, the Electro-Nucleonics Inc. *GEMSAEC* system, in 1970  
1945 <sup>250</sup>. Centrifugal analyzers exploited centrifugal forces to pump liquid from one point to  
1946 another, but did not make use of unit operations, e.g., valving to control the fluidic process  
1947 <sup>251</sup>. Following these early days, multiple companies developed and/or commercialized  
1948 centrifugal analyzers (Centri Union Carbide's "*CentrifiChem*", American Instruments'  
1949 "*Rotochem*", Instrumentation Laboratories Inc.'s "*Multistat*", and Roche's "*Cobas Bio*" <sup>13</sup>). For  
1950 a more detailed overview of the history, we refer the reader to "Landmark Papers in Clinical  
1951 Chemistry" <sup>252</sup> and *Gorkin et al.* <sup>13</sup>.

1952 The field gained momentum again with the introduction of the Abaxis Piccolo XPress for the  
1953 panel analysis of different blood parameters in 1995, a still successful product (**Table 9**).  
1954 Besides the success story of the *Piccolo XPress*, many well-known companies in the field of  
1955 centrifugal microfluidics discontinued their development for different reasons. The US start-  
1956 up Gamera developed a "*LabCD*" system for drug development assays. Gamera was  
1957 acquired by Tecan in 2000, and Tecan discontinued the development program for "*LabCD*" in  
1958 2005, giving difficulties in the development and delays in the commercialization as the  
1959 reasons (Tecan press release, July 14, 2005). Spin-X, which used a proprietary virtual laser  
1960 valve technology for "on-the-fly" valve generation and generic cartridges, discontinued their  
1961 developments in 2011. Other embodiments of centrifugal microfluidics that have generated  
1962 IPs include "*BCD*" by Burstein Technologies; "*BioCD*" by Quadraspec, which later became  
1963 Perfinity Biosciences Inc.; Advanced Array Technologies, which later (from 2002 on) became  
1964 Eppendorf Array Technologies, and Lingvitae.

1965 Furthermore, it is worth naming prominent research groups from academia that made great  
1966 contributions to progress in the field. Based on the number of publications, the most  
1967 prominent groups are UC Irvine (Prof. Marc Madou), UNIST (Prof. Yoon-Kyoung Cho), the

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1968 joint group at IMTEK and HSG-IMIT (Prof. Roland Zengerle), and BDI (Prof. Jens Ducreé),  
1969 while many other groups are entering the field and moving forward the state of the art of  
1970 centrifugal microfluidics at a high pace.

## 1971 **6 General conclusions and outlook**

1972 This review aimed to provide a comprehensive description of centrifugal microfluidics,  
1973 together with its various embodiments (platforms). It also aimed to provide an up-to-date  
1974 overview of the available set of unit operations (providing basic fluidic functionalities) and  
1975 how they can be concatenated for the automation of complex laboratory workflows.  
1976 Additionally, we outlined how recent advances in unit operation development might  
1977 significantly contribute to the development of centrifugal microfluidics as an enabling  
1978 technology in the future. We introduced the category “*process chain*” as an assembly of unit  
1979 operations representing workflows on a higher level of integration. Process chains can be  
1980 used as stand-alone solutions for the automation of a particular laboratory process step, or  
1981 multiple process chains can be combined to realize more complex (bio-medical) applications.  
1982 Vice-versa, we demonstrated how some of the recently published applications using  
1983 centrifugal microfluidics for automation are already based on the provided set of unit  
1984 operations.

1985 When aiming at the automation of laboratory workflows, the suitability of using centrifugal  
1986 microfluidics for the desired application must first be evaluated. The decision about the  
1987 suitability depends (1) on rather general aspects like the overall feasibility of miniaturization,  
1988 integration, and parallelization, but also (2) on assay-specific details like the available  
1989 volumes and required assay sensitivity, specificity, yield/efficiency, and reproducibility. The  
1990 manufacturing technologies for cartridges, which typically need to be disposable, the hybrid  
1991 integration, and the need for surface treatments will have large influences on the price-per-  
1992 part and need to be cross checked with the requirements and reimbursement. Equally  
1993 important are the specifications of the processing device and required auxiliary means.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

1994 Finally, all the involved processing steps must cope with the application-specific regulations  
1995 and certifications. The platform approach, with its well-defined unit operations (e.g., known  
1996 max/min volume, tolerances, and reproducibility) and process chains (e.g., known yield,  
1997 sensitivity, and specificity) of prior knowledge and art, plays a key role in a cost- and time-  
1998 efficient layout and design.

1999 The above outlined features are valid for all microfluidic platforms. Nonetheless, we conclude  
2000 that the specific advantages of centrifugal microfluidics are evident. The single propulsion  
2001 mechanism of the rotating frame enables the standardization of unit operations with minimum  
2002 waste of sample and reagent volumes. Volume forces can be adjusted by rotation which  
2003 enables the efficient removal of any disturbing bubbles and the separation of residual  
2004 volumes from channels, chambers and sensor matrixes. For sample preparation, the density  
2005 based separation is inherently available, for example for blood plasma separation. Sample  
2006 supply is particularly simple: The sample is applied to an inlet cavity and transported further by  
2007 centrifugation. Hence, the known cross-contamination from systems that need to be  
2008 connected by a pump is avoided.

2009 Until today, high throughput analysis systems based on centrifugal microfluidics have been  
2010 realized for clinical chemistry and immunoassays. Gyros, for example, demonstrated the  
2011 generation of 112 immunoassay data points per cartridge in less than one hour<sup>197</sup>. Different  
2012 Gyrolab CDs comprise the same or very similar centrifugal microfluidic operations such as  
2013 hydrophobic patch valves, overflow metering and the integration of same sized affinity  
2014 columns, supporting the idea of using validated unit operations and process chains for  
2015 efficient product development. For nucleic acid analysis, however, a remaining challenge is  
2016 the limited number of individual samples that are processed in a given timeframe and a high-  
2017 throughput nucleic acid analysis system for centrifugal microfluidics has not yet been  
2018 presented, but might be addressed in future work.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

2019 Lately, the storage of pneumatic energy for liquid routing has enabled the monolithic  
2020 integration of increasingly complex assays, which is a clear trend in centrifugal microfluidics.  
2021 In this context, the overall system integration, including all aspects of the automation of  
2022 laboratory workflows, still requires research. For immunoassays and clinical chemistry  
2023 applications for example, Roche (cobas 101b) and Abaxis (picolo express) presented fully  
2024 integrated concepts for the automated pre-storage and release of reagents. For nucleic acid  
2025 applications however, the cost-efficient mass production of the disposables, including the  
2026 onboard long-term storage and automated release of reagents, is still a major problem to be  
2027 solved. Special care must be taken in relation to the properties of the different polymers  
2028 used. The vapor permeability of the substrate material may cause liquid loss during storage,  
2029 and the undesired adsorption of target molecules may occur during processing.

2030 These are just a few examples where further research and development is needed. As a  
2031 consequence, we foresee major research activity in the field of overall system integration,  
2032 manufacturing, packaging, and parallelization.

2033 Another approach, aiming at a lower market entry barrier, is the concept of using  
2034 microfluidics as an "App"<sup>191</sup>, i.e., using already existing laboratory instruments for processing,  
2035 and thus minimizing the need for high initial investments for processing devices. Microfluidic  
2036 Apps have successfully been demonstrated for sample preparation in nucleic acid analysis<sup>38</sup>  
2037<sup>181</sup> and for the automated generation of dilution series<sup>253</sup>. Both Apps are operated on  
2038 standard laboratory centrifuges. Other examples have demonstrated multiplexed PCR on  
2039 different targets on a centrifugal microfluidic cartridge that can be operated in a commercially  
2040 available PCR thermocycler<sup>254</sup>.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

## 2041 7 References

- 2042 1 H. Becker, *Lab Chip*, 2010, **10**, 271.
- 2043 2 N. Blow, *Nat Meth*, 2009, **6**, 683–686.
- 2044 3 J. Ducreé, S. Haeberle, S. Lutz, S. Pausch, F. von Stetten and R. Zengerle, *J.*  
2045 *Micromech. Microeng.*, 2007, **17**, S103.
- 2046 4 S. Haeberle and R. Zengerle, *Lab Chip*, 2007, **7**, 1094.
- 2047 5 Cepheid - GeneXpert, *Cepheid - GeneXpert*, available at:  
2048 <http://www.cepheid.com/us/cepheid-solutions/systems/genexpert-systems/genexpert-iv>,  
2049 accessed 29 October 2014.
- 2050 6 R. Burger, N. Reis, J. G. Fonseca and J. Ducreé, *Proc. of IEEE MEMS*, 2009, 443–446.
- 2051 7 A. Lee, J. Park, M. Lim, V. Sunkara, S. Y. Kim, G. H. Kim, M.-H. Kim and Y.-K. Cho,  
2052 *Anal. Chem.*, 2014, **86**, 11349–11356.
- 2053 8 Abbott Point of Care - i-STAT system, *i-STAT® System - Point-of-Care Testing -*  
2054 *Handheld Blood Analyzer*, available at: <http://www.abbottpointofcare.com/>, accessed 29  
2055 October 2014.
- 2056 9 Yole Développement SA: POC 2014 Point of Care Testing: Applications of Microfluidic  
2057 Technologies, 2014.
- 2058 10 D. Mark, S. Haeberle, G. Roth, F. von Stetten and R. Zengerle, *Chem. Soc. Rev.*, 2010,  
2059 **39**, 1153.
- 2060 11 M. L. Sin, J. Gao, J. C. Liao and P. K. Wong, *Journal of biological engineering*, 2011, **5**,  
2061 6.
- 2062 12 M. Madou, J. Zoval, G. Jia, H. Kido, J. Kim and N. Kim, *Annu. Rev. Biomed. Eng.*, 2006,  
2063 **8**, 601–628.
- 2064 13 R. Gorkin, J. Park, J. Siegrist, M. Amasia, B. S. Lee, J.-M. Park, J. Kim, H. Kim, M.  
2065 Madou and Y.-K. Cho, *Lab Chip*, 2010, **10**, 1758.
- 2066 14 M. C. R. Kong and E. D. Salin, *Anal. Chem.*, 2010, **82**, 8039–8041.
- 2067 15 Abaxis, *Abaxis: Piccolo Xpress*, available at: <http://www.piccoloxpress.com/>, accessed 8  
2068 May 2014.
- 2069 16 LaMotte, *LaMotte: WaterLink Spin Lab*, available at: <http://www.lamotte.com/en/pool-spa/labs/3576.html>, accessed 8 May 2014.
- 2071 17 M. Inganäs, H. Dérand, A. Eckersten, G. Ekstrand, A.-K. Honerud, G. Jesson, G.  
2072 Thorsén, T. Söderman and P. Andersson, *Clinical Chemistry*, 2005, **51**, 1985–1987.
- 2073 18 S. Haeberle, T. Brenner, H.-P. Schlosser, R. Zengerle and J. Ducreé, *Chem. Eng.*  
2074 *Technol.*, 2005, **28**, 613–616.
- 2075 19 A. P. Bouchard, D. A. Duford and E. D. Salin, *Anal. Chem.*, 2010, **82**, 8386–8389.
- 2076 20 M. Karle, J. Wöhrle, F. von Stetten, R. Zengerle, D. Mark, *Proceedings of Transducers*,  
2077 **2013**, 1235–1238.
- 2078 21 M. Rombach, S. Lutz, D. Mark, G. Roth, R. Zengerle, C. Dumschat, A. Witt, S. Hensel, S.  
2079 Frenzel, F. Aßmann, F. Gehring, T. Reiner, H. Drechsel, P. Szallies and F. von Stetten,  
2080 *Proc. of  $\mu$ TAS*, **2012**, 782–784.
- 2081 22 Roche, *cobas b 101 POC System*, available at: [https://www.roche-](https://www.roche-diagnostics.ch/de/ProductsRDS/Seiten/cobas-b-101.aspx)  
2082 [diagnostics.ch/de/ProductsRDS/Seiten/cobas-b-101.aspx](https://www.roche-diagnostics.ch/de/ProductsRDS/Seiten/cobas-b-101.aspx).
- 2083 23 M. Hitzbleck and E. Delamarche, *Chem. Soc. Rev.*, 2013, **42**, 8494–8516.
- 2084 24 J. Hoffmann, S. Hin, F. von Stetten, R. Zengerle and G. Roth, *RSC Adv.*, 2012, **2**, 3885.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

- 2085 25 S. K. Vashist, E. Lam, S. Hrapovic, K. B. Male and Luong, John H T, *Chemical reviews*,  
2086 2014, **114**, 11083–11130.
- 2087 26 J. Hoffmann, D. Mark, S. Lutz, R. Zengerle and F. von Stetten, *Lab Chip*, 2010, **10**, 1480.
- 2088 27 Abaxis, *Piccolo Xpress*, available at:  
2089 <http://www.piccoloxpress.com/products/piccolo/overview/>.
- 2090 28 S. Lutz, P. Weber, M. Focke, B. Faltin, J. Hoffmann, C. Müller, D. Mark, G. Roth, P.  
2091 Munday, N. Armes, O. Piepenburg, R. Zengerle and F. von Stetten, *Lab Chip*, 2010, **10**,  
2092 887.
- 2093 29 T. van Oordt, Y. Barb, R. Zengerle and F. von Stetten, *J. Appl. Polym. Sci.*, 2014, **131**,  
2094 40291.
- 2095 30 T. van Oordt, Y. Barb, J. Smetana, R. Zengerle and F. von Stetten, *Lab Chip*, 2013, **13**,  
2096 2888–2892.
- 2097 31 G. Czilwik, T. Messinger, O. Strohmeier, F. von Stetten, R. Zengerle, P. Saarinen, J.  
2098 Niittymäki, K. McAllister, O. Sheils, J. Drexler and D. Mark, *Proc. of  $\mu$ TAS*, **2014**, 2528–  
2099 2529.
- 2100 32 H. Hwang, Y. Kim, J. Cho, J.-y. Lee, M.-S. Choi and Y.-K. Cho, *Anal. Chem.*, 2013, **85**,  
2101 2954–2960.
- 2102 33 T. Kawai, N. Naruishi, H. Nagai, Y. Tanaka, Y. Hagihara and Y. Yoshida, *Anal. Chem.*,  
2103 2013, 130626145849006.
- 2104 34 J. L. Garcia-Cordero, F. Benito-Lopez, D. Diamond, J. Ducreé and A. J. Ricco, in *Proc. of*  
2105 *IEEE MEMS 2009*, pp. 439–442.
- 2106 35 J. L. Garcia-Cordero, D. Kurzbuch, F. Benito-Lopez, D. Diamond, L. P. Lee and A. J.  
2107 Ricco, *Lab Chip*, 2010, **10**, 2680.
- 2108 36 T.-H. Kim, K. Abi-Samra, V. Sunkara, D.-K. Park, M. Amasia, N. Kim, J. Kim, H. Kim, M.  
2109 Madou and Y.-K. Cho, *Lab Chip*, 2013, **13**, 3747.
- 2110 37 K. Abi-Samra, R. Hanson, M. Madou and R. A. Gorkin III, *Lab Chip*, 2011, **11**, 723.
- 2111 38 A. Kloke, A. R. Fiebach, S. Zhang, L. Drechsel, S. Niekrawietz, M. M. Hoehl, R. Kneusel,  
2112 K. Panthel, J. Steigert, F. von Stetten, R. Zengerle and N. Paust, *Lab Chip*, 2014, **14**,  
2113 1527.
- 2114 39 M. Focke, F. Stumpf, G. Roth, R. Zengerle and F. von Stetten, *Lab Chip*, 2010, **10**, 3210.
- 2115 40 M. Focke, F. Stumpf, B. Faltin, P. Reith, D. Bamarni, S. Wadle, C. Müller, H. Reinecke, J.  
2116 Schrenzel, P. Francois, D. Mark, G. Roth, R. Zengerle and F. von Stetten, *Lab Chip*,  
2117 2010, **10**, 2519.
- 2118 41 O. Strohmeier, S. Laßmann, B. Riedel, D. Mark, G. Roth, M. Werner, R. Zengerle and F.  
2119 von Stetten, *Microchimica Acta*, 2014, DOI 10.1107/s00604-013-1099-z.
- 2120 42 M. Rombach, D. Kosse, B. Faltin, S. Wadle, G. Roth, R. Zengerle and F. von Stetten,  
2121 *BioTechniques*, 2014, **57**, 151–155.
- 2122 43 O. Strohmeier, N. Marquart, D. Mark, G. Roth, R. Zengerle and F. von Stetten, *Anal.*  
2123 *Methods*, 2014, **6**, 2038.
- 2124 44 A. LaCroix-Fralish, J. Clare, C. D. Skinner and E. D. Salin, *Talanta*, 2009, **80**, 670–675.
- 2125 45 O. Strohmeier, B. Kanat, D. Bär, P. Patel, J. Drexler, M. Weidmann, T. van Oordt, G.  
2126 Roth, D. Mark, R. Zengerle and F. von Stetten, *Proc. of  $\mu$ TAS*, 2012, 779–881.
- 2127 46 M. C. R. Kong, A. P. Bouchard and E. D. Salin, *Micromachines*, 2012, **3**, 1–9.
- 2128 47 S. Soroori, L. Kulinsky, H. Kido and M. Madou, *Microfluid Nanofluid*, 2014, **16**, 1117–  
2129 1129.
- 2130 48 K. Abi-Samra, L. Clime, L. Kong, R. Gorkin, T.-H. Kim, Y.-K. Cho and M. Madou,  
2131 *Microfluid Nanofluid*, 2011, **11**, 643–652.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

- 2132 49 T. H. G. Thio, F. Ibrahim, W. Al-Faqheri, J. Moebius, N. S. Khalid, N. Soin, Kahar, Maria  
2133 Kahar Bador Abdul and M. Madou, *Lab Chip*, 2013, **13**, 3199.
- 2134 50 Z. Noroozi, H. Kido and M. J. Madou, *J. Electrochem. Soc.*, 2011, **158**, P130.
- 2135 51 S. Zehnle, F. Schwemmer, G. Roth, F. von Stetten, R. Zengerle and N. Paust, *Lab Chip*,  
2136 2012, **12**, 5142.
- 2137 52 J. L. Garcia-Cordero, L. Basabe-Desmots, J. Ducreé and A. J. Ricco, *Microfluid*  
2138 *Nanofluid*, 2010, **9**, 695–703.
- 2139 53 C. Li, X. Dong, J. Qin and B. Lin, *Analytica Chimica Acta*, 2009, **640**, 93–99.
- 2140 54 R. Gorkin, L. Clime, M. Madou and H. Kido, *Microfluid Nanofluid*, 2010, **9**, 541–549.
- 2141 55 S. Haeberle, N. Schmitt, R. Zengerle and J. Ducreé, *Sensors and Actuators A: Physical*,  
2142 2007, **135**, 28–33.
- 2143 56 R. Gorkin, S. Soroori, W. Southard, L. Clime, T. Veres, H. Kido, L. Kulinsky and M.  
2144 Madou, *Microfluid Nanofluid*, 2012, **12**, 345–354.
- 2145 57 W. Al-Faqheri, F. Ibrahim, T. H. G. Thio, J. Moebius, K. Joseph, H. Arof and M. Madou,  
2146 *PLoS ONE*, 2013, **8**, e58523.
- 2147 58 D. J. Kinahan, S. M. Kearney, O. P. Faneuil, M. T. Glynn, N. Dimov and J. Ducreé, *RSC*  
2148 *Adv*, 2015, **5**, 1818–1826.
- 2149 59 Y. Ukita, M. Ishizawa, Y. Takamura and Y. Utsumi, *Proc. of  $\mu$ TAS*, 2012, 1465–1467.
- 2150 60 D. C. Duffy, H. L. Gillis, J. Lin, N. F. Sheppard and G. J. Kellogg, *Anal. Chem.*, 1999, **71**,  
2151 4669–4678.
- 2152 61 S. Lai, S. Wang, J. Luo, L. J. Lee, S.-T. Yang and M. J. Madou, *Anal. Chem.*, 2004, **76**,  
2153 1832–1837.
- 2154 62 M. J. Madou, L. J. Lee, S. Daunert, S. Lai and C.-H. Shih, *Biomed Microdevices*, 2001, **3**,  
2155 245–254.
- 2156 63 F. Schwemmer, S. Zehnle, N. Paust, C. Blanchet, M. Rössle, F. von Stetten, R. Zengerle  
2157 and D. Mark, *Proc. of  $\mu$ TAS*, 2012, 1450–1452.
- 2158 64 H. Cho, H.-Y. Kim, J. Y. Kang and T. S. Kim, *J Colloid Interface Sci*, 2007, **306**, 379–385.
- 2159 65 M. Liu, J. Zhang, Y. Liu, W. M. Lau and J. Yang, *Chem. Eng. Technol.*, 2008, **31**, 1328–  
2160 1335.
- 2161 66 J. M. Chen, P.-C. Huang and M.-G. Lin, *Microfluid Nanofluid*, 2008, **4**, 427–437.
- 2162 67 H. Zhang, H. H. Tran, B. H. Chung and N. Y. Lee, *Analyst*, 2013, **138**, 1750.
- 2163 68 A. LaCroix-Fralish, E. J. Templeton, E. D. Salin and C. D. Skinner, *Lab Chip*, 2009, **9**,  
2164 3151.
- 2165 69 A. Kazarine, M. C. R. Kong, E. J. Templeton and E. D. Salin, *Anal. Chem.*, 2012, **84**,  
2166 6939–6943.
- 2167 70 M. Focke, R. Feuerstein, F. Stumpf, D. Mark, T. Metz, R. Zengerle and F. von Stetten,  
2168 *Proc. of  $\mu$ TAS*, 2009, 1397–1399.
- 2169 71 P. Andersson, G. Jesson, G. Kylberg, G. Ekstrand and G. Thorsén, *Anal. Chem.*, 2007,  
2170 **79**, 4022–4030.
- 2171 72 L. Riegger, M. M. Mielnik, A. Gulliksen, D. Mark, J. Steigert, S. Lutz, M. Clad, R.  
2172 Zengerle, P. Koltay and J. Hoffmann, *J. Micromech. Microeng.*, 2010, **20**, 045021.
- 2173 73 N. Honda, U. Lindberg, P. Andersson, S. Hoffmann and H. Takei, *Clinical Chemistry*,  
2174 2005, **51**, 1955–1961.
- 2175 74 Y. Ouyang, S. Wang, J. Li, P. S. Riehl, M. Begley and J. P. Landers, *Lab Chip*, 2013, **13**,  
2176 1762.
- 2177 75 D. Mark, T. Metz, S. Haeberle, S. Lutz, J. Ducreé, R. Zengerle and F. von Stetten, *Lab*  
2178 *Chip*, 2009, **9**, 3599.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

- 2179 76 R. Gorkin III, C. E. Nwankire, J. Gaughran, X. Zhang, G. G. Donohoe, M. Rook, R.  
2180 O'Kennedy and J. Ducreé, *Lab Chip*, 2012, **12**, 2894.
- 2181 77 D. J. Kinahan, S. M. Kearney and J. Ducreé, *Proceedings of Transducers*, 2013, 2189–  
2182 2192.
- 2183 78 J. Siegrist, R. Gorkin, M. Bastien, G. Stewart, R. Peytavi, H. Kido, M. Bergeron and M.  
2184 Madou, *Lab Chip*, 2010, **10**, 363.
- 2185 79 W. Al-Faqheri, F. Ibrahim, T. H. G. Thio, N. Bahari, H. Arof, H. A. Rothan, R. Yusof and  
2186 M. Madou, *Sensors*, 2015, **15**, 4658–4676.
- 2187 80 J. Hoffmann, D. Mark, R. Zengerle and F. von Stetten, *Proceedings of Transducers*,  
2188 2009, 1991–1994.
- 2189 81 H. Hwang, H.-H. Kim and Y.-K. Cho, *Lab Chip*, 2011, **11**, 1434.
- 2190 82 C. T. Schembri, T. L. Burd, A. R. Kopf-Sill, L. R. Shea and B. Braynin, *The Journal of*  
2191 *Automatic Chemistry*, 1995, **17**, 99–104.
- 2192 83 J. Siegrist, R. Gorkin, L. Clime, E. Roy, R. Peytavi, H. Kido, M. Bergeron, T. Veres and  
2193 M. Madou, *Microfluid Nanofluid*, 2010, **9**, 55–63.
- 2194 84 N. Godino, E. Vereshchagina, R. Gorkin and J. Ducreé, *Microfluid Nanofluid*, 2013, **16**,  
2195 895–905.
- 2196 85 N. Godino, R. Gorkin III, A. V. Linares, R. Burger and J. Ducreé, *Lab Chip*, 2013, **13**,  
2197 685.
- 2198 86 F. Schwemmer, S. Zehnle, D. Mark, F. von Stetten, R. Zengerle and N. Paust, *Lab Chip*,  
2199 2015, **15**, 1545–1553.
- 2200 87 D. Kinahan, S. M. Kearney, N. Dimov, M. T. Glynn and J. Ducreé, *Lab Chip*, 2014.
- 2201 88 J.-M. Park, Y.-K. Cho, B.-S. Lee, J.-G. Lee and C. Ko, *Lab Chip*, 2007, **7**, 557.
- 2202 89 U. Y. Schaff and G. J. Sommer, *Clinical Chemistry*, 2011, **57**, 753–761.
- 2203 90 Y.-K. Cho, J.-G. Lee, J.-M. Park, B.-S. Lee, Y. Lee and C. Ko, *Lab Chip*, 2007, **7**, 565.
- 2204 91 M. Amasia, M. Cozzens and M. J. Madou, *Sensors and Actuators B: Chemical*, 2012,  
2205 **161**, 1191–1197.
- 2206 92 L. Swayne, A. Kazarine, E. J. Templeton and E. D. Salin, *Talanta*, 2015, **134**, 443–447.
- 2207 93 T. Brenner, T. Glatzel, R. Zengerle and J. Ducreé, *Lab Chip*, 2005, **5**, 146.
- 2208 94 J. Kim, H. Kido, R. H. Rangel and M. J. Madou, *Sensors and Actuators B: Chemical*,  
2209 2008, **128**, 613–621.
- 2210 95 T. T. Thuy, M. Inganäs, G. Ekstrand and G. Thorsén, *Journal of Chromatography B*,  
2211 2010, **878**, 2803–2810.
- 2212 96 D. Mark, M. Rombach, S. Lutz and R. Zengerle, *Proc. of  $\mu$ TAS*, 2009, 110–112.
- 2213 97 M. Müller, D. Mark, M. Rombach, G. Roth, J. Hoffmann, R. Zengerle and F. von Stetten,  
2214 *Proc. of  $\mu$ TAS*, 2010, 405–407.
- 2215 98 M. C. R. Kong and E. D. Salin, *Anal. Chem.*, 2011, **83**, 1148–1151.
- 2216 99 D. Mark, P. Weber, S. Lutz, M. Focke, R. Zengerle and F. Stetten, *Microfluid Nanofluid*,  
2217 2011, **10**, 1279–1288.
- 2218 100 J. Steigert, T. Brenner, M. Grumann, L. Riegger, S. Lutz, R. Zengerle and J. Ducreé,  
2219 *Biomed Microdevices*, 2007, **9**, 675–679.
- 2220 101 J. Steigert, M. Grumann, T. Brenner, L. Riegger, J. Harter, R. Zengerle and J. Ducreé,  
2221 *Lab Chip*, 2006, **6**, 1040.
- 2222 102 S. O. Sundberg, C. T. Wittwer, C. Gao and B. K. Gale, *Anal. Chem.*, 2010, **82**, 1546–  
2223 1550.
- 2224 103 G. Li, Q. Chen, J. Li, X. Hu and J. Zhao, *Anal. Chem.*, 2010, **82**, 4362–4369.
- 2225 104 M. Grumann, A. Geipel, L. Riegger, R. Zengerle and J. Ducreé, *Lab Chip*, 2005, **5**, 560.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

- 2226 105 Y. Ren and W. W.-F. Leung, *International Journal of Heat and Mass Transfer*, 2013, **60**,  
2227 95–104.
- 2228 106 Z. Noroozi, H. Kido, M. Micic, H. Pan, C. Bartolome, M. Princevac, J. Zoval and M.  
2229 Madou, *Rev. Sci. Instrum.*, 2009, **80**, 075102.
- 2230 107 Z. Noroozi, H. Kido, R. Peytavi, R. Nakajima-Sasaki, A. Jasinskas, M. Micic, P. L.  
2231 Felgner and M. J. Madou, *Rev. Sci. Instrum.*, 2011, **82**, 064303.
- 2232 108 M. M. Aeinehvand, F. Ibrahim, S. W. Harun, W. Al-Faqheri, T. H. G. Thio, A.  
2233 Kazemzadeh and M. Madou, *Lab Chip*, 2014, **14**, 988–997.
- 2234 109 S. Haeberle, T. Brenner, H.-P. Schlosser, R. Zengerle and J. Ducee, *Chem. Eng.*  
2235 *Technol.*, 2005, **28**, 613–616.
- 2236 110 J. Ducee, T. Brenner, S. Haeberle, T. Glatzel and R. Zengerle, *Microfluid Nanofluid*,  
2237 2006, **2**, 78–84.
- 2238 111 J. Ducee, S. Haeberle, T. Brenner, T. Glatzel and R. Zengerle, *Microfluid Nanofluid*,  
2239 2006, **2**, 97–105.
- 2240 112 D. Chakraborty, M. Madou and S. Chakraborty, *Lab Chip*, 2011, **11**, 2823.
- 2241 113 Y. Ukita and Y. Takamura, *Microfluid Nanofluid*, 2013, **15**, 829–837.
- 2242 114 J.-N. Kuo and L.-R. Jiang, *Microsyst Technol*, 2014, **20**, 91–99.
- 2243 115 M. La, S. J. Park, H. W. Kim, J. J. Park, K. T. Ahn, S. M. Ryew and D. S. Kim, *Microfluid*  
2244 *Nanofluid*, 2013, **15**, 87–98.
- 2245 116 J. Liebeskind, A. Kloke, A. R. Fiebach, F. von Stetten, R. Zengerle and Paust N., *Proc. of*  
2246 *μTAS*, 2013, 967–969.
- 2247 117 M. C. R. Kong and E. D. Salin, *Microfluid Nanofluid*, 2012, **13**, 519–525.
- 2248 118 M. Czugala, R. Gorkin III, T. Phelan, J. Gaughran, V. F. Curto, J. Ducee, D. Diamond  
2249 and F. Benito-Lopez, *Lab Chip*, 2012, **12**, 5069.
- 2250 119 E. J. Templeton and E. D. Salin, *Microfluid Nanofluid*, 2014, **17**, 245–251.
- 2251 120 R. Martinez-Duarte, R. A. Gorkin III, K. Abi-Samra and M. J. Madou, *Lab Chip*, 2010, **10**,  
2252 1030.
- 2253 121 M. Boettcher, M. S. Jaeger, L. Riegger, J. Ducee, R. Zengerle and C. DUSCHL,  
2254 *Biophys. Rev. Lett.*, 2006, **1**, 443–451.
- 2255 122 R. Burger, P. Reith, G. Kijanka, V. Akujobi, P. Abgrall and J. Ducee, *Lab Chip*, 2012, **12**,  
2256 1289.
- 2257 123 D. Kirby, J. Siegrist, G. Kijanka, L. Zavattoni, O. Sheils, J. O’Leary, R. Burger and J.  
2258 Ducee, *Microfluid Nanofluid*, 2012, **13**, 899–908.
- 2259 124 M. Glynn, D. Kirby, D. Chung, D. J. Kinahan, G. Kijanka and J. Ducee, *J Lab Autom*,  
2260 2013, **19**, 285–296.
- 2261 125 R. Burger, N. Reis, J. G. da Fonseca and J. Ducee, *J. Micromech. Microeng.*, 2013, **23**,  
2262 035035.
- 2263 126 S. Zehnle, M. Rombach, F. von Stetten, R. Zengerle and N. Paust, *Proc. of μTAS*, 2012,  
2264 869–871.
- 2265 127 S. Haeberle, T. Brenner, R. Zengerle and J. Ducee, *Lab Chip*, 2006, **6**, 776.
- 2266 128 B.-S. Li and J.-N. Kuo, *NEMS*, 2013, 462–465.
- 2267 129 Boom R. et al., *Journal of Clinical Microbiology*, 1990, 495–503.
- 2268 130 J. H. Jung, B. H. Park, Y. K. Choi and T. Seo, *Lab Chip*, 2013, **13**, 3383–3388.
- 2269 131 B. H. Park, J. H. Jung, H. Zhang, N. Y. Lee and T. S. Seo, *Lab Chip*, 2012, **12**, 3875.
- 2270 132 X. Y. Peng, P. C. Li, H.-Z. Yu, M. Parameswaran and W. L. Chou, *Sensors and*  
2271 *Actuators B: Chemical*, 2007, **128**, 64–69.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

- 2272 133 G. Jia, K.-S. Ma, J. Kim, J. V. Zoval, R. Peytavi, M. G. Bergeron and M. J. Madou,  
2273 *Sensors and Actuators B: Chemical*, 2006, **114**, 173–181.
- 2274 134 R. Peytavi, F. R. Raymond, D. Gagne, F. J. Picard, G. Jia, J. Zoval, M. Madou, K.  
2275 Boissinot, M. Boissinot, L. Bissonnette, M. Ouellette and M. G. Bergeron, *Clinical*  
2276 *Chemistry*, 2005, **51**, 1836–1844.
- 2277 135 B. S. Lee, J.-N. Lee, J.-M. Park, J.-G. Lee, S. Kim, Y.-K. Cho and C. Ko, *Lab Chip*, 2009,  
2278 **9**, 1548.
- 2279 136 H. Nagai, Y. Narita, M. Ohtaki, K. Saito and S.-I. Wakida, *Anal. Sci.*, 2007, **23**, 975–979.
- 2280 137 B. S. Lee, Y. U. Lee, H.-S. Kim, T.-H. Kim, J. Park, J.-G. Lee, J. Kim, H. Kim, W. G. Lee  
2281 and Y.-K. Cho, *Lab Chip*, 2011, **11**, 70.
- 2282 138 O. Strohmeier, A. Emperle, G. Roth, D. Mark, R. Zengerle and F. von Stetten, *Lab Chip*,  
2283 2013, **13**, 146–155.
- 2284 139 K.-C. Chen, T.-P. Lee, Y.-C. Pan, C.-L. Chiang, C.-L. Chen, Y.-H. Yang, B.-L. Chiang, H.  
2285 Lee and A. M. Wo, *Clinical Chemistry*, 2011, **57**, 586–592.
- 2286 140 S. Haeberle, R. Zengerle and J. Ducreé, *Microfluid Nanofluid*, 2007, **3**, 65–75.
- 2287 141 D. Chakraborty and S. Chakraborty, *Appl. Phys. Lett.*, 2010, **97**, 234103.
- 2288 142 D. Mark, S. Haeberle, R. Zengerle, J. Ducreé and G. T. Vladisavljević, *J Colloid Interface*  
2289 *Sci*, 2009, **336**, 634–641.
- 2290 143 S. Haeberle, L. Naegele, R. Burger, F. von Stetten, R. Zengerle and J. Ducreé, *J*  
2291 *Microencapsul*, 2008, **25**, 267–274.
- 2292 144 K. Maeda, H. Onoe, M. Takinoue and S. Takeuchi, *Adv. Mater. Weinheim*, 2012, **24**,  
2293 1340–1346.
- 2294 145 F. Schuler, F. Schwemmer, M. Trotter, S. Wadle, R. Zengerle, F. von Stetten and N.  
2295 Paust, *Lab Chip (Lab on a Chip) (submitted)*.
- 2296 146 T.-H. Kim, J. Park, C.-J. Kim and Y.-K. Cho, *Anal. Chem.*, 2014, **86**, 3841–3848.
- 2297 147 M. M. Hoehl, E. S. Bocholt, A. Kloke, N. Paust, F. von Stetten, R. Zengerle, J. Steigert  
2298 and A. H. Slocum, *Analyst*, 2014, **16**, 375–385.
- 2299 148 L. Riegger, M. Grumann, J. Steigert, S. Lutz, C. P. Steinert, C. Mueller, J. Viertel, O.  
2300 Prucker, J. Rühle, R. Zengerle and J. Ducreé, *Biomed Microdevices*, 2007, **9**, 795–799.
- 2301 149 M. Grumann, J. Steigert, L. Riegger, I. Moser, B. Enderle, K. Riebeseel, G. Urban, R.  
2302 Zengerle and J. Ducreé, *Biomed Microdevices*, 2006, **8**, 209–214.
- 2303 150 C. E. Nwankire, G. G. Donohoe, X. Zhang, J. Siegrist, M. Somers, D. Kurzbuch, R.  
2304 Monaghan, M. Kitsara, R. Burger, S. Hearty, J. Murrell, C. Martin, M. Rook, L. Barrett, S.  
2305 Daniels, C. McDonagh, R. O’Kennedy and J. Ducreé, *Analytica Chimica Acta*, 2013, **781**,  
2306 54–62.
- 2307 151 L. Riegger, M. Grumann, T. Nann, J. Riegler, O. Ehlert, W. Bessler, K. Mittenbuehler, G.  
2308 Urban, L. Pastewka, T. Brenner, R. Zengerle and J. Ducreé, *Sensors and Actuators A:*  
2309 *Physical*, 2006, **126**, 455–462.
- 2310 152 Y. Ukita and Y. Takamura, *Microfluid Nanofluid*, 2015, **18**, 245–252.
- 2311 153 A. S. Watts, A. A. Urbas, E. Moschou, V. G. Gavalas, J. V. Zoval, M. Madou and L. G.  
2312 Bachas, *Anal. Chem.*, 2007, **79**, 8046–8054.
- 2313 154 K. Otsuka, A. Hemmi, T. Usui, A. Moto, T. Tobita, N. Soh, K. Nakano, H. Zeng, K.  
2314 Uchiyama, T. Imato and H. Nakajima, *J. Sep. Science*, 2011, **34**, 2913–2919.
- 2315 155 S. Morais, L. A. Tortajada-Genaro, T. Arnandis-Chover, R. Puchades and A. Maquieira,  
2316 *Anal. Chem.*, 2009, **81**, 5646–5654.
- 2317 156 R. Burger, M. Kitsara, J. Gaughran, C. Nwankire and J. Ducreé, *Future Medicine*, 2014,  
2318 72–92.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

- 2319 157 Y. Li, L. M. L. Ou and H.-Z. Yu, *Anal. Chem.*, 2008, **80**, 8216–8223.
- 2320 158 S. A. Lange, G. Roth, S. Wittemann, T. Lacoste, A. Vetter, J. Grässle, S. Kopta, M.
- 2321 Kolleck, B. Breitingner, M. Wick, J. K. H. Hörber, S. Dübel and A. Bernard, *Angew. Chem.*
- 2322 *Int. Ed.*, 2006, **45**, 270–273.
- 2323 159 F. G. Bosco, E.-T. Hwu, C.-H. Chen, S. Keller, M. Bache, M. H. Jakobsen, I.-S. Hwang
- 2324 and A. Boisen, *Lab Chip*, 2011, **11**, 2411–2416.
- 2325 160 K. Abi-Samra, T.-H. Kim, D.-K. Park, N. Kim, J. Kim, H. Kim, Y.-K. Cho and M. Madou,
- 2326 *Lab Chip*, 2013, **13**, 3253–3260.
- 2327 161 T. Li, Y. Fan, Y. Cheng and J. Yang, *Lab Chip*, 2013, **13**, 2634.
- 2328 162 W. Lee, J. Jung, Y. K. Hahn, S. K. Kim, Y. Lee, J. Lee, T.-H. Lee, J.-Y. Park, H. Seo, J.
- 2329 N. Lee, J. H. Oh, Y.-S. Choi and S. S. Lee, *Analyst*, 2013, **138**, 2558–2566.
- 2330 163 C. P. Steinert, J. Mueller-Dieckmann, M. Weiss, M. Roessle, R. Zengerle and P. Koltay,
- 2331 *Proc. of MEMS*, 2007, 561–564.
- 2332 164 C.-L. Chen, K.-C. Chen, Y.-C. Pan, T.-P. Lee, L.-C. Hsiung, C.-M. Lin, C.-Y. Chen, C.-H.
- 2333 Lin, B.-L. Chiang and A. M. Wo, *Lab Chip*, 2011, **11**, 474.
- 2334 165 J. Kim, M. Johnson, P. Hill and B. K. Gale, *Integr. Biol.*, 2009, **1**, 574.
- 2335 166 P.-A. Auroux, Y. Koc, A. deMello, A. Manz and P. J. R. Day, *Lab Chip*, 2004, **4**, 534.
- 2336 167 J. Kim, S. Hee Jang, G. Jia, J. V. Zoval, N. A. Da Silva and M. J. Madou, *Lab Chip*, 2004,
- 2337 **4**, 516.
- 2338 168 H. Kido, M. Micic, D. Smith, J. Zoval, J. Norton and M. Madou, *Colloids and Surfaces B:*
- 2339 *Biointerfaces*, 2007, **58**, 44–51.
- 2340 169 T. Brenner, T. Glatzel, R. Zengerle and J. Ducree, *Proc. of  $\mu$ TAS*, 2003, 903–906.
- 2341 170 S. Wadle, O. Strohmeier, M. Rombach, D. Mark, R. Zengerle and F. von Stetten, *Proc. of*
- 2342  *$\mu$ TAS*, 2012, 1381–1383.
- 2343 171 O. Strohmeier, S. Keil, B. Kanat, P. Patel, M. Niedrig, M. Weidmann, F. Hufert, J.
- 2344 Drexler, R. Zengerle and F. von Stetten, *RSC Adv*, 2015.
- 2345 172 J. H. Jung, S. J. Choi, B. H. Park, Y. K. Choi and T. S. Seo, *Lab Chip*, 2012, **12**, 1598.
- 2346 173 S. Furutani, H. Nagai, Y. Takamura and I. Kubo, *Anal Bioanal Chem*, 2010, **398**, 2997–
- 2347 3004.
- 2348 174 Espira Inc., *Espira Inc: Digital PCR*, available at: [http://www.espirainc.com/digital-](http://www.espirainc.com/digital-pcr.html)
- 2349 [pcr.html](http://www.espirainc.com/digital-pcr.html), accessed 8 May 2014.
- 2350 175 M. Focke, D. Kosse, D. Al-Bamerni, S. Lutz, C. Müller, H. Reinecke, R. Zengerle and F.
- 2351 von Stetten, *J. Micromech. Microeng.*, 2011, **21**, 115002.
- 2352 176 G. Czilwik, I. Schwarz, M. Keller, S. Wadle, S. Zehnle, F. von Stetten, D. Mark, R.
- 2353 Zengerle and N. Paust, *Lab Chip*, 2015, **15**, 1084–1091.
- 2354 177 GenomeWeb, [http://www.genomeweb.com/pcrsample-](http://www.genomeweb.com/pcrsample-prep/fda-clears-focus-diagnostics-flu-test-3m-integrated-cycler)
- 2355 [prep/fda-clears-focus-diagnostics-flu-test-3m-integrated-cycler](http://www.genomeweb.com/pcrsample-prep/fda-clears-focus-diagnostics-flu-test-3m-integrated-cycler),
- 2356 [available at: http://www.genomeweb.com/pcrsample-](http://www.genomeweb.com/pcrsample-prep/fda-clears-focus-diagnostics-flu-test-3m-integrated-cycler)
- 2357 [prep/fda-clears-focus-diagnostics-flu-test-3m-integrated-cycler](http://www.genomeweb.com/pcrsample-prep/fda-clears-focus-diagnostics-flu-test-3m-integrated-cycler), accessed 21 October
- 2358 2013.
- 2359 178 Focus Diagnostics, [http://www.mikrogen.de/uploads/tx\\_oemikrogentables/dokumente/PI-](http://www.mikrogen.de/uploads/tx_oemikrogentables/dokumente/PI-UM-MOL1101-DE.pdf)
- 2360 [UM-MOL1101-DE.pdf](http://www.mikrogen.de/uploads/tx_oemikrogentables/dokumente/PI-UM-MOL1101-DE.pdf), available at:
- 2361 [http://www.mikrogen.de/uploads/tx\\_oemikrogentables/dokumente/PI-UM-MOL1101-](http://www.mikrogen.de/uploads/tx_oemikrogentables/dokumente/PI-UM-MOL1101-DE.pdf)
- 2362 [DE.pdf](http://www.mikrogen.de/uploads/tx_oemikrogentables/dokumente/PI-UM-MOL1101-DE.pdf), accessed 21 October 2013.
- 2363 179 L. Wang, P. C. Li, H.-Z. Yu and A. M. Parameswaran, *Analytica Chimica Acta*, 2008,
- 2364 **610**, 97–104.
- 180 L. Wang and P. C. Li, *Analytical Biochemistry*, 2010, **400**, 282–288.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

- 2365 181 M. M. Hoehl, M. Weißert, A. Dannenberg, T. Nesch, N. Paust, F. Stetten, R. Zengerle, A.  
2366 H. Slocum and J. Steigert, *Biomed Microdevices*, 2014, **16**, 375–385.
- 2367 182 G. Czilwik, O. Strohmeier, I. Schwarz, N. Paust, S. Zehnle, F. von Stetten, R. Zengerle  
2368 and D. Mark, *Proc. of  $\mu$ TAS*, 2013, 1607–1609.
- 2369 183 J. H. Jung, B. H. Park, S. J. Choi and T. S. Seo, *Proc. of  $\mu$ TAS*, 2012, 1966–1968.
- 2370 184 *The 3M™ Integrated Cyclor Direct Amplification Disc - International*, available at:  
2371 <https://www.focusdx.com/3m-integrated-cyclor/dad-intl>, accessed 15 July 2014.
- 2372 185 US20130022963A, 2013.
- 2373 186 US20120291538A1, 2012.
- 2374 187 US2012/0291565A1, 2010.
- 2375 188 WP2012/120463A1.
- 2376 189 GenePOC Inc., <http://www.genepoc-diagnostics.com/Technology.shtml>, available at:  
2377 <http://www.genepoc-diagnostics.com/Technology.shtml>, accessed 21 October 2013.
- 2378 190 P. J. Asiello and A. J. Baeumner, *Lab Chip*, 2011, **11**, 1420.
- 2379 191 D. Mark, F. von Stetten and R. Zengerle, *Lab Chip*, 2012, **12**, 2464.
- 2380 192 H. He, Y. Yuan, W. Wang, N.-R. Chiou, A. J. Epstein and L. J. Lee, *Biomicrofluidics*,  
2381 2009, **3**, 22401.
- 2382 193 R. D. Johnson, Badr, Ibrahim H. A., G. Barrett, S. Lai, Y. Lu, M. J. Madou and L. G.  
2383 Bachas, *Anal. Chem.*, 2001, **73**, 3940–3946.
- 2384 194 J. Park, V. Sunkara, T.-H. Kim, H. Hwang and Y.-K. Cho, *Anal. Chem.*, 2012, **84**, 2133–  
2385 2140.
- 2386 195 L. Riegger, J. Steigert, M. Grumann, S. Lutz, G. Olofsson, M. Kayyami, W. Bessler, K.  
2387 Mittenbuehler, R. Zengerle and J. Ducree, *Proc. of  $\mu$ TAS*, 2006, 819–821.
- 2388 196 G. Welte, S. Lutz, B. Cleven, H. Brahms, C. Gärtner, G. Roth, D. Mark, R. Zengerle and  
2389 F. von Stetten, *Proc. of  $\mu$ TAS*, 2010, 818–820.
- 2390 197 Gyros AB, *Gyros: Gyrolab*, available at: <http://www.gyros.com/>, accessed 8 May 2014.
- 2391 198 C. Y. Koh, U. Y. Schaff, A. K. Singh and G. J. Sommer, in  *$\mu$ TAS*, 2011.
- 2392 199 H. Cho, J. Kang, S. Kwak, K. Hwang, J. Min, J. Lee, D. Yoon and T. Kim, *Proc. of*  
2393 *IEEE MEMS*, 2005, 698–701.
- 2394 200 Gyrolab Bioaffy system, *Gyrolab CDs*, available at:  
2395 <http://www.gyros.com/products/gyrolab-cds/>, accessed 7 May 2015.
- 2396 201 G. P. Zaloga, *CHEST*, 1990, **97**, 185S.
- 2397 202 J. Zhang, Q. Guo, M. Liu and J. Yang, *J. Micromech. Microeng.*, 2008, **18**, 125025.
- 2398 203 M. Amasia and M. Madou, *Bioanalysis*, 2010, **2**, 1701–1710.
- 2399 204 T. Li, L. Zhang, K. M. Leung and J. Yang, *J. Micromech. Microeng.*, 2010, **20**, 105024.
- 2400 205 C. A. Burtis, J. C. Mailen, W. F. Johnson, C. D. Scott, T. O. Tiffany and N. G. Anderson,  
2401 *Clinical Chemistry*, 1972, **18**, 753–761.
- 2402 206 C. E. Nwankire, M. Czugala, R. Burger, K. J. Fraser, T. M. O'Connell, T. Glennon, B. E.  
2403 Onwuliri, I. E. Nduaguibe, D. Diamond and J. Ducree, *Biosensors and Bioelectronics*,  
2404 2014, **56**, 352–358.
- 2405 207 C.-H. Lin, C.-H. Shih and C.-H. Lu, *Journal of Nanoscience and Nanotechnology*, 2013,  
2406 **13**, 2206–2212.
- 2407 208 C.-H. Lin, C.-Y. Liu, C.-H. Shih and C.-H. Lu, *Biomicrofluidics*, 2014, **8**, 052105.
- 2408 209 C.-H. Lin, K.-W. Lin, D. Yen, C.-H. Shih, C.-H. Lu, J.-M. Wang and C.-Y. Lin, *Journal of*  
2409 *Nanoscience and Nanotechnology*, 2015, **15**, 1401–1407.
- 2410 210 Y. Tanaka, S. Okuda, A. Sawai and S. Suzuki, *Anal Sci*, 2012, **28**, 33–38.
- 2411 211 T. L. Burd, *Clinical Chemistry*, 1992, **38**, 1665–1670.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

- 2412 212 Jamikorn Suk-Anake and Chamras Promptmas, *Clin. Lab.*, 2012, **58**.  
2413 213 R. Burger, D. Kirby, M. Glynn, C. Nwankire, M. O'Sullivan, J. Siegrist, D. Kinahan, G.  
2414 Aguirre, G. Kijanka, R. A. Gorkin and J. Ducreé, *Current Opinion in Chemical Biology*,  
2415 2012, **16**, 409–414.  
2416 214 S.-W. Lee, J. Y. Kang, I.-H. Lee, S.-S. Ryu, S.-M. Kwak, K.-S. Shin, C. Kim, H.-I. Jung  
2417 and T.-S. Kim, *Sensors and Actuators A: Physical*, 2008, **143**, 64–69.  
2418 215 H. Chen, X. Li, L. Wang and P. C. Li, *Talanta*, 2010, **81**, 1203–1208.  
2419 216 R. Burger, D. Kurzbuch, R. Gorkin, G. Kijanka, M. Glynn, C. McDonagh and J. Ducreé,  
2420 *Lab Chip*, 2015, **15**, 378–381.  
2421 217 K.-C. Chen, Y.-C. Pan, C.-L. Chen, C.-H. Lin, C.-S. Huang and A. M. Wo, *Analytical*  
2422 *Biochemistry*, 2012, **429**, 116–123.  
2423 218 D. Kirby, G. Kijanka, J. Siegrist, J. Burger, O. Sheils, J. O'Leary and J. Ducreé, *Proc. of*  
2424 *μTAS*, 2012, 1126–1128.  
2425 219 M. Boettcher, M. S. Jaeger, L. Riegger, J. Ducreé, R. Zengerle and C. Duschl, *Biophys.*  
2426 *Rev. Lett.*, 2006, **1**, 443–451.  
2427 220 J. L. Garcia-Cordero, L. M. Barrett, R. O'Kennedy and A. J. Ricco, *Biomed Microdevices*,  
2428 2010, **12**, 1051–1059.  
2429 221 S. M. Imaad, N. Lord, G. Kulsharova and G. L. Liu, *Lab Chip*, 2011, **11**, 1448.  
2430 222 U. Schaff, A. Tentori and G. Sommer, *Proc. of μTAS*, 2010, 103–105.  
2431 223 David J. Kinahan, Macdara T. Glynn, Sinéad M. Kearney, and Jens Ducreé, *Proc. of*  
2432 *μTAS*, 2012, 1363–1365.  
2433 224 J.-M. Park, M. S. Kim, H.-S. Moon, C. E. Yoo, D. Park, Y. J. Kim, K.-Y. Han, J.-Y. Lee, J.  
2434 H. Oh, S. S. Kim, W.-Y. Park, W.-Y. Lee and N. Huh, *Anal. Chem.*, 2014, **86**, 3735–3742.  
2435 225 S. Rodriguez-Mozaz, Lopez de Alda, Maria J. and D. Barceló, *Anal Bioanal Chem*, 2006,  
2436 **386**, 1025–1041.  
2437 226 *Global Water Intelligence*, 2009.  
2438 227 LaMotte, *WaterLink Spin Lab*, available at: [http://www.lamotte.com/en/pool-](http://www.lamotte.com/en/pool-spa/labs/3576.html)  
2439 [spa/labs/3576.html](http://www.lamotte.com/en/pool-spa/labs/3576.html).  
2440 228 Y. Xi, E. J. Templeton and E. D. Salin, *Talanta*, 2010, **82**, 1612–1615.  
2441 229 M. C. R. Kong and E. D. Salin, *Anal. Chem.*, 2012, **84**, 10038–10043.  
2442 230 J. P. Lafleur and E. D. Salin, *J. Anal. At. Spectrom.*, 2009, **24**, 1511.  
2443 231 J. P. Lafleur, A. A. Rackov, S. McAuley and E. D. Salin, *Talanta*, 2010, **81**, 722–726.  
2444 232 D. A. Duford, Y. Xi and E. D. Salin, *Anal. Chem.*, 2013, 130718102006007.  
2445 233 Y. Xi, D. A. Duford and E. D. Salin, *Talanta*, 2010, **82**, 1072–1076.  
2446 234 T. van Oordt, G. B. Stevens, S. K. Vashist, R. Zengerle and F. von Stetten, *RSC Adv.*,  
2447 2013, **3**, 22046.  
2448 235 L. Li and R. F. Ismagilov, *Annu. Rev. Biophys.*, 2010, **39**, 139–158.  
2449 236 V. Gubala, J. Siegrist, R. Monaghan, B. O'Reilly, R. P. Gandhiraman, S. Daniels, D. E.  
2450 Williams and J. Ducreé, *Analytica Chimica Acta*, 2013, **760**, 75–82.  
2451 237 A. Bruchet, V. Taniga, S. Descroix, L. Malaquin, F. Goutelard and C. Mariet, *Talanta*,  
2452 2013, **116**, 488–494.  
2453 238 S.-K. Lee, G.-R. Yi and S.-M. Yang, *Lab Chip*, 2006, **6**, 1171.  
2454 239 N. R. Glass, R. J. Shilton, Chan, Peggy P. Y., J. R. Friend and L. Y. Yeo, *Small*, 2012, **8**,  
2455 1881–1888.  
2456 240 Samsung, *Samsung: LABGEO IB10*, available at:  
2457 [http://www.samsungmedison.de/labgeo\\_ib10.aspx](http://www.samsungmedison.de/labgeo_ib10.aspx), accessed 19 September 2013.

Hauptautor: Strohmeier, Keller, Schwemmer, Zehnle, Paust

Title: Centrifugal microfluidic platforms: advanced unit operations and applications

- 2458 241 Focus Diagnostics, *3M INTEGRATED CYCLER*, available at:  
2459 <http://www.focusdx.com/3m-integrated-cycler>, accessed 8 May 2014.
- 2460 242 Roche, *Roche: COBAS b 101*, available at: [http://www.cobas.com/home/product/cobas-](http://www.cobas.com/home/product/cobas-b-101-poc-system.html)  
2461 [b-101-poc-system.html](http://www.cobas.com/home/product/cobas-b-101-poc-system.html), accessed 8 May 2014.
- 2462 243 Capitalbio, *Capitalbio: RTisochip*, available at:  
2463 [http://www.bioon.com.cn/product/show\\_product.asp?id=284704](http://www.bioon.com.cn/product/show_product.asp?id=284704), accessed 8 May 2014.
- 2464 244 Skyla, *Skyla: VB 1: Veterinary Clinical Chemistry Analyzer*, available at:  
2465 <http://www.skyla.com/veterinarydetail.php?id=3>, accessed 16 September 2014.
- 2466 245 Biosurfit, *Biosurfit: SpinIt*, available at: <http://www.biosurfit.com/>, accessed 8 May 2014.
- 2467 246 Radisens Diagnostics, *Radisens Diagnostics*, available at: <http://www.radisens.com/>,  
2468 accessed 8 May 2014.
- 2469 247 Gene POC, *Gene POC*, available at: <http://www.genepoc-diagnostics.com/Home.shtml>,  
2470 accessed 8 May 2014.
- 2471 248 SpinChip Diagnostics AS, *SpinChip Diagnostics AS*, available at:  
2472 <http://www.spinchip.no/>, accessed 8 May 2014.
- 2473 249 J. Euske, *Sandia National Laboratories : Licensing/Technology Transfer SpinDx™:*  
2474 *Point-of-Care Diagnostics Using Centrifugal Microfluidics*, available at:  
2475 <https://ip.sandia.gov/technology.do/techID=82>, accessed 8 May 2014.
- 2476 250 N. G. Anderson, *Clinica Chimica Acta*, 1969, **25**, 321–330.
- 2477 251 M. J. Felton, *Anal. Chem.*, 2003, **75**, 302 A.
- 2478 252 R. M. Rocco, *Clinical Chemistry*, 2006, **52**, 1977.
- 2479 253 O. Strohmeier, M. Rombach, D. Mark, R. Zengerle, G. Roth and F. von Stetten,  
2480 *Proceedings of Transducers*, 2011, 2952–2955.
- 2481 254 M. Focke, O. Strohmeier, P. Reith, G. Roth, D. Mark, R. Zengerle and F. von Stetten,  
2482 *Proc. of  $\mu$ TAS*, 2011, 659–661.